Insulin & Cancer: How Insulin Literally Protects Cancer Cells From Being Killed

INSULIN PROTECTS CANCER CELLS FROM APOPTOSIS
Insulin can promote the growth and survival of cancer cells. Here’s how:

1. Insulin promotes cell growth and proliferation: Insulin is a hormone that regulates glucose metabolism and promotes the uptake of glucose into cells. Cancer cells have a high demand for glucose to fuel their rapid growth and proliferation. Insulin stimulates the uptake of glucose into cancer cells, providing them with the energy and nutrients they need to grow and divide.

2. Insulin activates signaling pathways: Insulin activates signaling pathways, such as the PI3K/Akt/mTOR pathway, which are involved in cell growth, survival, and metabolism. Dysregulation of these pathways is commonly observed in cancer cells and contributes to their uncontrolled growth. Insulin can enhance the activity of these pathways in cancer cells, promoting their survival and proliferation.

3. Insulin increases insulin-like growth factor (IGF) levels: Insulin can stimulate the production of insulin-like growth factors (IGFs), particularly IGF-1. IGFs are growth factors that can bind to receptors on cancer cells and promote their growth and survival. Elevated levels of IGF-1 have been associated with an increased risk of various cancers.

4. Insulin reduces apoptosis: Apoptosis is a programmed cell death process that helps eliminate damaged or abnormal cells, including cancer cells. Insulin can inhibit apoptosis in cancer cells, allowing them to evade cell death and continue to proliferate.

5. Insulin promotes inflammation: Chronic inflammation is a hallmark of cancer development and progression. Insulin can contribute to inflammation by activating inflammatory signaling pathways and promoting the release of pro-inflammatory molecules. Inflammation creates a favorable environment for cancer growth and can support tumor angiogenesis, invasion, and metastasis.

It’s important to note that insulin itself is not the sole factor in cancer development and progression. Other factors, such as genetic mutations, lifestyle factors, and other hormones, also play significant roles. However, the relationship between insulin and cancer highlights the potential impact of metabolic factors on cancer development and suggests that strategies to reduce insulin levels, such as dietary interventions, may have therapeutic benefits in cancer treatment.

If you are serious about beating and preventing cancer then you want to be secreting as little insulin as possible while remaining as insulin sensitive as possible. That means you only want a tiny amount of insulin being utilized to maintain healthy blood sugar levels.
How?

Simple! 22/2 daily intermittent fasting with blends and strict non dairy paleo keto LOW INSULIN INDEX diet.

SCIENCE
“We report here that insulin and insulin-like growth factor-I (IGF-I) fully protect HT29-D4 colon carcinoma cell”
Insulin-like Growth Factor-I Protects Colon Cancer Cells from Death Factor-induced Apoptosis by Potentiating Tumor Necrosis Factor α-induced Mitogen-activated Protein Kinase and Nuclear Factor κB Signaling Pathways
The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitro cause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death, and that its protective action is even more striking in vivo than in vitro
The Insulin-like Growth Factor I Receptor Protects Tumor Cells from Apoptosis in Vivo
Insulin‐like growth factor (IGF)‐I protects many cell types from apoptosis. As a result, it is possible that IGF‐I‐responsive cancer cells may be resistant to apoptosis‐inducing chemotherapies. Therefore, we examined the effects of IGF‐I on paclitaxel and doxorubicin‐induced apoptosis in the IGF‐I‐responsive breast cancer cell line MCF‐7. Both drugs caused DNA laddering in a dose‐dependent fashion, and IGF‐I reduced the formation of ladders. We next examined the effects of IGF‐I and estradiol on cell survival following drug treatment in monolayer culture. IGF‐I, but not estradiol, increased survival of MCF‐7 cells in the presence of either drug. Cell cycle progression and counting of trypan‐blue stained cells showed that IGF‐I was inducing proliferation in paclitaxel‐treated but not doxorubicin‐treated cells. However, IGF‐I decreased the fraction of apoptotic cells in doxorubicin‐ but not paclitaxel‐treated cells. Recent work has shown that mitogen‐activated protein kinase (MAPK) and phosphotidylinositol‐3 (PI‐3) kinase are activated by IGF‐I in these cells. PI‐3 kinase activation has been linked to anti‐apoptotic functions while MAPK activation is associated with proliferation. We found that IGF‐I rescue of doxorubicin‐induced apoptosis required PI‐3 kinase but not MAPK function, suggesting that IGF‐I inhibited apoptosis. In contrast, IGF‐I rescue of paclitaxel‐induced apoptosis required both PI‐3 kinase and MAPK, suggesting that IGF‐I‐mediated protection was due to enhancement of proliferation. Therefore, IGF‐I attenuated the response of breast cancer cells to doxorubicin and paclitaxel by at least two mechanisms: induction of proliferation and inhibition of apoptosis. Thus, inhibition of IGF‐I action could be a useful adjuvant to cytotoxic chemotherapy in breast cancer.
Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects
Extracellular matrix (ECM) is known to influence the apoptotic response of cells; therefore, the antiapoptotic effect of IGF-1 on breast cancer cells was examined using different ECMs: laminin, collagen IV, or Matrigel. IGF-1 protected cells from apoptosis induced by methotrexate on all ECMs tested, providing the first evidence that IGF-1 protects against apoptosis in three-dimensional culture systems. These data provide the rationale to search for drugs that lower serum IGF-1 in an effort to improve the efficacy of chemotherapeutic drugs for the treatment of breast cancer.
Insulin-like Growth Factor 1 (IGF-1) Alters Drug Sensitivity of HBL100 Human Breast Cancer Cells by Inhibition of Apoptosis Induced by Diverse Anticancer Drugs
The extent of apoptosis in vivo is correlated to the decrease in IGF-IR levels and, in turn, tumorigenesis in nude mice is correlated to the fraction of surviving cells. In syngeneic rats, a host response leads to complete inhibition of tumorigenesis. These findings establish, for the first time on a quantitative basis, the relationship between IGF-IR levels and the extent of apoptosis, as well as the relationship between the initial apoptotic event and the time of appearance of transplantable tumors.
Correlation between Apoptosis, Tumorigenesis, and Levels of Insulin-like Growth Factor I Receptors
Ketosis was associated inversely with serum insulin levels (P = 0.03).
Conclusion
Preliminary data demonstrate that an insulin-inhibiting diet is safe and feasible in selected patients with advanced cancer.
https://www.sciencedirect.com/science/article/pii/S0899900712001864
As with insulin, inhibition of IGF-1 signaling has anti-cancer effects.
The Links Between Insulin Resistance, Diabetes, and Cancer
The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitrocause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death.

Multiple myeloma cell lines express functional receptors for insulin‐like growth factors (IGFs) and several cell types that make up the bone marrow microenvironment produce these cytokines. This suggests that IGFs may play a role in survival and/or expansion of the malignant clone within the marrow in patients with multiple myeloma. We tested the effects of these growth factors on myeloma cells challenged with dexamethasone. Dye exclusion and MTT assays demonstrated that both IGF‐I and IGF‐II protected the 8226 and dox‐40 myeloma cell lines and three primary myeloma cultures from dexamethasone‐induced cytotoxicity in a dose‐dependent fashion. Morphologic studies of target cells and their nuclei as well as DNA electrophoresis confirmed the IGFs afforded protection against dexamethasone‐induced apoptosis. Insulin also protected but was less impressive and required much higher concentrations. IGFs also protected against cycloheximide‐induced apoptosis but were ineffective against serum starvation, topoisomerase II inhibitors, or anti‐fas antibodies. IGF‐induced protection against dexamethasone was not associated with any alteration in quantitative or qualitative expression of BCL‐2, BAX or BCL‐X proteins. These data indicate that insulin‐like growth factors may play a role in maintenance of the malignant clone in patients with myeloma by protecting tumour cells from apoptotic death.

Resistance of cancer cells against apoptosis induced by death factors contributes to the limited efficiency of immune- and drug-induced de­struction of tumors. We report here that insulin and insulin-like growth factor-I (IGF-I) fully protect HT29-D4 colon carcinoma cells from IFN­g/tumor necrosis factor-a (TNF) induced apoptosis. Survival signaling initiated by IGF-I was not dependent on the canonical survival pathway involving phosphatidylinositol 3*-kinase. In addition, neither pp70S6K nor protein kinase C conveyed IGF-I antiapoptotic function. Inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) with the MAPK/ERK kinase inhibitor PD098059 and MAPK/p38 with the specific inhibitor SB203580 partially reversed, in a nonadditive manner, the IGF-I survival effect. Inhibition of nuclear factor kB (NF-kB) activity by preventing degradation of the inhibitor of NF-kB (IkB-a) with BAY 11-7082 also blocked in part the IGF-I antiapoptotic effect. However, the complete reversal of the IGF-I effect was obtained only when NF-kB and either MAPK/ERK or MAPK/p38 were inhibited together. Because these pathways are also those used by TNF to signal inflammation and survival, these data point to a cross talk between IGF-I­and TNF-induced signaling. We further report that TNF-induced IL-8 production was indeed strongly enhanced upon IGF-I addition, and this effect was totally abrogated by both MAPK and NF-kB inhibitors. The IGF-I antiapoptotic function was stimulus-dependent because Fas- and IFN/Fas-induced apoptosis was not efficiently inhibited by IGF-I. This was correlated with the weak ability of Fas ligation to enhance IL-8 production in the presence or absence of IGF-I. These findings indicate that the antiapoptotic function of IGF-I in HT29-D4 cells is based on the enhancement of the survival pathways initiated by TNF, but not Fas, and mediated by MAPK/p38, MAPK/ERK, and NF-kB, which act in concert to suppress the proapoptotic signals. In agreement with this model, we show that it was possible to render HT29-D4 cells resistant to Fas-induced apoptosis provided that IGF-I and TNF receptors were activated simul­taneously.

Diet contributes to over one-third of cancer deaths in the Western world, yet the factors in the diet that influence cancer are not elucidated. A reduction in caloric intake dramatically slows cancer progression in rodents, and this may be a major contribution to dietary effects on cancer. Insulin-like growth factor I (IGF-I) is lowered during dietary restriction (DR) in both humans and rats. Because IGF-I modulates cell proliferation, apoptosis, and tumorigenesis, the mechanisms behind the protective effects of DR may depend on the reduction of this multifaceted growth factor. To test this hypothesis, IGF-I was restored during DR to ascertain if lowering of IGF-I was central to slowing bladder cancer progression during DR. Heterozygous p53-deficient mice received a bladder carcinogen, p-cresidine, to induce preneoplasia. After confirmation of bladder urothelial preneoplasia, the mice were divided into three groups: (a) ad libitum; (b) 20% DR; and (c) 20% DR pius IGF-I (IGF-I/DR). Serum IGF-I was lowered 24% by DR but was completely restored in the IGF-I/DR-treated mice using recombinant IGF-I administered via osmotic minipumps. Although tumor progression was decreased by DR, restoration of IGF-I serum levels in DR-treated mice increased the stage of the cancers. Furthermore, IGF-I modulated tumor progression independent of changes in body weight. Rates of apoptosis in the preneoplastic lesions were 10 times higher in DR-treated mice compared to those in IGF/DR- and ad libitum-treated mice. Administration of IGF-I to DR-treated mice also stimulated cell proliferation 6-fold in hyperplastic foci. In conclusion, DR lowered IGF-I levels, thereby favoring apoptosis over cell proliferation and ultimately slowing tumor progression. This is the first mechanistic study demonstrating that IGF-I supplementation abrogates the protective effect of DR on neoplastic progression.

1. A chimeric humanized single-chain antibody against the type I Insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of …
2. A Common Promoter Polymorphism (-23HphI) in Insulin Gene and Susceptibility to Colorectal cancer
3. A dominant negative mutant of the Insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
4. A dominant negative type I Insulin-like growth factor receptor inhibits metastasis of human cancer cells
5. A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of Insulin analogues
6. A higher prediagnostic Insulin level is a prospective risk factor for incident prostate cancer
7. A ketogenic diet reduces central obesity and serum Insulin in women with ovarian or endometrial cancer
8. A kinome-wide screen identifies the Insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer
9. A longitudinal study of serum Insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women
10. A Mechanistic Investigation of Insulin Receptor Substrate 2 Function in Breast cancer Progression
11. A mendelian randomization study for the potential causal effect of genetically driven Insulin resistance on invasive breast cancer
12. A nested case-control study of stomach cancer and serum Insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3
13. A New Insulin-Like Growth Factor Binding Protein (mac25) and its Role in Breast cancer and Cell Growth Control
14. A New Insulin-Like Growth Factor Binding Protein and Its Role in Breast cancer and Cell Growth
15. A new single nucleotide polymorphism in the Insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese
16. A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks Insulin-like growth factor-1 induced tumorigenesis in breast cancer cells
17. A novel autocrine loop involving IGF-II and the Insulin receptor isoform-A stimulates growth of thyroid cancer
18. A novel mechanism underlying prostate cancer progression: an investigation into the impact of Insulin like growth factors (IGFs), PTEN and IGFBP2 on TMPRSS2 …
19. A Novel Member of the Insulin-Like Growth Factor Binding Protein Superfamily in Prostate cancer
20. A novel role for Insulin resistance in the connection between obesity and postmenopausal breast cancer
21. A novel synthetic human Insulin super promoter for targeting PDX-1-expressing pancreatic cancer
22. A novel targeted oral Insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A phase I clinical …
23. A novel unidirectional cross-talk from the Insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells
24. A phase II study of Insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
25. A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, Insulin resistance and colonic inflammation
26. A pilot safety-feasibility dietary trial targeting Insulin inhibition in ten patients with advanced cancer
27. A population-based cohort study in Taiwan––use of Insulin sensitizers can decrease cancer risk in diabetic patients?
28. A preliminary study on the relationship of Insulin-like growth factor-Ⅰ receptor and the carcinogenesis of gastde cancer
29. A prospective evaluation of Insulin and Insulin-like growth factor-I as risk factors for endometrial cancer.
30. A prospective study of anthropometric and clinical measurements associated with Insulin resistance syndrome and colorectal cancer in male smokers
31. A prospective study of C-peptide, Insulin-like growth factor-I, Insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women
32. A prospective study of Insulin‐like growth factor‐I, IGF‐binding proteins‐1,‐2 and‐3 and lung cancer risk in women
33. A prospective study of serum Insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk
34. A prospective study of the Insulin-like growth factor axis in relation with prostate cancer in the SU. VI. MAX trial
35. A protease resistant Insulin like growth factor binding protein 4 as a treatment for prostate cancer
36. A review of obesity, Insulin resistance, and the role of exercise in breast cancer patients
37. A Salutary Tale—Glargine Insulin and cancer risk
38. A sequence repeat in the Insulin‐like growth factor‐1 gene and risk of breast cancer
39. A serum-free and Insulin-supplemented cell culture medium ensures fatty acid synthesis gene activation in cancer cells
40. A Significance of Insulin-like Growth Factors (IGFs) and Insulin-like Growth Factor Binding Proteins (IGFBPs) in Ascites of Ovarian cancer Patients
41. A study of prostate cancer and its association with dyslipidemia, elevated Insulin levels in blood, and relative Insulin resistance prevalent in South East Asia
42. A study on Insulin receptor on human hepatocellular cancer cell membrane
43. A Study on Insulin Resistance and Obesity Among Women at High Risk for Breast cancer Using Cluster Analysis.
44. A synergistic combination strategy for optimal inhibition of colon cancer stem cells: Simultaneous inhibition of Insulin-like growth factor-1 receptor-AKT-mammalian …
45. A tale of two receptors: Insulin and Insulin-like growth factor signaling in cancer
46. A twenty-first century cancer epidemic caused by obesity: the involvement of Insulin, diabetes, and Insulin-like growth factors
47. A Type I Insulin-Like Growth Factor Receptor Kinase Inhibitor (PQIP) Enhances the Cytotoxicity of Doxorubicin in Human cancer Cell Lines.
48. A63 DEATH TO THE INFIDELS! CELLULAR APOPTOSIS IN LUNG DISEASE: Insulin Receptor Suppresses Apoptosis In H-292 Human Bronchial Epithelial cancer …
49. Abdominal visceral and subcutaneous fat increase, Insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy
50. Aberrant cross-talk and expression of β1 integrins and type 1 Insulin-like growth factor receptor during prostate cancer progression.
51. Aberrant neuronal cell cycle re-entry: The pathological confluence of Alzheimer’s disease and brain Insulin resistance, and its relation to cancer
52. Abnormality of growth hormone and Insulin-like growth factor I axis in advanced cancer patients
53. About the Role of Insulin in the Interaction Between Human Immune and Colon cancer Cells
54. Absence of down-regulation of Insulin receptors in human breast cancer cells (MCF-7) cultured in serum-free medium: comparison with epidermal growth factor
55. Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women
56. Absence of the full-length breast cancer–associated gene-1 leads to increased expression of Insulin-like growth factor signaling axis members
57. Abstract A10: Insulin resistance’s effect on PSA level for prostate cancer screening
58. Abstract A33: Utilizing Insulin the treatment of prostate cancer with BKM120 abrogates the therapeutic effect of PI3K pathway inhibition
59. Abstract A35: Insulin and hypoxia-inducible factor-1 cooperate to increase the viability of pancreatic cancer cells
60. Abstract A43: Basal expression of Insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a PI3K inhibitor ZSTK474
61. Abstract A44: Suppression of Insulin-induced fatty acid synthase gene expression and colon cancer cell proliferation by members of the Krüppel-like family of …
62. Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an Insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced …
63. Abstract A58: Role of Insulin-like growth factor binding protein acid labile complex in ER-PR-Her2+ breast cancer in African American women.
64. Abstract A61: Smoking modifies the association of Insulin sensitivity biomarkers and pancreatic cancer risk
65. Abstract B115: Plasma Insulin‐like growth factor 1, binding protein‐3, and risk of prostate cancer: An update from the Health Professional Follow‐up Study 1993–2004
66. Abstract B129: Preclinical assessment of targeting Insulin‐like growth factor‐2 in bone metastasis from prostate cancer by a human neutralizing antibody (m610) and …
67. Abstract B22: Modulation of Insulin-like growth factor binding proteins expression in human prostate cancer cells in vitro by american cranberry (Vaccinium …
68. Abstract B232: Preclinical evaluation of AMG479 a fully human Insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells
69. Abstract B39: Modulation of Insulin receptor alternative splicing to develop cancer therapeutics
70. Abstract B51: The tyrphostin, NT157, suppresses Insulin receptor substrates and augments therapeutic response of prostate cancer
71. Abstract B59: Race-related differential splicing of the Insulin receptor: A novel target underlying prostate cancer disparities
72. Abstract B76: Evidence of a causal association between fasting Insulin concentrations and endometrial cancer: A Mendelian randomization analysis
73. Abstract CN13-04: Obesity, Insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug
74. Abstract D118: Insulin receptor splicing regulation as a potential target for improved prostate cancer disparity outcomes
75. Abstract ES9-1: Role for IGF/Insulin signaling in breast cancer
76. Abstract KN01: Keynote Lecture: PI 3-kinase links obesity, Insulin resistance, and cancer
77. Abstract LB-187: Dietary energy balance modulation of Kras-and Ink4a/Arf+/-driven pancreatic cancer: the role of Insulin-like growth factor-1.
78. Abstract LB-28: The IGF/Insulin signaling axis TMPRSS2: ERG and prostate cancer survival.
79. Abstract LB-329: Use of Insulin sensitizers is associated with better hormone-receptor pattern and improved breast cancer outcomes
80. Abstract NTOC-097: VACCINATION TARGETING Insulin–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN cancer: SAFETY …
81. Abstract P1-04-03: Knocking down Suppressor of Cytokine Signaling 7 in breast cancer: The role in Insulin-like Growth Factor-I/Phospholipase Cγ-1 signaling
82. Abstract P1-07-03: Dual inhibition of IGF1R and Insulin receptor in estrogen receptor positive and triple negative breast cancer and monitoring blockade of metastasis …
83. Abstract P1-08-10: Insulin resistance and breast cancer incidence and mortality in postmenopausal women
84. Abstract P1-12-12: The Insulin like growth factor axis and development of tamoxifen resistance in breast cancer
85. Abstract P1-21-05: A novel long-acting Insulin for cancer therapy reduces xenograft tumor growth
86. Abstract P2-06-03: Insulin receptor isoform signaling in breast cancer
87. Abstract P2-07-03: Insulin and breast cancer risk: Novel insights from mammographic density analyses
88. Abstract P2-16-18: Does Insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?
89. Abstract P3-05-13: Overexpression of Insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells
90. Abstract P3-07-03: Insulin-like growth factor-1 receptor variant associated with decreased breast cancer risk in women with pregnancy-induced hypertension
91. Abstract P3-07-54: Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer …
92. Abstract P3-10-09: Gene deletion of IRS1 inhibited IGF-I, Insulin and estradiol stimulated MCF-7L breast cancer cell growth
93. Abstract P4-04-07: Heterogeneous gene fusions detected by RNASeq show enrichment of Insulin signaling pathway genes in breast cancer
94. Abstract P4-06-02: Insulin receptor targeting in breast cancer through yeast surface display
95. Abstract P4-06-03: Targeting the Insulin receptor with a small peptide (S961) in cancer
96. Abstract P4-11-02: Worse breast cancer prognosis in Insulin treated diabetic patients-A population based registry study in Sweden
97. Abstract P4-13-07: Meta-analysis of epidemiological studies of Insulin Glargine and Breast cancer Risk
98. Abstract P5-07-05: Insulin-like growth factor binding protein-3 is a key component of the breast cancer cell response to DNA-damaging therapy
99. Abstract P6-09-05: Insulin Resistance, Diabetes Mellitus and Breast cancer Risk in Pre-and Postmenopausal Women: Modification Effect by Moderate Physical …
100. Abstract P6-12-05: Inducible suppression of Insulin receptor substrate I inhibits IGF-I/Insulin/estradiol dependent cell growth in MCF-7L breast cancer cells
101. Abstract P6-15-09: Insulin-Like Growth Factor Receptor I (IGF1R) Inhibitors May Be Synergistic with Chemotherapy in Basal Breast cancer
102. Abstract PD2-07: Insulin receptor substrate (IRS) targeting by the tyrophostin NT157 inhibits breast cancer cell growth
103. Abstract PD2-5: Low carbohydrate dietary intervention improves Insulin, hormonal levels and inflammatory markers in early stage, postmenopausal breast cancer …
104. Abstract# 34: Colored potato functional compounds suppress Insulin-like growth factor-1-promoted prostate cancer cell proliferation and elevate apoptosis through …
105. Abstract# 3421: Her-2 over expression induces metabolic transformation resulting in Insulin-independence in human breast cancer cells
106. Abstract# 3900: Resveratrol suppresses Insulin-like growth factor-1 promoted colon cancer cell growth via activation of p53/AMPK/TSC-2 and suppression of IGF-1R …
107. Abstract# 4288: Differential Insulin-like growth factor II (IGF-II) expression may impact breast cancer incidence and survival among African-American and Caucasian …
108. Abstract# 4404: Possible role of Insulin-like growth factor I in breast cancer proliferation via the CYP1A1 epoxygenase pathway
109. Abstract# 4874: Insulin, Insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
110. Abstract# 5048: Deoxycholic acid induces endocytosis of the Insulin-like growth factor-I receptor in colorectal cancer cells
111. Abstract# 793: Elevated epithelial Insulin-like growth factor expression is a risk factor for lung cancer development
112. Abstract# 794: Gonadotropin-releasing hormone promotes motility and invasiveness of ovarian cancer cells through transactivation of the Insulin-like growth factor-1 …
113. Abstract# 795: The role of tissue expressed Insulin-like growth factor (IGF) and the Janus effects of IGFBP-3 in lung cancer development
114. Abstract# 827: Antitumor effect of diethylstilbestrol (DES) in combination with an Insulin-like growth factor-1 (IGF-1) antibody in preclinical prostate cancer.
115. Abstract# LB-280: Expression of early placenta Insulin-like growth factor in breast cancer a prerequisite of metastasis forming disseminated tumor cells?
116. Acanthosis nigricans and severe Insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy
117. Acquired resistance to tamoxifen is associated with loss of the type I Insulin-like growth factor receptor: implications for breast cancer treatment
118. Actions of pituitary prolactin and Insulin-like growth factor II in human breast cancer
119. Activated Insulin-like growth factor (IGF) signaling pathway is a potential therapeutic target for brain metastasis from lung cancer.
120. Activated α2-macroglobulin binding to human prostate cancer cells triggers Insulin-like responses
121. Activation of epidermal growth factor receptor/Insulin-like growth factor 1 receptor-β-Catenin-CD44 pathway in periampullary cancer
122. Activation of Insulin receptors and IGF-1 receptors in COLO-205 colon cancer xenografts by Insulin and Insulin analogue X10 does not enhance growth under …
123. Activation of Insulin-like growth factor 1 receptor in patients with non-small cell lung cancer
124. Activation of Insulin-like growth factor 1 receptor regulates the radiation-induced lung cancer cell apoptosis
125. Activation of Insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
126. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of Insulin-like growth factor I (IGF-I) in human breast cancer cell lines
127. Activator protein-2 overexpression accounts for increased Insulin receptor expression in human breast cancer
128. Adipocyte-released Insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro
129. Adipocytokines, obesity, and Insulin resistance during combined androgen blockade for prostate cancer
130. Adipokines and Insulin resistance in young adult survivors of childhood cancer
131. Adipokines, Insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study
132. Adiponectin, leptin, and Insulin-pathway receptors as endometrial cancer subtyping markers
133. Adiponectin: the “unusual suspect” between Insulin resistance and cancer?
134. Adipose Estrogen and Increased Breast cancer Risk in Obesity: Regulation by Leptin and Insulin
135. Adiposity and estrogen receptor‐positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting Insulin and free estradiol
136. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes Insulin resistance in β cells and mice
137. Advance on Insulin-like Growth Factor Binding Protein 2 in Lung cancer and Other Solid Tumors
138. Advances in Insulin-like growth factor biology and-directed cancer therapeutics
139. Advances in targeting Insulin-like growth factor signaling pathway in cancer treatment
140. Affinity for the Insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.
141. Age and Insulin levels in breast cancer women and healthy women
142. Aging and cancer-related loss of Insulin-like growth factor 2 imprinting in the mouse and human prostate
143. AIB1/SRC-3 deficiency affects Insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice
144. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
145. AKT activation up-regulates Insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells
146. Alterations in laminin expression modulate prostate cancer cell behavior through changes in integrin and Insulin-like growth factor receptor actions
147. Alterations in promoter usage and expression levels of Insulin-like growth factor-II and H19 genes in cervical and endometrial cancer
148. Alterations in Promoter Usage and Expression Levels of Insulin-like Growth Factor-II and H19 Genes in Cervical andEndometrial cancer
149. Alterations in serum levels of Insulin‐like growth factors and Insulin‐like growth‐factor‐binding proteins in patients with colorectal cancer
150. Alterations in the expression of Insulin-like growth factors and their binding proteins in lung cancer
151. Alterations in the Insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
152. Alterations of Insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer
153. Altered expression of Insulin receptor isoforms in breast cancer
154. Altered expression of Insulin-like growth factor II receptor in human pancreatic cancer.
155. Altered glucose metabolism and Insulin resistance in cancer-induced cachexia: a sweet poison
156. Altered Insulin response to glucose in weight-losing cancer patients.
157. Altered serum levels of Insulin-like growth-factor binding proteins in breast cancer patients
158. Alternative splicing of Insulin receptor mRNA in cancer and type 2 diabetes mellitus: a review
159. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the Insulin‐like growth factor receptor …
160. An anti-Insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
161. An antibody targeting the type I Insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
162. An epidemiologic investigation of the roles of plasma lipids, endogenous Insulin, and CYP17 genotype in breast cancer causation.
163. An evaluation of compliance in cancer patients and non-Insulin dependent diabetics.
164. An exon variant in Insulin receptor gene is associated with susceptibility to colorectal cancer in women
165. An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with cancer
166. An Insulin effect on cytoplasmic estrogen receptor in the human breast cancer cell line MCF-7.
167. An Insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival
168. An investigation into the role of the transcription factor ERG and its regulation of the members of the Insulin-growth factor signalling pathway in prostate cancer
169. An N-terminal fragment of Insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner
170. Analysis of apoptosis-related gene expression in different serum level of Insulin-like growth factor-1 in mice breast cancer tissue
171. Analysis of expression profile of gene encoding proteins of signal cascades activated by Insulin-like growth factors in colorectal cancer
172. Analysis of genomic imprinting of Insulin-like growth factor 2 in colorectal cancer
173. Analysis of Insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer
174. ANALYSIS OF Insulin-LIKE GROWTH FACTOR-H IN HUMAN BREAST cancer CELLS
175. Analyzing structural differences between Insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents
176. Androgen receptor up-regulates Insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft
177. Androgens up-regulate the Insulin-like growth factor-I receptor in prostate cancer cells
178. Animal Models of HyperInsulinemia, Insulin Resistance, and cancer
179. ANTI-Insulin RESISTANCE TREATMENTS SUPPRESS HER2+ BREAST cancer GROWTH VIA ALTERING METABOLISM
180. Anti-Insulin-like growth factor strategies in breast cancer
181. Anti‐Insulin‐like growth factor‐I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines
182. Anticarcinogenic effect of quercetin by inhibition of Insulin-like growth factor (IGF)-1 signaling in mouse skin cancer
183. Antimetastatic activity of Insulin-like growth factor binding protein-3 in lung cancer is mediated by Insulin-like growth factor–independent urokinase-type plasminogen …
184. Antiproliferative actions of Insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells
185. Antiproliferative and apoptotic effects of a specific anti-Insulin-like growth factor I receptor single chain antibody on breast cancer cells
186. Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of Insulin-like growth factor 1 …
187. Antiproliferative MCR peptides block physical interaction of Insulin with retinoblastoma protein (RB) in human lung cancer cells
188. Antisense oligonucleotide targeting of Insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer
189. Antisense oligonucleotide to Insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line
190. Antisense phosphorothioate oligodeoxynucleotide down‐regulation of the Insulin‐like growth factor I receptor in ovarian cancer cells
191. Antisense RNA to the type I Insulin-like growth factor receptor reversed the transformed phenotype of PC-3 human prostate cancer cell line in vitro
192. Antisense RNA to the type I Insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
193. Antitumor effects of a soluble Insulin-like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo
194. Antitumor effects of an adenovirus expressing antisense Insulin-like growth factor I receptor on human lung cancer cell lines
195. Antitumor effects of dual inhibition of the Src and Insulin-like growth factor-1 receptor (IGF-1R) pathways in prostate cancer (PCa).
196. Apigenin attenuates Insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model
197. Apigenin modulates Insulin-like growth factor axis: implications for prevention and therapy of prostate cancer
198. Apigenin suppresses Insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study
199. Apigenin: a promising anticancer agent for the modulation of the Insulin-like Growth Factor (IGF) axis in prostate cancer
200. Application of Insulin in external treatment of radioactive dermatitis in nasopharyngeal cancer patients with hyperglycemia
201. Applications of Insulin-like growth factor system in the colorectal cancer
202. Are dietary influences on the risk of prostate cancer mediated through the Insulin‐like growth factor system?
203. Are plasma Insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
204. Are racial differences in obesity and Insulin resistance related to aggressive breast cancer?
205. Are sulfonylurea and Insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis
206. Are the Insulin-like growth factors relevant to cancer?
207. Are there Relationships between the VDR-FokI Polymorphism and Vitamin D and the Insulin Resistance in Non-melanoma Skin cancer (NMSC) Patients? A Protocol …
208. Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of Insulin like growth factor-I, its binding protein and …
209. Aspects of Insulin-like growth factor binding proteins in cancer
210. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an Insulin-related pathway
211. Assessing the role of Insulin‐like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating …
212. Assessment of Insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk
213. Association between adiponectin, Insulin resistance, and endometrial cancer
214. Association between androgen deprivation and serum Insulin levels among Ugandan men with advanced prostate cancer in Mulago Hospital
215. Association between cognitive impairment patient with solid cancer and Insulin resistance
216. Association between components of the Insulin-like growth factor system and endometrial cancer risk
217. Association between components of the Insulin-like growth factor system and epithelial ovarian cancer risk
218. Association between expression of Insulin resistance (IR) related genes and breast cancer outcome
219. Association between Insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk
220. Association between Insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent
221. Association between Insulin resistance and luminal B subtype breast cancer in postmenopausal women
222. Association between Insulin therapy and risk of liver cancer among diabetics: a meta-analysis of epidemiological studies
223. Association between Insulin-like growth factor 1 gene rs35767 polymorphisms and cancer risk: A meta-analysis
224. Association between Insulin-like growth factor binding protein-3 promoter polymorphism of− 1590 C> A and lung cancer susceptibility in a Chinese Han population
225. Association between Insulin-like growth factor receptors & cell density in breast cancer cells
226. Association between Insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer
227. Association between Insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis
228. Association between Insulin‐like growth factor‐1 polymorphisms and stomach cancer risk in a Japanese population
229. Association between polymorphisms of Insulin-like growth factor receptor gene and susceptibility to non-small-cell lung cancer in Fujian Chinese
230. Association between preoperative serum Insulin levels and lymph node metastasis in endometrial cancer—a prospective cohort study
231. Association Between Serum Insulin and C-Peptide Levels and Breast cancer: An Updated Systematic Review and Meta-Analysis
232. Association between serum Insulin and serum lipid substances and breast cancer
233. Association between the Insulin-like growth factor 1 gene rs2195239 and rs2162679 polymorphisms and cancer risk: a meta-analysis
234. Association between two functional polymorphisms of Insulin-like growth factor binding protein 3 and colorectal cancer risk in a Chinese population
235. Association of abnormal glucose metabolism and Insulin resistance in patients with atypical and typical endometrial cancer
236. Association of adipokines and Insulin, which have a role in obesity, with colorectal cancer
237. Association of Adipokines and Insulin, Which Have a Role in Obesity, with Colorectal cancer
238. Association of angiopoietin-2, C-reactive protein and markers of obesity and Insulin resistance with survival outcome in colorectal cancer
239. Association of biomarkers of Insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC).
240. Association of biomarkers of Insulin resistance and inflammation with skeletal muscle index (SMI) in stage IV non-small cell lung cancer (NSCLC).
241. Association of circulating Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 with the risk of ovarian cancer: a systematic review and …
242. Association of Circulating Insulin-like Growth Factors and IGF Binding Protein with Early Cases of cancer Cervix.
243. Association of dyslipidemia, increased Insulin resistance, and serum CA 15-3 with increased risk of breast cancer in urban areas of North and Central India
244. Association of fasting serum Insulin and cancer mortality in a healthy population–28-year follow-up of the French TELECOM Study
245. Association of Insulin Receptor Substrate-1 G972R Variant with Non-small Cell Lung cancer Risk.
246. Association of Insulin-like growth factor-1 polymorphism and risk of esophageal cancer [J]
247. Association of Insulin-like growth factor-I receptor polymorphism with colorectal cancer development
248. Association of Insulin‐like growth‐factor‐I‐induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF‐7 cells
249. Association of Insulin, Insulin-like growth factor and Insulin-like growth factor binding proteins with the risk of colorectal cancer
250. Association of Insulin, Metformin, and Statin with Mortality in Breast cancer Patients
251. Association of markers of Insulin and glucose control with subsequent colorectal cancer risk
252. Association of metabolic parameters, lipid and cytokine profiling, androgens and Insulin levels in Precancer and Prostate cancer: A cross-sectional study in …
253. Association of monocyte chemoattractant protein-1 with age, glucose, BMI, Insulin and other breast cancer biomarkers
254. Association of NAFLD and Insulin Resistance with Non Metastatic Bladder cancer Patients: A Cross-Sectional Retrospective Study
255. Association of polymorphisms and haplotypes in the Insulin-like growth factor 1 receptor (IGF1R) gene with breast cancer in Korean women
256. Association of polymorphisms and haplotypes in the Insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women
257. Association of prognosis with Insulin-like growth factor receptor type I expression in gastric cancer patients: a meta-analysis
258. Association of prostate cancer risk with Insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging
259. Association of serum hemoglobin A1c, C‑peptide and Insulin‑like growth factor‑1 levels with the occurrence and development of lung cancer
260. Association of the Insulin gene polymorphism and colorectal cancer.
261. Association of visceral adiposity and Insulin resistance with colorectal adenoma and colorectal cancer
262. Associations between circulating Insulin-like growth factor 1 and mortality in women with invasive breast cancer
263. Associations between Insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
264. Associations between plasma Insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
265. Associations of adipokines & Insulin resistance with sex steroids in patients with breast cancer.
266. Associations of chronic inflammation, Insulin resistance, and severe obesity with mortality, myocardial infarction, cancer, and chronic pulmonary disease
267. Associations of hyperglycemia and Insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry
268. Associations of Insulin and IGFBP-3 with lung cancer susceptibility in current smokers
269. Associations of Insulin resistance and adiponectin with mortality in women with breast cancer
270. Associations of Insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB …
271. Associations of Insulin‐like growth factor and Insulin‐like growth factor binding protein‐3 with mortality in women with breast cancer
272. Associations of obesity and circulating Insulin and glucose with breast cancer risk: a Mendelian randomization analysis
273. Associations of serum C-peptide and Insulin-like growth factor binding proteins-3 with breast cancer deaths
274. Associations of serum isoflavone, adiponectin and Insulin levels with risk for epithelial ovarian cancer: results of a case-control study
275. AT1-IR-beta association: A new mechanism for the inhibition of Insulin receptor function in breast cancer
276. Augmentation of response to nab-paclitaxel by inhibition of Insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models
277. Aurora-A down-regulates IkappaBα via Akt activation and interacts with Insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer …
278. Authors’ response: Associations of obesity and circulating Insulin and glucose with breast cancer risk
279. Autoantibodies against Insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer
280. Autocrine function for Insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells
281. Autocrine IGF-I/Insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
282. Autocrine production of Insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells.
283. Autocrine role of Insulin-like growth factor (IGF)-I in a human thyroid cancer cell line
284. Azathioprine desensitizes liver cancer cells to Insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1
285. Basal expression of Insulin‐like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3‐kinase inhibitor ZSTK474
286. Baseline Insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients
287. Beta-cell function and Insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance
288. Bidirectional crosstalk between leptin and Insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal …
289. Bifurcation analysis of Insulin regulated mTOR signalling pathway in cancer cells
290. Binding characteristics of pro-Insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to-6
291. Bioavailable Insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women
292. Biochemical and Genetic Markers in Aggressiveness and Recurrence of Prostate cancer: Race-Specific Links to Inflammation and Insulin Resistance
293. Biochemical characterization of individual human glycosylated pro-Insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer
294. Biologic roles of estrogen receptor-β and Insulin-like growth factor-2 in triple-negative breast cancer
295. Biological activity of rainbow trout Ea4‐peptide of the pro‐Insulin‐like growth factor (pro‐IGF)‐I on promoting attachment of breast cancer cells (MDA‐MB‐231) via α2 …
296. Biological effects of Insulin and its analogs on cancer cells with different Insulin family receptor expression
297. Biology of Insulin-like growth factor binding protein-4 and its role in cancer
298. Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast cancer Risk in Chinese Women
299. Biomarkers of the Insulin-like growth factor pathway predict progression and outcome in lung cancer
300. Bisphosphonates inhibit Insulin-like growth factor I-induced HIF-1α protein accumulation and VEGF expression in human beast cancer cells
301. Bisphosphonates suppress Insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells
302. Blockade of Insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer
303. Blockade of Insulin-like growth factor signaling induces apoptosis and reduces tumorigenesis and tumor progression in gastric cancer.
304. Blockade of Insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
305. Blockade of the Insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF‐II‐mediated autocrine loop
306. Blocking the Insulin-like growth factor-I receptor as a strategy for targeting cancer
307. Blood Insulin and Insulin sensitivity in breast cancer patients of various ages: the effect of smoking
308. BMAL1 rewires mitochondrial metabolism and promotes tumor progress of triple negative breast cancer during Insulin resistance
309. BMS-754807, a small-molecule inhibitor of Insulin-like growth factor-1 receptor/Insulin receptor, enhances gemcitabine response in pancreatic cancer
310. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous Insulin
311. Body mass index influences the prognostic impact of combined nuclear Insulin receptor and estrogen receptor expression in primary breast cancer
312. Body mass index, type 2 diabetes, and Insulin prescription in adolescents and young adults with cancer
313. Body Size, Physical Activity, Early-Life Energy Restriction, and Associations with Methylated Insulin-like Growth Factor–Binding Protein Genes in Colorectal cancer
314. Body size, physical activity, genetic variants in the Insulin-like growth factor pathway and colorectal cancer risk
315. Bone stromal production of Insulin-like growth factor binding protein 5 promotes growth and survival of prostate cancer
316. Bone turnover markers and Insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
317. Boostrapping at Several Frequencies Supports Plasma Insulin As a Potential Marker of Breast cancer Risk
318. Branched chain amino acid suppressed Insulin-initiated proliferation of human cancer cells through induction of autophagy
319. BRCA1 regulates Insulin‑like growth factor 1 receptor levels in ovarian cancer
320. Breast cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment
321. Breast cancer is associated to impaired glucose/Insulin homeostasis in premenopausal obese/overweight patients
322. Breast cancer Resistance Protein 1 deficient male mice exhibit impaired estrogen action and Insulin resistance
323. Breast cancer Risk and Insulin Resistance: Post Genome-Wide Gene–Environment Interaction Study Using a Random Survival Forest
324. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, Insulin-like growth factor-1 receptor, and Ki67 expression in normal breast …
325. Breast cancer Risk in Japanese Women with Special Reference to the Growth Hormone-Insulin-Iike Growth Factor Axis
326. Breast cancer stem cells cultured without Insulin and effect of estrogen induction
327. Breast cancer: Worse Prognosis in Insulin-Treated Diabetic Patients
328. Bufalin inhibited cell proliferation and expression of Insulin-like growth factor 2 and type 1 receptor in human colorectal cancer cells
329. C-105 Insulin and IGFBP-3 associated with lung cancer susceptibility in current smokers
330. c‐Src, Insulin‐like growth factor I receptor, G‐protein‐coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes
331. CA repeat polymorphism in the Insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia
332. Caffeine and caffeic acid inhibit growth and modify estrogen receptor (ER)-α and Insulin-like growth factor I receptor (IGF-IR) levels in human breast cancer
333. Caffeine and caffeic acid inhibit growth and modify estrogen receptor and Insulin-like growth factor I receptor levels in human breast cancer
334. Caloric restriction and Insulin-like growth factors in aging and cancer
335. Calories and cancer: the role of Insulin-like growth factor-1
336. Can the Insulin-like growth factors regulate breast cancer growth?
337. cancer and Insulin-like growth factor-I: a potential mechanism linking the environment with cancer risk
338. cancer at Insulin injection site
339. cancer causes metabolic perturbations associated with reduced Insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular …
340. cancer causes metabolic perturbations associated with reduced Insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion
341. cancer cell-derived clusterin modulates the phosphatidylinositol 3′-kinase-Akt pathway through attenuation of Insulin-like growth factor 1 during serum deprivation
342. cancer incidence among those initiating Insulin therapy with glargine versus human NPH Insulin
343. cancer incidence and mortality in patients with Insulin-treated diabetes: a UK cohort study
344. cancer incidence and mortality in patients with type 2 diabetes treated with human Insulin: a cohort study in Shanghai
345. cancer occurrence in Danish diabetic patients: duration and Insulin effects
346. cancer risk among Insulin users: comparing analogues with human Insulin in the CARING five-country cohort study
347. cancer risk associated with Insulin glargine among adult type 2 diabetes patients–a nationwide cohort study
348. cancer risk factors associated with Insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status
349. cancer specific mortality in Insulin-treated type 2 diabetes patients
350. cancer-drug induced Insulin resistance: innocent bystander or unusual suspect
351. cancer: A Paradoxical Form of Adaptation? Insulin-Cortisol Dominance and Epigenetic Aspects
352. Carbohydrate restriction, prostate cancer growth, and the Insulin‐like growth factor axis
353. Cardiopulmonary fitness, adiponectin, chemerin associated fasting Insulin level in colorectal cancer patients
354. Cardiovascular risk and Insulin resistance in childhood cancer survivors
355. CARING (cancer Risk and Insulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants-a systematic review and a …
356. Case–control study of markers of Insulin resistance and endometrial cancer risk
357. Castration aggravates Insulin resistance, reduces immune function and improves quality of life of prostate cancer patients
358. Celecoxib inhibits Insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer
359. Cell-associated Insulin-like growth factor-binding proteins inhibit Insulin-like growth factor-I-induced endometrial cancer cell proliferation.
360. Cell-Cell Adhesion and Insulin-Like Growth Factor I Receptor in Breast cancer
361. Central and Peripheral Effects of Insulin/IGF‐1 Signaling in Aging and cancer: Antidiabetic Drugs as Geroprotectors and Anticarcinogens
362. Ceritinib aggravates glycemic control in Insulin-treated patients with diabetes and metastatic ALK-positive lung cancer
363. Cervical Epidermal Growth Factor‐Receptor (EGF‐R) and Serum Insulin‐Like Growth Factor II (IGF‐II) Levels are Potential Markers for Cervical cancer 1
364. Cetuximab-induced Insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells
365. Challenges in modulating Insulin receptor signalling as a therapeutic strategy for cancer
366. Change of the growth hormone–Insulin-like growth factor-I axis in patients with gastrointestinal cancer: related to tumour type and nutritional status
367. Changes in glucose, Insulin, and Insulin resistance from presurgery to post adjuvant treatment for breast cancer.
368. Changes in Insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
369. Changes in metabolic risk, Insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors
370. Changes of androgen receptor and Insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
371. Changes of CD4+ CD25+ Foxp3+ regulatory T cells in the peripheral blood and their correlation with Insulin resistance in different stages of prostate cancer
372. Characterization of an amino-terminal fragment of Insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells
373. Characterization of Insulin regulation of lipid synthesis in MCF-7 human breast cancer cells
374. Characterization of Insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines.
375. Characterization of Insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of …
376. Characterization of Insulin-like growth factor binding proteins from human breast cancer cells
377. Characterization of Insulin-like growth factor I (IGF-I) receptors of human breast cancer cells
378. Characterization of Insulin-like growth factor I binding sites in human bladder cancer cell lines
379. Characterization of Insulin-like growth factor I receptors and growth effects in human lung cancer cell lines
380. Characterization of Insulin-like growth factor II receptors in human small cell lung cancer cell lines
381. Characterization of the Insulin and Transferrin Receptors of Two cancer Cell Lines.
382. Characterization of the Role of Insulin, IGF-1 and their Receptor Signaling in Proliferation and Survival of Non-Small Cell Lung cancer Cells
383. Characterization of the Role of Integrins in Insulin Like Growth Factor 1 and 2 (IGF1 and IGF2) Intracellular Signaling In cancer
384. Characterizing the role of Insulin signalling in advanced prostate cancer
385. Chemoresistance in pancreatic cancer is driven by stroma-derived Insulin-like growth factors
386. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to Insulin-like growth factor-I receptor inhibition
387. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 Insulin‐like growth factor receptor
388. Cholesterol synthetase DHCR24 induced by Insulin aggravates cancer invasion and progesterone resistance in endometrial carcinoma
389. Chronic inhibition of mammalian target of rapamycin signaling downregulates Insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and …
390. Chronic Insulin exposure does not cause Insulin resistance but is associated with chemo-resistance in colon cancer cells
391. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver cancer Risks: A Nationwide Population-Based Study
392. Chronological Effect on Insulin and Glycemic Status in cancer Pain Patients
393. Cigarette smoking exposure, serum Insulin-like growth factors, and cancer risk: A population-based study
394. Circ_0000003 promotes the proliferation and metastasis of non-small cell lung cancer cells via miR-338-3p/Insulin receptor substrate 2
395. Circadian aspects of growth hormone–Insulin-like growth factor axis function in patients with lung cancer
396. Circulating adipokines data associated with Insulin secretagogue use in breast cancer patients
397. Circulating concentrations of Insulin-like growth factor I and risk of breast cancer
398. Circulating free Insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case …
399. Circulating growth factors data associated with Insulin secretagogue use in women with incident breast cancer
400. Circulating Insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women
401. Circulating Insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
402. Circulating Insulin-like growth factor binding protein-1 and the risk of pancreatic cancer
403. Circulating Insulin-like growth factor-1 level and ovarian cancer risk
404. Circulating Insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
405. Circulating Insulin-like growth factor-I and binding protein-3 and the risk of breast cancer
406. Circulating Insulin-like growth factor-I in pregnancy and maternal risk of breast cancer
407. Circulating Insulin-like growth factor-I levels regulate colon cancer growth and metastasis
408. Circulating Insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case–control study ProtecT
409. Circulating Insulin‐like growth factor I in relation to melanoma risk in the European Prospective investigation into cancer and nutrition
410. Circulating Insulin‐like growth factor peptides and prostate cancer risk: a systematic review and meta‐analysis
411. Circulating Insulin‐like growth factor‐I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank
412. Circulating interleukin 6 concentrations and Insulin resistance in patients with cancer
413. Circulating Levels of C-Peptide (Pancreatic Marker of Insulin Secretion) in Cervical cancer
414. Circulating levels of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and …
415. Circulating levels of Insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
416. Circulating levels of Insulin-like growth factors, their binding proteins, and breast cancer risk
417. Circulating levels of Insulin‐like growth factor I, its binding proteins‐1,‐2,‐3, C‐peptide and risk of postmenopausal breast cancer
418. Circulating levels of Insulin‐like growth factor‐I and risk of ovarian cancer
419. Circulation Insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis
420. Classifying the adverse mitogenic mode of action of Insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel
421. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor Insulin-like growth factor-1
422. Clinical implications of Insulin-like growth factor 1 system in early-stage cervical cancer
423. Clinical implications of Insulin-like growth factor I (IGF-I) and II (IGF-II) in stage IIIB cervical cancer.
424. Clinical prospects of Insulin-like growth factors and IGF binding proteins study in blood serum of ovarian cancer patients
425. Clinical relevance of Insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
426. Clinical significance of Insulin like growth factor binding protein 3 in patients with lung cancer
427. Clinical significance of Insulin receptor substrate-I down-regulation in non-small cell lung cancer
428. Clinical Significance of Insulin-like Growth Factor 1 and Insulin Like Growth Factor Binding Protein 3 in Serum of Patients with Lung cancer [J]
429. Clinical significance of Insulin-like growth factor 1 receptor (IGF1R) expression in pancreatic cancer
430. Clinical significance of Insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer
431. Clinical significance of Insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis
432. Clinical significance of Insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small cell lung cancer
433. Clinical significance of Insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer
434. Clinical significance of measurement of serum Insulin-like growth factor Ⅱ levels in patients with cervical cancer [J]
435. Clinical significance of serum Insulin like growth factor 1 and Insulin like growth factor binding protein 3 in prostate cancer and benign prostatic hyperplasia
436. Clinical significance of serum Insulin-like growth factor-1 (IGF-1) and Insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer
437. Clinical significance of serum Insulin-like growth factor-1 (IGF-1) and Insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer
438. Clinical significance of serum Insulin-like growth factor-1 levels in prostatic cancer
439. Clinical value of circulating lipocalins and Insulin-like growth factor axis in pancreatic cancer diagnosis
440. Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic cancer Diagnosis
441. Clinical value of selected markers of angiogenesis, inflammation, Insulin resistance and obesity in type 1 endometrial cancer
442. Clinical value of serum level of Insulin-like growth factor-1 diagnosis and treatment for gastric and colorectal cancer
443. Clinical, haemodynamic, anthropometric, metabolic and Insulin profile of men with high‐stage and high‐grade clinical prostate cancer
444. Clinicopathological implication of Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) expression in gastric cancer
445. Clinicopathological significance of Insulin-like growth factor-1 receptor expression in breast cancer.
446. Cloning of a novel Insulin-regulated ghrelin transcript in prostate cancer
447. Co-expression of genes of the Insulin-and estrogen signaling system and correlation with clinical parameters in breast cancer patients
448. Co-inhibition of epidermal growth factor receptor and Insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells
449. Co-operativity between oestrogen and Insulin/IGF-I in the control of breast cancer cell proliferation.
450. Co-targeting HER2/ErbB2 and Insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
451. Co-targeting Insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer
452. Co-targeting leptin and Insulin-like growth factor I signaling: dramatic effects of epidermal growth factor receptor inhibitors on triple negative breast cancer cells.
453. Co-targeting the HER and IGF/Insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
454. Co-targeting the Insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
455. Cohort study of Insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes
456. Colon cancer promotion, Insulin resistance and metabolic measures, the role of dietary calcium, vitamin D and fat
457. Colorectal cancer and pancreatic cancer in patients with type 2 diabetes mellitus. Study of the effect of Insulin therapy
458. COLORECTAL cancer AND THE GROWTH HORMONE/Insulin-LIKE GROWTH FACTOR-I AXIS
459. Colorectal cancer mortality and factors related to the Insulin resistance syndrome
460. Colorectal cancer: Genomic variations in Insulin-like growth factor-1 and-2
461. Combination of Insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer
462. Combination therapy approaches to target Insulin-like growth factor receptor signaling in breast cancer
463. Combination therapy of Insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo
464. Combination treatment strategies with a focus on rosiglitazone and adriamycin for Insulin resistant liver cancer
465. Combined in vivo effect of A12, a type 1 Insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors
466. Combined inhibition of Insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line
467. Combined treatment with GH, Insulin, and indomethacin alleviates cancer cachexia in a mouse model
468. Comment on association between Insulin-like growth factor-I (IGF-I) and bone mineral density: further evidence linking IGF-I to breast cancer risk
469. Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident cancer: A Retrospective Cohort Study of Older Medicare …
470. Comment on: Need for Differentiating Diabetes-Specific Mortality from Total Mortality when Comparing Metformin with Insulin Regarding cancer Survival
471. Comment on: Yang et al.(2010) Associations of Hyperglycemia and Insulin Usage With the Risk of cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry …
472. Comment on: Yang et al.(2010) Associations of hyperglycemia and Insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes …
473. Commentary on Validation of the type 1 Insulin-like growth factor receptor as a therapeutic target in renal cancer: Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S …
474. Comparative Analysis of Insulin-like Growth Factor I and Tumour-associated Antigens in cancer Patients at the Time of Diagnosis
475. Comparative gene expression and proteomic analysis of IGF-I and Insulin signaling in a large panel of breast cancer cell lines
476. Comparative study of blood Insulin levels in breast and endometrial cancer patients
477. Comparative study of Insulin resistance after open and laparoscopic Miles radical resection of rectal cancer
478. Comparing pioglitazone to Insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights
479. Comparison of clinical efficacy between laparotomy and laparoscopic radical surgery for gastric cancer and their effects on CRP, CEA and Insulin resistance.
480. Comparison of telomere length and Insulin‐like growth factor‐binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in …
481. Comparisons of Endothelial Dysfunction, Inflammation and Insulin Resistance in Differentiated Thyroid cancer Patients According to Their Radioactive Iodine …
482. Compensatory Insulin receptor (IR) activation on inhibition of Insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
483. Compensatory Insulin receptor (IR) activation upon inhibition of Insulin-like growth factor receptor (IGF-1R): Rationale for co-targeting IGF-1R and IR in cancer
484. Comprehensive analysis of expression patterns of Insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent …
485. Comprehensive analysis of potential predictive biomarkers for Insulin-like growth factor type-1 receptor (IGF-1R) targeted therapy in pancreatic cancer.
486. Concentration of Insulin-like growth factor is linked with breast cancer
487. Concordant loss of imprinting of the human Insulin-like growth factor II gene promoters in cancer
488. Conditioned media from MCF7 and BT474 breast cancer cells induce Insulin resistance in skeletal muscle myotubes
489. Conjugated linoleic acid decreases mcf-7 human breast cancer cell growth and Insulin-like growth factor-1 receptor levels
490. Conjugated linoleic acid downregulates Insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells
491. Connecting Pathway Errors in the Insulin Signaling Cascade: The Molecular Link to Inflammation, Obesity, cancer, and Alzheimer’s Disease
492. Constitutive Activation of Insulin Receptor Substrate 1 in Breast cancer: Therapeutic Implication
493. Consumption of fresh yellow onion ameliorates hyperglycemia and Insulin resistance in breast cancer patients during doxorubicin-based chemotherapy: a …
494. Control of Expression of Insulin-Like Growth Factor II in Stromal Cells of Breast cancer
495. Control of luminal type A intrinsic subtype enriched transcription factor network by Insulin: implications of diabetes on breast cancer classification.
496. Correction: Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD
497. Correlation among Insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture
498. Correlation between Body Mass Index, Insulin and Insulin-like Growth Factor-1 in Breast cancer Research [J]
499. Correlation between Insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer
500. Correlation of Insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
501. Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast cancer in the UAE
502. Correlation of Insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice
503. Correlation of Insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors …
504. Correlation of proliferation of pancreatic cancer cells with both saturation index and cell membrane Insulin receptors
505. Correlation of Proliferation of Pancreatic cancer Cells With Both Saturation Index and Cell Membrane Insulin Receptors
506. Correlation of Serum Insulin-like Growth Factor 1 with Prostate cancer
507. Correlation of the sectetion of Insulin and C-peptide in cancer patients
508. Correlations of Insulin-like growth factor I and Insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer.
509. Correlations of recurrence after radical surgery for esophageal cancer with glucose-lipid metabolism, Insulin resistance, inflammation, stress and serum p53 …
510. Corrigendum to” Effects of a home-based exercise program on the Insulin-like growth factor axis in patients operated for colorectal cancer in Sweden: Results from the …
511. Could exemestane affect Insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on …
512. Critical appraisal of the recent data published on the link between Insulin and cancer
513. Cross-talk among estrogen receptor, epidermal growth factor, and Insulin-like growth factor signaling in breast cancer
514. Cross-talk between the ErbB/HER family and the type I Insulin-like growth factor receptor signaling pathway in breast cancer
515. Cross-talk between β1 Integrins and Insulin-like Growth Factor I Receptor in Prostate cancer
516. Crosstalk between epidermal growth factor receptor-and Insulin-like growth factor-1 receptor signaling: implications for cancer therapy
517. Crosstalk between Insulin receptor and G protein-coupled receptor signaling systems leads to Ca2+ oscillations in pancreatic cancer PANC-1 cells
518. Crosstalk between Insulin-like growth factor 1 signaling and the estrogen receptor: Implications for breast cancer cell survival
519. Crosstalk between Insulin/IGF-1 and GPCR signaling systems: a novel target for the anti-diabetic drug metformin in pancreatic cancer
520. Crosstalk between Runx2 regulatory network and Insulin-like growth factor receptor/Akt signaling pathway in bone metastasis of breast cancer
521. Crosstalk between the Insulin-like growth factors and estrogens in breast cancer
522. Crosstalk of the Insulin-like growth factor receptor with the Wnt signaling pathway in breast cancer
523. Curcumin upregulates Insulin‐like growth factor binding protein‐5 (IGFBP‐5) and C/EBPα during oral cancer suppression
524. Cyclooxygenase-2 modulates the Insulin-like growth factor axis in non–small-cell lung cancer
525. Cytotoxic gene therapy for human breast cancer in vitro using thymidine kinase directed by the Insulin promoter
526. Data report on inflammatory C–C chemokines among Insulin-using women with diabetes mellitus and breast cancer
527. Dataset on granulopoiesis-and lymphopoiesis-stimulating cytokine levels in Insulin secretagogue users with incident breast cancer
528. Dataset on growth factor levels and Insulin use in patients with diabetes mellitus and incident breast cancer
529. De novo lipogenesis is required for Insulin-mediated hepatocarcinogenesis and contributes to human liver cancer prognosis
530. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on Insulin-like growth factor-1 and …
531. Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer
532. Decreased expression of the mannose 6-phosphate/Insulin-like growth factor-II receptor promotes growth of human breast cancer cells
533. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using Insulin: a pilot study
534. Decreased production of Insulin‐like growth factor‐binding protein (IGFBP)‐6 by transfection of colon cancer cells with an antisense IGFBP‐6 cDNA construct leads to …
535. Decreased prostate cancer cell migration by inhibition of the Insulin-like growth factor II/Mannose-6-Phosphate receptor
536. Decreased serum levels of Insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels.
537. Deficiency of proton-sensing ovarian cancer G protein-coupled receptor 1 attenuates glucose-stimulated Insulin secretion
538. Defining the Critical role for the Insulin-Like Growth Factor-1 (IGF-1) axis in prostate cancer using genetically engineered mouse (GEM) models
539. Defining the pathway to Insulin-like growth factor system targeting in cancer
540. Degradation of Insulin‐like growth factor‐I receptor occurs via ubiquitin‐proteasome pathway in human lung cancer cells
541. Dehydroepiandrosterone, Insulin-like growth factor-I, and prostate cancer
542. Deleterious Effect of Chemotherapy on Measures of Insulin Resistance in Patients with Newly-Diagnosed Invasive Breast cancer.
543. Demonstration of Insulin-like growth factor (IGF-I and-II) receptors and binding protein in human breast cancer cell lines
544. Demonstration of receptors for Insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.
545. Depletion of Insulin-like growth factor 1 receptor increases radiosensitivity in colorectal cancer
546. Detection of Insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues
547. Determination of the levels of serum leptin and Insulin in patients with primary liver cancer and correlative analysis
548. Development and preclinical evaluation of cixutumumab drug conjugates in a model of Insulin growth factor receptor I (IGF-1R) positive cancer
549. Development of an insturmal method to evaluate Insulin receptors and Insulin-like growth factor-1 receptors homodimers and hybrid receptors in breast cancer
550. Development of resistance to Insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells
551. Development of the monoclonal antibody figitumumab, targeting the Insulin-like growth factor-1 receptor, for the treatment of patients with non–small-cell lung cancer
552. Diabetes and Insulin therapy, but not metformin, are related to hepatocellular cancer risk
553. Diabetes but not Insulin increases the risk of lung cancer: a Taiwanese population-based study
554. Diabetes but not Insulin is associated with higher colon cancer mortality
555. Diabetes may increase risk for oral cancer through the Insulin receptor substrate-1 and focal adhesion kinase pathway
556. Diabetes mellitus and increased risk of cancer: focus on metformin and the Insulin analogs
557. Diabetes mellitus, genetic variants in the Insulin‐like growth factor pathway and colorectal cancer risk
558. Diabetes mellitus, Insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort
559. Diabetes, body fatness, and Insulin prescription among adolescents and young adults with cancer
560. Diabetes, Insulin and cancer risk
561. Diabetes, Insulin and cancer risk The molecular role of Insulin signaling and hyperInsulinemia in cancer development and progression in diabetes patients
562. Diabetes, Insulin and cancer risk: you and your patient
563. Diabetes, Insulin Resistance, and cancer: An Update
564. Diabetes, Insulin resistance, and metabolic syndrome in women at high risk for breast cancer.
565. Diabetes, Insulin therapy, and colorectal cancer
566. Diabetes, Insulin treatment, and cancer risk: what is the evidence?
567. Diabetes, Insulin use, and cancer risk: are observational studies part of the solution–or part of the problem?
568. Diabetes, Insulin use, and gastric cancer: a population-based analysis of the Taiwanese
569. Diabetes, Insulin use, smoking, and pancreatic cancer mortality in Taiwan
570. Diabetes, Insulin-use and risk of colorectal cancer in a US cohort study
571. Diabetes, Insulin, and risk of cancer
572. Diabetes, obesity, Insulin resistance: different pathways to cancer?
573. Diagnostic accuracy of serum Insulin-like growth factor-binding protein 2 for ovarian cancer
574. Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal cancer
575. Diarylureas are small-molecule inhibitors of Insulin-like growth factor I receptor signaling and breast cancer cell growth
576. Diazoxide for Lowering Insulin Levels in Breast cancer Patients
577. Diet and Endometrial cancer: Insulin related factors
578. Diet-induced obesity and Insulin resistance spur tumor growth and cancer cachexia in rats bearing the yoshida sarcoma
579. Diet, Insulin-like growth factor-1 and cancer risk
580. Dietary and pharmacological modification of the Insulin/IGF-1 system: exploiting the full repertoire against cancer
581. Dietary energy balance modulation of Kras-and Ink4a/Arf+/−-driven pancreatic cancer: the role of Insulin-like growth factor-I
582. Dietary fiber is associated with serum sex hormones and Insulin-related peptides in postmenopausal breast cancer survivors
583. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of Insulin-like growth factor and epidermal growth factor receptor
584. Dietary glycemic and Insulin scores and colorectal cancer survival by tumor molecular biomarkers
585. Dietary glycemic index, glycemic load and Insulin index, in relation to risk of prostate cancer
586. Dietary glycemic index, glycemic load, Insulin index, fiber and whole-grain intake in relation to risk of prostate cancer
587. Dietary Insulin index and Insulin load in relation to endometrial cancer risk in the Nurses’ Health Study
588. Dietary Insulin load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803 (Alliance)
589. Dietary Insulin load, dietary Insulin index, and colorectal cancer
590. Dietary Insulin load, dietary Insulin index, and risk of pancreatic cancer–
591. Different contribution of substrates oxidation to Insulin resistance in malnourished elderly patients with cancer
592. Different expression of liver-specific Insulin-like growth factor I gene in breast cancer; expression with mice
593. Differential effects of Insulin and IGF1 receptors on ERK and AKT subcellular distribution in breast cancer cells
594. Differential effects of Insulin-like growth factor binding protein-6 (IGFBP-6) on migration of two ovarian cancer cell lines
595. Differential effects of Insulin-like growth factor-1 CA repeat polymorphism on breast cancer risk along with race: a meta-analysis
596. Differential effects of metformin on breast cancer proliferation according to Insulin resistance and tumor subtype in a presurgical trial.
597. Differential effects of metformin on breast cancer proliferation according to markers of Insulin resistance and tumor subtype in a randomized presurgical trial
598. Differential expression and signaling activation of Insulin receptor isoforms A and B: a link between breast cancer and diabetes
599. Differential expression of IGF-I and Insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines
600. Differential expression of Insulin receptor isoforms in human lung cancer.
601. Differential expression of Insulin-like growth factor 1 in human primary liver cancer.
602. Differential expression of Insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer
603. Differential expression of Insulin-like growth factor binding proteins in human non-small cell lung cancer cell lines
604. Differential Expression of Insulin‐Like Growth Factor‐1 Receptor in Breast cancer Subtypes: A Marker of Early Metastasis in HER‐2 Subtype
605. Differential expression of the Insulin-like growth factor receptor among early breast cancer subtypes
606. Differential expression of the mannose 6-phosphate/Insulin-like growth factor-II receptor in human breast cancer cell lines of different invasive potential.
607. Differential expression patterns of the Insulin-like growth factor 2 gene in human colorectal cancer
608. Differential impacts of Insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development
609. Differential Insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells
610. Differential Insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity
611. Differential regulation of Insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-β1
612. Differential regulation of Insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells
613. Differential Roles of Insulin Receptor Substrate-1 and-2 (IRS-1, IRS-2) in Insulin-Like Growth Factor Signaling in Breast cancer Cells
614. Diffusion of Insulin-like growth factor 1 in human breast cancer explants
615. Direct inhibition of growth and antagonism of Insulin action by glucocorticoids in human breast cancer cells in culture
616. Discoidin domain receptor 1 modulates Insulin receptor signaling and biological responses in breast cancer cells
617. Disrupting Insulin and IGF Receptor Function in cancer
618. Disrupting Insulin-like growth factor signaling as a potential cancer therapy
619. Disruption of Insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells
620. Disruption of ligand binding to the Insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations
621. Dissecting the cellular and molecular mechanisms of Insulin-like growth factor binding protein-2 (IGFBP-2) action in a cancer cell model
622. Distribution of a single nucleotide polymorphism of Insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma
623. Diverse functions of IGF/Insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells
624. Diversity of Insulin and IGF signaling in breast cancer: implications for therapy
625. DNA repair, Insulin signaling and sirtuins: at the crossroads between cancer and aging.
626. Do Insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients
627. Do Insulin-like growth factors mediate the effect of alcohol on breast cancer risk?
628. Doctors seek to prevent breast cancer recurrence by lowering Insulin levels
629. Does Insulin glargine increase the risk of cancer compared with other basal Insulins?: A French nationwide cohort study based on national administrative databases
630. Does Insulin resistance influence breast cancer outcomes?
631. Does Insulin-like growth factor moderate the association between height and risk of cancer at 24 sites?
632. Does milk intake promote prostate cancer initiation or progression via effects on Insulin-like growth factors (IGFs)? A systematic review and meta-analysis
633. Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, Insulin, and IGF-1 serum levels in breast cancer patients?
634. Does the negative correlation found in breast cancer patients between plasma melatonin and Insulin-like growth factor-I concentrations imply the existence of an …
635. Dominant‐negative effect of truncated mannose 6‐phosphate/Insulin‐like growth factor II receptor species in cancer
636. Dopamine, by acting through its D2 receptor, inhibits Insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel …
637. Dose–response effects of exercise on Insulin among colon cancer survivors
638. Doses of Insulin and its analogues and cancer occurrence in Insulin-treated type 2 diabetic patients
639. Down-regulation of the Insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines
640. Down-regulation of type I Insulin-like growth factor receptor increases sensitivity of breast cancer cells to Insulin
641. Down‐regulation of Insulin‐like growth factor‐I receptor and Insulin receptor substrate‐1 expression in advanced human breast cancer
642. Downregulation of Insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer
643. Downregulation of microRNA‑126 is inversely correlated with Insulin receptor substrate‑1 protein expression in colorectal cancer and is associated with advanced …
644. Downregulation of type I IGF receptor increases Insulin sensitivity of breast cancer cells
645. DPP4i, thiazolidinediones, or Insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate …
646. Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the Insulin-like growth factor receptor/Insulin receptor inhibitor, BMS-536924.
647. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole Insulin-like growth factor receptor/Insulin receptor inhibitor, BMS …
648. Drug evaluation: CP-751871, a human antibody against type I Insulin-like growth factor receptor for the potential treatment of cancer.
649. Dual blockade of epidermal growth factor receptor and Insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized …
650. Dual role of Insulin-like growth factor-1 in acetyl-CoA carboxylase-alpha activity in human colon cancer cells HCT-8: downregulating its expression and …
651. Dual silencing of Insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and …
652. Dual silencing of type 1 Insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells
653. Dual targeting of the Insulin-like growth factor and collateral pathways in cancer: combating drug resistance
654. Early and progressive Insulin resistance in young, non‐obese cancer survivors treated with hematopoietic stem cell transplantation
655. Early Breast cancer Agressiveness does not Differ Between Insulin-Sensitive and Insulin-Resistant Postmenopausal Non-Diabetic Women
656. Early changes of muscle Insulin‐like growth factor‐1 and myostatin gene expression in gastric cancer patients
657. Early diet and later cancer risk: prospective associations of dietary patterns during critical periods of childhood with the GH-IGF axis, Insulin resistance and body …
658. Early placenta Insulin-like growth factor (EPIL) indicates highly motile breast cancer cells and poor prognostic breast cancer subgroups
659. Editor’s Note: Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-small Cell Lung cancer Xenografts by Targeting Insulin-Like Growth Factor Binding …
660. Effect of 12 weeks of selected Pilates exercise training on serum adiponectin level and Insulin resistance in female survivors of breast cancer and its role in prevention …
661. Effect of 12-week home-based exercise program on fasting Insulin in stage II-III colorectal cancer survivors: A randomized controlled trial.
662. Effect of aerobic exercise intervention on markers of Insulin resistance in breast cancer women
663. Effect of AMPK/mTOR/S6K1 pathways and the Insulin-sensitizing effect for adiponectin in endometrial cancer cells
664. Effect of Androgen Deprivation Therapy on Indices of Glycaemia and Insulin Resistance in Native African Prostate cancer Patients
665. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and Insulin metabolism—A systematic review
666. Effect of cholecystokinin and secretin on Insulin binding to rat pancreatic acini and pancreatic cancer cell line AR42J cells
667. Effect of diallyl disulfide on Insulin-like growth factor signaling molecules involved in cell survival and proliferation of human prostate cancer cells in vitro and in silico …
668. Effect of different doses of metformin on serum testosterone and Insulin in non-diabetic women with breast cancer: a randomized study
669. Effect of dual inhibition of the Src and Insulin-like growth factor-1 receptor (IGF-1R) pathways on antitumor effects in prostate cancer (PCa).
670. Effect of elevated basal Insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study
671. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of Insulin-like growth factor II (IGF-II)
672. Effect of Fast Track Surgery on Insulin Resistance Indexes and Inflammatory Reaction in Colorectal cancer Patients with Laparoscopic Surgery
673. Effect of fast track surgery on Insulin resistance indexes of esophageal cancer patients
674. Effect of fenretinide and low-dose tamoxifen on Insulin sensitivity in premenopausal women at high risk for breast cancer
675. Effect of FTS on TRB3 Expression of Insulin Signaling Pathway in Patients with Colorectal cancer.
676. Effect of glargine on Insulin resistance in type 2 diabetic patients with esophageal cancer during perioperative period [J]
677. Effect of home-based exercise intervention on fasting Insulin and adipocytokines in colorectal cancer survivors: a randomized controlled trial
678. Effect of human Insulin on breast cancer risk in Taiwanese women with type 2 diabetes.
679. Effect of inhibition of Src and Insulin/Insulin-like growth factor-1 receptor (IR/IGF-1R) on tumor activity and bone turnover in prostate cancer (PCa) models in vivo …
680. Effect of Insulin at dilution endpoint concentrations on macromolecular synthesis in normal mouse mammary and human breast cancer epithelial cells
681. Effect of Insulin glargine and human Insulin on proliferation of a human breast cancer cell line MDA-MB-231
682. Effect of Insulin like growth factor binding protein 3 on non-small cell lung cancer
683. Effect of Insulin on cell cycle progression in MCF-7 breast cancer cells: direct and potentiating influence
684. Effect of Insulin on functional status of cord blood-derived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines.
685. Effect of Insulin on the proliferation of human breast cancer cell line MDA-MB-543 growth
686. Effect of Insulin-like growth factor 1 receptor inhibitor on sensitization of head and neck cancer cells to cetuximab and methotrexate
687. Effect of Insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells
688. Effect of Insulin-like growth factor binding protein-3 (IGFBP-3) on colon cancer epithelial cells growth and apoptosis
689. Effect of Insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer
690. Effect of Insulin-like growth factor-I (IGF-I) on apoptosis of colon cancer cell and its mechanism
691. Effect of Insulin-like Growth Factor-I on Apoptosis of Colon cancer Cell Through Signaling Pathway of PI-3K/Akt
692. Effect of intensive Insulin therapy on glutathione synthesis rate in cancer patients with stress hyperglycemia after major surgery.
693. Effect of intensive Insulin therapy on the clinical results of postoperative patients with gastric cancer
694. Effect of intraoperative glucose and Insulin infusion on the metabolism in patients undergoing esophageal cancer surgery under combined general anesthesia with …
695. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the Insulin-like growth factor axis
696. Effect of isoliquiritigenin (ISL) on Insulin‐like growth factor‐I receptor and ErbB3 signaling in prostate cancer cells
697. Effect of kaempferol on Insulin‐like growth factor‐I receptor and ErbB3 signaling in HT‐29 human colon cancer cells
698. Effect of L-arginine supplementation on Insulin resistance and adipocitokines levels in head and neck cancer non diabetic patients after surgery
699. Effect of long-acting Insulin analogs on the risk of cancer: a systematic review of observational studies
700. Effect of lycopene on Insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells
701. Effect of lycopene on the Insulin-like growth factor-I receptor signaling pathway in human colon cancer HT-29 cells
702. Effect of metformin and Insulin-/IGF1-receptor inhibitor combination drug therapy in triple negative breast cancer
703. Effect of metformin on Insulin binding to receptors in cultured human lymphocytes and cancer cells
704. Effect of obesity on plasma Insulin-like growth factor-I in cancer patients.
705. Effect of systemic Insulin on protein kinetics in postoperative cancer patients
706. Effect of tamoxifen on plasma Insulin-like growth factor I in patients with breast cancer
707. Effect of transforming growth factor-β 1, Insulin-like growth factor-I and Insulin-like growth factor-II on cell growth and oestrogen metabolism in human breast cancer …
708. Effect of Twelve Weeks Concurrent Yoga and Pilates Training on Glucose Homeostasis and Insulin Resistance in Breast cancer Survivors: A Clinical Trial Study
709. Effect of two 4-hydroxyandrostenedione doses on serum Insulin-like growth factor I levels in advanced breast cancer
710. Effect of type 1 Insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved
711. Effect of zinc on regulation of Insulin-like growth factor signaling in human androgen-independent prostate cancer cells
712. Effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) on Insulin-induced responses in MCF-7 human breast cancer cells
713. Effects of a 12-week home-based exercise program on the level of physical activity, Insulin, and cytokines in colorectal cancer survivors: a pilot study
714. Effects of a home-based exercise program on the Insulin-like growth factor axis in patients operated for colorectal cancer in Sweden: results from the randomised …
715. Effects of alcohol consumption on Insulin sensitivity and breast cancer development.
716. Effects of anti-Insulin-like growth factor-I receptor (IGF-IR) antibodies with or without the ER-retention signal KDEL on cancer cell growth
717. Effects of aromatase complex selective inhibition on Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 circulating levels in breast cancer
718. Effects of bisphosphonates and Insulin-like growth factor-1 (IGF-1) on prostate cancer cells in vitro
719. Effects of Carbohydrate-electrolyte Solution on Serum Glucose and Peptide C and Insulin Levels and Its Safety in Postoperative Patients with Lung cancer
720. Effects of different n-6/n-3 polyunsaturated fatty acid ratio on Insulin-like growth factor receptor-1 expression in human breast cancer cells
721. Effects of endogenous Insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells
722. Effects of exercise on Insulin, IGF axis, adipocytokines, and inflammatory markers in breast cancer survivors: a systematic review and meta-analysis
723. Effects of exogenous growth hormone on Growth Hormone-Insulin-Like growth factor axis of human gastric cancer cell
724. Effects of genetic blockade of the Insulin-like growth factor receptor in human colon cancer cell lines
725. Effects of Hormones on Tumor Growth and Immunoreactive Insulin–like Growth Factor–1 of Estrogen Receptor–positive Human Breast cancer (MCF‐7) Transplanted …
726. Effects of Insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer
727. Effects of Insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines
728. Effects of Insulin Degrading Enzyme (IDE)-activity on the liver cancer cell transcriptome
729. Effects of Insulin on human pancreatic cancer progression modeled in vitro
730. Effects of Insulin on proliferation and invasion of human pancreatic cancer PANC1 cells
731. Effects of Insulin-1ike growth factor 1 and its receptor on proliferation of ovarian cancer cells [J]
732. Effects of Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) on endometrial cancer (HHUA) cell apoptosis and EGF stimulated cell proliferation in vitro
733. Effects of Insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer
734. Effects of Insulin-like growth factor binding protein 7 gene on the biological characteristics of colorectal cancer
735. Effects of Insulin-like growth factor binding protein 7 on cell cycle and proliferation of gastric cancer in vitro and in vivo
736. Effects of Insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non–small-cell lung cancer cells
737. Effects of Insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells
738. Effects of Insulin-like growth factors I and II on oestrone sulphatase activity in human breast cancer cell lines.
739. Effects of isoflavones and lycopene on the Insulin-like growth factor (IGF) system in men and women at increased colorectal cancer risk; randomized cross-over trials.
740. Effects of isoflavones on the Insulin-like growth factor (IGF) system: A randomized trial in women with high colorectal cancer risk.
741. Effects of Long-acting Insulin Analogues on Breast and Colon cancer Promotion
742. Effects of lycopene on the Insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk
743. Effects of metformin on markers of Insulin resistance and on breast cancer proliferation: the putative role of IGFBP-1 as a predictive biomarker
744. Effects of monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against Insulin-like growth factor-I receptor, on colon cancer cell growth
745. Effects of octreotide and Insulin on colon cancer cellular proliferation and correlation with hTERT activity
746. Effects of quercetin on Insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer …
747. Effects of serum and Insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens
748. Effects of Tai Chi Chuan on Insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors
749. Effects of tamoxifen on Insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.
750. Effects of tumor removal and body weight loss on Insulin resistance in patients with cancer.
751. Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against Insulin-like growth factor-I receptor, on the growth of colon cancer cells
752. EGCG inhibits activation of the Insulin-like growth factor-1 receptor in human colon cancer cells
753. Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer
754. Eighteen Insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer
755. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH Insulin
756. Elevated epithelial Insulin-like growth factor expression is a risk factor for lung cancer development
757. Elevated Gluconeogenesis in Aging and Lung cancer is Related to Inflammation and Blunted Insulin‐Induced Protein Anabolism
758. Elevated Insulin and Insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population
759. Elevated Insulin receptor content in human breast cancer.
760. Elevated Insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
761. Elevated Insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with …
762. Elevated levels of Insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
763. Elevated serum Insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer
764. Elevated serum Insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer
765. Elevated serum Insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and …
766. Emodin increases expression of Insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer
767. Employing Quantitative Systems Pharmacology to Characterize Differences in IGF1 and Insulin Signaling Pathways in Breast cancer
768. Endogenous hyperInsulinaemia and exogenous Insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities
769. Endogenous Insulin contributes to pancreatic cancer development
770. Endometrial cancer Insulin-like growth factor 1 receptor (IGF1R) expression increases with body mass index and is associated with pathologic extent and prognosis
771. Endometrial expression of hormonal and Insulin/IGF receptors in relation to cancer risk factors
772. Endurance training improves Insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy
773. Energy balance and cancer: the role of Insulin and Insulin-like growth factor-I
774. Energy balance, Insulin resistance biomarkers, and breast cancer risk
775. Energy balance, Insulin‐related genes and risk of colon and rectal cancer
776. Energy imbalance, fat, fiber, and pancreatic cancer: Role of Insulin resistance
777. Energy restriction at young age, genetic variants in the Insulin‐like growth factor pathway and colorectal cancer risk in the Netherlands Cohort Study
778. Engineered ubiquitin ligase PTB-U-box targets Insulin/Insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy
779. Enhanced expression of Insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells
780. Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of Insulin-like growth factor-II
781. Enhanced expression of the Insulin receptor substrate-2 docking protein in human pancreatic cancer
782. Enhanced function of TRPV1 via up‐regulation by Insulin‐like growth factor‐1 in a rat model of bone cancer pain
783. Enhanced Insulin signaling via Shc in human breast cancer
784. Enhancement of 5-Flurouracil Uptake by Insulin in Human Colonic cancer
785. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of Insulin receptor and type I IGF receptor
786. Enhancement of Insulin-Like Growth Factor Signaling in Human Breast cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo
787. Enhancement of tumor necrosis factor-α-induced growth inhibition by Insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer …
788. Enhancing the apoptotic potential of Insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation
789. Epidemiology and biology of Insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule
790. Epidermal growth factor induces Insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell …
791. Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to Insulin‐like growth factor 1 receptor tyrosine kinase inhibitors
792. Epidermal growth factor receptor/HER2/Insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer
793. Epidermal growth factor, Insulin-like growth factor-1 and basic fibroblast growth factor modulate the cytostatic effect of tumour necrosis factor-α on the breast cancer …
794. Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of Insulin-like growth factor …
795. Epigenetic regulation of Insulin-like growth factor binding protein-3 (IGFBP-3) in cancer
796. Epithelial Insulin receptor expression–prognostic relevance in colorectal cancer
797. epithelial-to-mesenchymal transition in breast cancer: a role for Insulin-like growth factor i and Insulin-like growth factor–binding protein 3?
798. Epsilon-aminocaproic acid prevents high glucose and Insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system
799. Equol, adiponectin, Insulin levels and risk of breast cancer
800. erbB3 recruitment of Insulin receptor substrate 1 modulates Insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines
801. Erratum to: Non-metabolisable Insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes
802. Essential considerations in the investigation of associations between Insulin and cancer risk using prescription databases
803. Essential fatty acids, Insulin resistance, and breast cancer risk
804. Establishment and characterization of MCF-7 human breast cancer cell clones expressing an intracellular form of Insulin-like growth factor II (IGF-II)
805. Estradiol and antiestrogens regulate a growth inhibitory Insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
806. Estradiol and Insulin cross-talk in breast cancer.
807. Estradiol down-regulates the mannose-6-phosphate/Insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation …
808. Estradiol increases IRS-1 gene expression and Insulin signaling in breast cancer cells
809. Estrogen and Insulin crosstalk: breast cancer risk implications
810. Estrogen and Insulin modulation of intracellular Insulin-like growth factor binding proteins in human breast cancer cells: possible involvement in lysosomal hydrolases …
811. Estrogen and Insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways
812. Estrogen and Insulin synergistically promote type 1 endometrial cancer progression
813. Estrogen and Insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth
814. Estrogen and Insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1
815. Estrogen and progesterone regulate secretion of Insulin-like growth factor binding proteins by human breast cancer cells
816. Estrogen receptor-α regulates the degradation of Insulin receptor substrates 1 and 2 in breast cancer cells
817. Estrogen receptor-β and the Insulin-like growth factor axis as potential therapeutic targets for triple-negative breast cancer
818. Ethnic Differences in Insulin Resistance as a Mediator of cancer Disparities
819. Ethyl Acetate Fraction of Helianthus tuberosus L. Induces Anti-Diabetic, and Wound-Healing Activities in Insulin-Resistant Human Liver cancer and Mouse Fibroblast …
820. Evaluating associations of diabetes, Insulin use, and BMI with efficacy in patients with resected pancreatic cancer: An ancillary analysis of NRG Oncology/RTOG 9704.
821. Evaluating serum Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis
822. Evaluation of breast cancer cell lines (MCF-7 & T47D): influence of Insulin and metformin on growth parameters
823. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of Insulin-like growth factors (IGFs) and IGF-binding proteins.
824. Evaluation of drug resistance to doxorubicin in MCF-7 breast cancer cell line as a result of Insulin treatment
825. Evaluation of Insulin like growth facror-1 genetic polymorphism with gastric cancer susceptibility and clinicopathological features
826. Evaluation of Insulin resistance among endometrial cancer patients.
827. Evaluation of Insulin-like Growth Factor Receptor 1 Inhibition as a Treatment for Prostate cancer: Preclinical Efficacy and Resistance
828. Evaluation of Insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene
829. Evaluation of the Insulin-like growth factor receptor pathway in patients with advanced breast cancer treated with trastuzumab
830. Evaluation of the Insulin-like growth factors (IGF) IGF-I and IGF binding protein 3 in patients at high risk for breast cancer
831. Evidence for autocrine mitogenic stimulation by somatomedin-C/Insulin-like growth factor I on an established human lung cancer cell line
832. Evidence of direct mitogenic activity of Insulin and the Insulin receptor in prostate cancer cell lines
833. Exercise intervention lowers aberrant serum WISP-1 levels with Insulin resistance in breast cancer survivors: a randomized controlled trial
834. Exosomal miR‑130a‑3p promotes the progression of differentiated thyroid cancer by targeting Insulin‑like growth factor 1
835. Exosomes derived from pancreatic cancer cells induce Insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway
836. Exploitation of the Ligand-Binding Properties of the Mannose 6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor to Inhibit IGF-II-Dependent Growth of cancer …
837. Expression and Activity of Both IGF and Insulin Signaling Pathways in a Large Panel of Breast cancer Cell Lines.
838. Expression and clinical significance of Insulin-like growth factor 1 in lung cancer tissues and perioperative circulation from patients with non-small-cell lung cancer
839. Expression and Clinical Significance of Insulin-like Growth Factor-Ⅰand Insulin-like Growth Factor-Ⅱ in Gastric cancer [J]
840. Expression and clinical significance of sushi domain-containing protein 3 (SUSD3) and Insulin-like growth factor-I receptor (IGF-IR) in breast cancer
841. Expression and function of the Insulin receptor substrate proteins in cancer
842. Expression and function of the Insulin‐like growth factor I system in human non‐small‐cell lung cancer and normal lung cell lines
843. Expression and prognostic analyses of the Insulin-like growth factor 2 mRNA binding protein family in human pancreatic cancer
844. Expression and prognostic significance of Insulin-like growth factor 1 in non-small-cell lung cancer [J]
845. Expression characteristics of proteins of the Insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus
846. Expression level of Insulin‐like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer
847. Expression levels of Insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer
848. Expression of a protease-resistant Insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer
849. Expression of early placenta Insulin-like growth factor (EPIL) in breast cancer cells provides an autocrine loop with enhancement of predominantly HER-2-related …
850. Expression of early placenta Insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility
851. Expression of epidermal growth factor receptor (EGFR), platelet growth factor receptor (PGFR) and Insulin growth factor-1 receptor (IGF-1R) on lung cancer cell
852. Expression of estrogen receptors in non-malignant mammary tissue modifies the association between Insulin-like growth factor 1 and breast cancer risk
853. Expression of hypoxia inducible factor-1α and Insulin in pancreatic cancer and their correlation
854. Expression of IGF/Insulin receptor in prostate cancer tissue and progression to lethal disease
855. EXPRESSION OF IGFBP-6 IN COLORECTAL cancer: THE RELATION WITH Insulin-LIKE GROWTH FACTOR RECEPTOR, ADIPONECTIN LEVEL AND ITS …
856. EXPRESSION OF Insulin LIKE GROWTH FACTOR Ⅱ RECEPTOR IN PANCREATIC cancer
857. Expression of Insulin receptor and c-MET is associated with clinicopathologic characteristics and molecular subtypes in premenopausal breast cancer patients
858. Expression of Insulin receptor substrate 1 in primary breast cancer and lymph node metastases
859. Expression of Insulin-like growth factor 1 and its receptors in colorectal cancer and their significances
860. Expression of Insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis
861. Expression of Insulin-like growth factor 2 mRNA in human gastric cancer.
862. Expression of Insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of …
863. Expression of Insulin-like growth factor binding protein-3 (IGFBP-3) is down regulated in breast cancer compared to normal breast tissue
864. Expression of Insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with …
865. Expression of Insulin-like growth factor binding proteins (IGFBPs) in human thyroid papillary cancer tissues
866. Expression of Insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens
867. Expression of Insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis
868. Expression of Insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients
869. Expression of Insulin-like Growth Factor Ⅰ Receptor in the Gastric cancer and its Significance
870. Expression of Insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer
871. Expression of Insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis
872. Expression of Insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis.
873. Expression of Insulin-like growth factor receptor 1 in breast cancer and its clinical significance [J]
874. Expression of Insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer
875. Expression of Insulin-like growth factor receptors I and II in normal human lung and in lung cancer
876. Expression of Insulin-like growth factor-1 in breast cancer tissues
877. Expression of Insulin-like growth factor-1 receptor in human colorectal cancer
878. Expression of Insulin-like growth factor-1 receptor in local and metastatic prostate cancer
879. Expression of Insulin-Like Growth Factor-1 Receptor mRNA in Human Breast cancer Tissues and Its Clinical Significance
880. Expression of Insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and …
881. Expression of Insulin-like growth factor-2, c-MET, matrix metalloproteinase-7 and MUC-1 in primary lesions and lymph node metastatic lesions of gastric cancer.
882. Expression of Insulin-like Growth Factor-Ⅰ Receptor (IGF-ⅠR) in Breast cancer and Its Significance [J]
883. Expression of Insulin-like growth factor-I receptor, estrogen receptor α, Bcl-2 and Bax proteins in human breast cancer
884. Expression of Insulin-like growth factor-related genes in breast cancer cell cultures and tissues
885. Expression of Insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line
886. Expression of Insulin‐like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
887. Expression of Insulin‐like growth factor II, α‐fetoprotein and hepatitis B virus transcripts in human primary liver cancer
888. Expression of Insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
889. Expression of Insulin‐Like Growth Factor‐I Receptor and Transferrin Receptor By Breast cancer Cells In Pleural Effusion Smears
890. Expression of messenger RNA for Insulin-like growth factors and Insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in …
891. Expression of metalloprotease Insulin-degrading enzyme (insulysin) in breast and ovarian cancer tissues
892. Expression of nuclear Insulin receptor substrate 1 in breast cancer
893. Expression of the Insulin Receptor Substrate 1 in primary tumors and lymph node metastases in breast cancer: correlations with Bcl-xL and Bax proteins.
894. Expression of the Insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an …
895. Expression of the Insulin-like Growth Factor Binding Proteins (IGFBPs) in Colon cancer.
896. Expression of the Insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention …
897. Expression of the Insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors α and β
898. Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast cancer and Lymph Node Metastases: Correlations with Estrogen Receptors α and β
899. Expression of the Insulin-like Growth Factors (IGFs) and Insulin-like Growth Factor Binding Proteins (IGFBPs) in Bladder cancer Tissue
900. Expression of the Insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells
901. Expression of the Insulin‐like growth factor system and cancer progression in hormone‐treated prostate cancer patients
902. Expression of the Insulin‐like growth factor‐I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer
903. Expression of the type 1 Insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease
904. Expression of tumor-associated vascular Insulin receptor in colorectal cancer and its relationship with tumor pathological features
905. Expression of two Insulin-like growth factor-binding proteins in a human endometrial cancer cell line: structural, immunological, and genetic characterization
906. Expression of various Insulin-like growth factor-1 mRNA isoforms in colorectal cancer
907. Expression patterns of Insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival
908. Expression profile, clinical significance, and biological function of Insulin-like growth factor 2 messenger RNA-binding proteins in non–small cell lung cancer
909. Expressions of Insulin-like growth factor binding protein 7 in human gastric cancer cell lines and methylation regulation [J]
910. Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non–Small-Cell Lung cancer
911. Expressions ofCLDN1and Insulin-like growth factor 2 are associated with poor prognosis in stage N2 non-small cell lung cancer
912. Extinction of Insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells
913. factor-i/Insulin receptor is present in all breast cancer subtypes and is related to poor survival
914. Factors associated with circulating levels of Insulin-like growth factor-I and Insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer
915. Factors associated with circulating levels of Insulin-like growth factor-I and Insulin-like growth factor binding protein-3 in women at risk for breast cancer
916. Family-based genetic association study of Insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk
917. Fast-track surgery improves postoperative clinical recovery and reduces postoperative Insulin resistance after esophagectomy for esophageal cancer
918. Fasting Insulin and outcome in early-stage breast cancer: results of a prospective cohort study
919. Fasting Insulin and risk of cancer related mortality in non-diabetic adults: A dose-response meta-analysis of cohort studies
920. Fasting serum Insulin concentration and risk of prostate cancer.
921. Fatty acid synthase: association with Insulin resistance, type 2 diabetes, and cancer
922. Fatty acid uptake by breast cancer cells (MDA-MB-231): Effects of Insulin, leptin, adiponectin, and TNFα
923. Fatty acid uptake by MDA-MB-231 breast cancer cells: Effects of Insulin, TNFalpha, adiponectin and leptin
924. Fenretinide, a synthetic retinoid, improves Insulin sensitivity in premenopausal women at increased risk for breast cancer
925. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the Insulin like growth factor …
926. Five genes influenced by obesity may contribute to the development of thyroid cancer through the regulation of Insulin levels
927. Flavonoids from Enicostema littorale blume enhances glucose uptake of cells in Insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathway
928. Fluorescent-antibody targeting of Insulin-like growth factor-1 receptor visualizes metastatic human colon cancer in orthotopic mouse models
929. FOXA1 Promotes Tumor Progression in Prostate cancer via the Insulin-Like Growth
930. FOXA1 promotes tumor progression in prostate cancer via the Insulin-like growth factor binding protein 3 pathway
931. Free Insulin‐like growth factor‐I and breast cancer risk
932. Freedom from Disease: The Breakthrough Approach to Preventing cancer, Heart Disease, Alzheimer’s, and Depression by Controlling Insulin
933. Frequency and circadian timing of eating may influence biomarkers of inflammation and Insulin resistance associated with breast cancer risk
934. Frequency of cancer among Insulin-treated diabetic patients in Denmark
935. Frequency of Insulin-like growth factor 1 (IGFR-1) expression and correlation with clinical and selected molecular parameters in advanced non-small cell lung cancer …
936. Frequent deletion of chromosome 19 and a rare rearrangement of 19p13. 3 involving the Insulin receptor gene in human ovarian cancer.
937. Fucoidan downregulates Insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells
938. Function of Insulin‑like growth factor 1 receptor in cancer resistance to chemotherapy
939. Functional imaging markers for blockade of breast cancer metastasis by IGF1R and Insulin receptor targeted drugs using novel MRI and targeted iron oxide …
940. Further exploration of the relationship between Insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients
941. Fusion of gelonin and anti-Insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy
942. GAIP-interacting protein, C-terminus is involved in the induction of zinc-finger protein 143 in response to Insulin-like growth factor-1 in colon cancer cells
943. Gastric cancer containing Insulin and associated with hypoglycemia
944. Gastric cancer: the role of Insulin‐like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6‐P/IGF 2R)
945. Gene expression and prognosis of Insulin‑like growth factor‑binding protein family members in non‑small cell lung cancer
946. Gene Expression Profiling And Insights Into The Involvement Of The Insulin Signaling Pathway In Oral cancer
947. Gene polymorphisms related to Insulin resistance and gene–environment interaction in colorectal cancer risk
948. Gene Targets of Insulin-Like Growth Factor-I Receptor (IGF-IR) Signaling and Their Potential Role in Breast cancer.
949. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the Insulin-like growth factor 2 imprinting system
950. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the Insulin-like growth factor 2 imprinting
951. Generation of engineered small protein scaffolds and Insulin receptor targeting in human breast cancer
952. Genetic and plasma variation of Insulin‐like growth factor binding proteins in relation to prostate cancer incidence and survival
953. Genetic blockade of Insulin‐like growth factor‐1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat
954. Genetic blockade of the Insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer
955. Genetic factors related to racial variation in plasma levels of Insulin-like growth factor-1: implications for premenopausal breast cancer risk
956. Genetic screen identifies Insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer
957. Genetic variants and traits related to Insulin-like growth factor-I and Insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer …
958. Genetic variants in Insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men
959. Genetic variants in the Insulin-like growth factor pathway and colorectal cancer risk in the Netherlands cohort study
960. Genetic variants, prediagnostic circulating levels of Insulin-like growth factors, Insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study
961. Genetic Variation at the Insulin-like Growth Factor 1 Gene and Association with Breast cancer, Breast Density and Anthropometric Measures
962. Genetic variation in Insulin-like growth factor 2 may play a role in ovarian cancer risk
963. Genetic variation in Insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
964. Genetic variation in Insulin-like growth factor-1 influences risk of colorectal cancer.
965. Genetic variation in the Insulin, Insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the …
966. Genetic variation in the SST gene and its receptors in relation to circulating levels of Insulin-like growth factor-I, IGFBP3, and prostate cancer risk
967. Genistein enhances Insulin-like growth factor signaling pathway in human breast cancer (MCF-7) cells
968. Genistein inhibits Insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein
969. Genome-wide gene-environmental interaction and random survival forest analyses: Insulin resistance and breast cancer risk
970. Genome-Wide Meta-analysis of Gene–Environmental Interaction for Insulin Resistance Phenotypes and Breast cancer Risk in Postmenopausal Women
971. Genome-wide profiling of congenital Insulin-like growth factor-1 deficient patients: translational implications in cancer prevention and metabolism
972. Genomic copy number of a carcinogenic single nucleotide polymorphism at 8q24 in non‐risk allele colorectal cancer associated with Insulin growth factor 2 receptor …
973. Genomic imprinting of Insulin-like growth factor II in prostate cancer and its clinical significance
974. Genomic imprinting of Insulin-like growth factorⅡ in colorectal cancer and its relationship with the presence of metastasis
975. German agency suspects that Insulin analogue glargine increases risk of cancer
976. GIPC mediates the generation of reactive oxygen species and the regulation of cancer cell proliferation by Insulin-like growth factor-1/IGF-1R signaling
977. Glucagon/Insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus
978. Glucagon/Insulin ratio in preoperative screening before pancreatic surgery: correlation with hemoglobin A 1C in subjects with and without pancreatic cancer
979. Glucose impairments and Insulin resistance in prostate cancer: The role of obesity, nutrition and exercise
980. Glucose lowering therapies and cancer specific mortality in adult Insulin-treated diabetes
981. Glucose tolerance and Insulin secretion in experimental pancreatic cancer in the Syrian hamster
982. Glucose tolerance and Insulin secretion in pancreatic cancer.
983. Glucose uptake in the human gastric cancer cell line, MKN28, is increased by Insulin stimulation
984. Glucose‐lowering with exogenous Insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer
985. Glutathione S-transferase M1 gene but not Insulin-like growth factor-2 gene or epidermal growth factor gene is associated with prostate cancer☆
986. Gly972Arg variant of Insulin receptor substrate 1 gene and colorectal cancer risk in overweight/obese subjects
987. Glycans as regulatory elements of the Insulin/IGF system: impact in cancer progression
988. Glycemic Status, Insulin Resistance, and Risk of Pancreatic cancer Mortality in Individuals With and Without Diabetes
989. GPER1 is regulated by Insulin in cancer cells and cancer-associated fibroblasts
990. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting Insulin-like growth factor binding protein-3, tumor cell …
991. Grb10, a negative regulator of Insulin signaling, is a tumor suppressor in prostate cancer.
992. GREEN TEA SUPPLEMENTATION LOWERS Insulin-LIKE GROWTH FACTOR I IN MEN AT HIGH RISK FOR PROSTATE cancer
993. Growth Factors and cancer—The Role of Insulin-Like Growth Factors
994. Growth hormone and Insulin like growth factor-1 in relation to prostate cancer and benign prostatic hyperplasia
995. Growth hormone and Insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients.
996. Growth hormone, alone and in combination with Insulin, increases whole body and skeletal muscle protein kinetics in cancer patients after surgery.
997. Growth Hormone, Insulin-like Growth Factor I and Insulin: their Relationship to Aging and cancer
998. Growth hormone, Insulin, and somatostatin therapy of cancer cachexia
999. Growth hormone, the Insulin-like growth factor axis, Insulin and cancer risk
1000. Growth inhibition and increase of Insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies
1001. Growth inhibition by Insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β …
1002. Growth inhibition of Insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells
1003. Growth inhibition of MCF-7 breast cancer cells by stable expression of an Insulin-like growth factor I receptor antisense ribonucleic acid
1004. Growth inhibition of pancreatic cancer by antisense oligonucleotide against the Insulin like growth factor Ⅰ receptor
1005. Growth regulation and co-stimulation of human colorectal cancer cell lines by Insulin-like growth factor I, II and transforming growth factor α
1006. Growth regulation by Insulin-like growth factors in lung cancer
1007. Growth regulation of human breast cancer by Insulin-like growth factors
1008. Growth-promoting effect, biological activity, and binding of Insulin in human intestinal cancer cells in culture
1009. Guidelines for investigation of associations between Insulin and cancer risk using prescription databases.
1010. Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid in Vitro and in Prostate cancer Cells
1011. Haplotype variation in Insulin-like growth factor I (IGF-I) and prostate cancer risk: the multiethnic cohort
1012. Hepatic steatosis and cancer development: role of Insulin-like growth factor 2 mRNA binding protein p62/IGF2BP2/IMP2-2 and fatty acid elongase ELOVL6
1013. Heterodimerization of glycosylated Insulin-like growth factor-1 receptors and Insulin receptors in cancer cells sensitive to anti-IGF1R antibody
1014. Heterotrimerization of the growth factor receptors erbB2, erbB3, and Insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin
1015. Heterozygous knockdown Insulin‐like growth factor‐1 receptor (IGF‐1R) regulates mitochondrial functions and prevents colitis and colorectal cancer
1016. Heterozygous knockout Insulin-like growth factor-1 receptor (IGF-1R) regulates mitochondrial functions and prevents colitis and colorectal cancer
1017. High dose human Insulin and Insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt
1018. High expression of Insulin receptor on tumour‐associated blood vessels in invasive bladder cancer predicts poor overall and progression‐free survival
1019. High glucose and Insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells
1020. High Insulin levels in newly diagnosed breast cancer patients reflect underlying Insulin resistance and are associated with components of the Insulin resistance …
1021. High Insulin levels linked to deaths from breast cancer
1022. High Insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts)
1023. High Insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer
1024. High Insulin‐like growth factor mRNA‐binding protein 3 (IMP3) protein expression is associated with poor survival in muscle‐invasive bladder cancer
1025. High levels of circulating Insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort
1026. High prevalence of papillary thyroid cancer in Korean women with Insulin resistance
1027. High-affinity Insulin binding to an atypical Insulin-like growth factor-I receptor in human breast cancer cells.
1028. Higher Concentrations of Glucose or Insulin Increase the Risk of Various Types of cancer in Obesity or Type 2 Diabetes by Decreasing the Expression of …
1029. Higher doses of Insulin glargine linked to cancer
1030. Higher glucose and Insulin levels are associated with risk of liver cancer and chronic liver disease mortality among men without a history of diabetes
1031. Higher Insulin resistance and adiposity in postmenopausal women with breast cancer treated with aromatase inhibitors
1032. Highly specific role of the Insulin receptor in breast cancer progression
1033. HMGA1 controls transcription of Insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells
1034. Hormonal and metabolic strategies to overcome Insulin resistance and prevent endometrial cancer
1035. Hormonal regulation of Insulin-like growth factor II and Insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal …
1036. Hormone responsive human breast cancer in long-term tissue culture: effect of Insulin
1037. Hospicells promote upregulation of the ATP-binding cassette genes by Insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer …
1038. Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy
1039. How the association between obesity and inflammation may lead to Insulin resistance and cancer
1040. Hsp27 promotes Insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD
1041. Human chorionic gonadotropin (hCG) inhibits cisplatin‐induced apoptosis in ovarian cancer cells: Possible role of up‐regulation of Insulin‐like growth factor‐1 by …
1042. Human colon cancer stem cells are enriched by Insulin-like growth factor-1 and are sensitive to figitumumab
1043. Human Insulin does not increase bladder cancer risk
1044. Human Insulin does not increase prostate cancer risk in Taiwanese
1045. Human Insulin therapy is associated with an increased risk of lung cancer: A population-based retrospective cohort study
1046. Human Insulin to increase breast cancer risk in Taiwanese women with type 2 diabetes.
1047. Human monoclonal antibodies targeting nonoverlapping epitopes on Insulin-like growth factor II as a novel type of candidate cancer therapeutics
1048. Human Prostate cancer Expresses the Low Affinity Insulin-like
1049. Human prostate cancer expresses the low affinity Insulin-like growth factor binding protein IGFBP-rP1
1050. Humoral autoimmune responses to Insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer
1051. Hyperactivation of the Insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells
1052. hyperglycemia Promotes TMPrss2-erg gene Fusion in Prostate cancer cells via Upregulating Insulin-like growth Factor-Binding Protein-2
1053. Hyperglycemia, Insulin Resistance, and the Risk of Pancreatic cancer
1054. Hyperglycemia, Insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer
1055. HyperInsulinemia, Insulin resistance, vitamin D, and colorectal cancer among whites and African Americans
1056. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low Insulin-like growth factor-II expression and favorable prognosis
1057. Hypoglyceamia due to Paranoeplastic Secretion of Insulin in a Patient with Metastasizing Colon cancer
1058. Hypoglycemia caused by co-secretion of Insulin from lung tumor and cardia cancer: First case report
1059. Hypogonadism might cause Insulin resistance in prostate cancer
1060. Hypoleptinemia in gastric cancer patients: relation to body fat mass, Insulin, and growth hormone
1061. Hypomethylation of 5’CpG island of Insulin-like growth factor binding protein-related protein 1 is associated with its overexpression in colorectal cancer
1062. Hypothalamus–pituitary–thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/Insulin-regulated aminopeptidase (IRAP) …
1063. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of Insulin-like growth factor 1 receptor
1064. Hypoxia inducible factor-1 mediates effects of Insulin on pancreatic cancer cells and disturbs host energy homeostasis
1065. Hypoxia negates hyperglycaemia-induced chemo-resistance in breast cancer cells: the role of Insulin-like growth factor binding protein 2
1066. Hypoxia‐inducible factor‐1α (HIF‐1α) gene polymorphisms, circulating Insulin‐like growth factor binding protein (IGFBP)‐3 levels and prostate cancer
1067. ID: 43: Insulin RESISTANCE AND ENDOMETRIAL cancer RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS
1068. Identification and regulation of Insulin-like growth factor binding proteins produced by hormone-dependent and-independent human breast cancer cell lines
1069. Identification and validation of the potential biomarker Insulin-like growth factor binding protein acid-labile subunit for breast cancer in African American women
1070. Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast cancer
1071. Identification of a Prognostic Signature Based on the Expression of Insulin-Related Genes in Early Breast cancer.
1072. Identification of BRCA1 as a potential biomarker for Insulin-like growth factor-1 receptor targeted therapy in breast cancer
1073. Identification of Insulin and Insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue
1074. Identification of Insulin-like growth factor 2 mRna-binding protein 3 as a radioresistance factor in squamous esophageal cancer cells
1075. Identification of Insulin-like growth factor binding proteins in breast cancer cells
1076. Identification of Insulin-like growth factor-I receptor (IGF-IR) gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells
1077. Identification of microRNAs involved in gefitinib resistance of non‑small‑cell lung cancer through the Insulin‑like growth factor receptor 1 signaling pathway
1078. Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in Insulin-stimulated cells
1079. Identification of the Insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells
1080. IFN-β is a potent inhibitor of Insulin and Insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells
1081. IGF and Insulin receptor signaling in breast cancer
1082. IGF-I and Insulin Receptor Families in cancer
1083. IGF-I and Insulin signaling enhances levels of choline kinase in breast cancer cells: Implications for developing noninvasive magnetic resonance spectroscopy of …
1084. IL‐17 and Insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44‐VCAM‐1 interaction
1085. Immunization with breast cancer cells treated with antisense oligodeoxynucleotides (AS [S] ODN) to type I Insulin-like growth factor receptor (IGF-IR) induced an …
1086. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I Insulin-like growth factor receptor induced an antitumoral effect …
1087. Immunochemical demonstration of immunoreactive Insulin in human breast cancer.
1088. Immunohistochemical evaluation of Insulin-like growth factor I receptor status in cervical cancer specimens
1089. Immunohistochemical expression of Insulin-like growth factor 1-receptor in invasive breast cancer from women of African ancestry.
1090. Immunohistochemical Modifications of “B Cells” in Experimentally-induced Pancreatic cancer—Correlation with Serum Insulin Values
1091. Immunohistochemical Staining of Insulin-like Growth Factor-1 in Human Lung cancer cells of NSCLC and SCLC.
1092. ImmunoPET imaging of Insulin-like growth factor 1 receptor (IGF-1R) in pancreatic cancer
1093. ImmunoPET imaging of Insulin-like growth factor 1 receptor in a subcutaneous mouse model of pancreatic cancer
1094. Impact of a behaviorally-based weight loss intervention on parameters of Insulin resistance in breast cancer survivors
1095. Impact of a mixed strength and endurance exercise intervention on Insulin levels in breast cancer survivors
1096. Impact of diabetes and Insulin use on prognosis in patients with resected pancreatic cancer: an ancillary analysis of NRG Oncology RTOG 9704
1097. Impact of diabetes mellitus and Insulin use on survival after colorectal cancer diagnosis: the cancer Prevention Study-II Nutrition Cohort
1098. Impact of diabetes, Insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer …
1099. IMPACT OF ESTROGEN, IGF-I AND Insulin SIGNALING ON BREAST cancer SPHEROIDS.
1100. Impact of Insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT).
1101. Impact of Insulin-like growth factor (igf) kinetics on the development of prostate cancer: age-adjusted and baseline Psa-adjusted case control study
1102. Impact of Insulin-like growth factor 1 receptor (IGF1R) and amphiregulin (AREG) expressions on survival in patients with stage II/III gastric cancer enrolled in the …
1103. Impact of Insulin-like growth factor gene polymorphisms on survival of patients with colorectal cancer.
1104. Impact of Insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer
1105. Impact of Insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer
1106. Impact of Insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis
1107. Impact of Intensive Insulin Therapy on C-Reactive Protein in Gastric cancer Patients with Complicated Type 2 Diabetes Mellitus
1108. Impact of intravenous Insulin on 18F-FDG PET in diabetic cancer patients
1109. Impact of metabolic disorders on prostate cancer growth: Androgen and Insulin resistance perspectives
1110. Impact of obesity on MMTV-Wnt-1 mammary cancer: role of the Insulin-like growth factor-1 (IGF-1)/Akt/mTOR pathway
1111. Impact of Obesity on MMTV-Wnt-1 Mammary cancer: Role of The Insulin-Like Growth Factor-1 (IGF-1)/Akt/mTOR Pathway
1112. Impact of phosphorylated Insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during …
1113. Impact of physical activity on Insulin levels in breast cancer survivors
1114. Impact of prediagnosis smoking, alcohol, obesity, and Insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study
1115. Impact of preoperative oral liquid carbohydrate on postoperative Insulin resistance in gastric cancer patients and its associated study
1116. Impact of systemic inflammation on the relationship between Insulin resistance and all-cause and cancer-related mortality
1117. Impact of treatment exposures on cardiovascular risk and Insulin resistance in childhood cancer survivors
1118. Impaired binding of Insulin to erythrocyte membrane receptor and the activation of nitric oxide synthase by the hormone in human breast cancer
1119. Impaired Insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients
1120. Impaired Insulin Signaling Is Associated with Decreased Incidence of Experimental Skin cancer.
1121. Impairment of stimulation by estrogen of Insulin‐activated nitric oxide synthase in human breast cancer
1122. Implication of Insulin-like growth factor (IGF)/IGF binding protein-3 and alpha-tocopherol in the chemopreventive activity of 9-cis retinoic acid in lung cancer
1123. Implication of milk and dairy products consumption through Insulin-like growth factor-I in induction of breast cancer risk factors in women
1124. Implication of the Insulin-like growth factor-IR pathway in the resistance of non–small cell lung cancer cells to treatment with gefitinib
1125. Implications for Prostate cancer of Insulin-Like Growth Factor-I (IGF-I) Genetic Variation and Circulating IGF-I Levels
1126. Implications of Insulin-like growth factor 1 receptor activation in lung cancer
1127. Implications of Insulin‐like growth factor‐I for prostate cancer therapies
1128. Importance of the type I Insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation
1129. In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and Insulin signaling in plasma extracellular vesicles
1130. in basal and estradiol-stimulated Insulin-like growth factor I secretion and action in breast cancer cells in culture
1131. In prostate cancer, low adiponectin levels are not associated with Insulin resistance
1132. In vitro downregulation of growth factors by Insulin-like growth factor binding protein-3 in cervical cancer☆
1133. In vitro enhancement of response to radiation of human lung cancer cells following Insulin-like growth factor 1 receptor inactivation
1134. In vitro immune response of Insulin-like growth factor 2 mRNA-binding protein 3 restricted cytotoxic T lymphocyte epitope from lung cancer immunotherapy target
1135. In Vivo Activity of Insulin-Like Growth Factor Binding Protein-3 in Prevention of Prostate cancer Progression
1136. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of Insulin-like growth factor I …
1137. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of Insulin-like growth factor binding protein-3 and inhibition of …
1138. In-utero exposures and breast cancer risk: joint effect of estrogens and Insulin-like growth factor?
1139. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and Insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells
1140. Incidence of Pancreatic cancer Associated Insulin Dependent Diabetes at an Inner City Hospital
1141. Increased Activity of Insulin‐like Growth Factor‐binding Protein in Human Thyroid Papillary cancer Tissue
1142. Increased apoptosis and decreased proliferation of colorectal cancer cells using Insulin‐like growth factor binding protein‐4 gene delivered locally by gene transfer
1143. Increased autocrine production of Insulin‐like growth factor II (IGF‐II) alters serum sensitivity of MCF‐7 human breast cancer cell proliferation
1144. Increased blood glucose and Insulin, body size, and incident colorectal cancer
1145. Increased cancer mortality in diabetic people treated with Insulin: a register-based follow-up study
1146. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or Insulin
1147. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or Insulin: Response to Bowker et Al.
1148. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or Insulin: Response to Farooki and Schneider
1149. Increased expression of Insulin receptor substrate-1 in human pancreatic cancer
1150. Increased Expression of Insulin-like Growth Factor-II Messenger RNA–Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung cancer
1151. Increased expression of the mannose 6‐phosphate/Insulin‐like growth factor‐II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo
1152. Increased Insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells
1153. Increased Insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer
1154. Increased Insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer …
1155. Increased levels of mannose-6-phosphate/Insulin-like growth factor 2 receptor (M6P/IGF2-R) found in serum of patients with breast cancer
1156. Increased life-time risk for colorectal cancer among patients with loss of genomic imprinting of Insulin-like growth factor 2: A survival analysis
1157. Increased plasma levels of Insulin-like growth factor 2 and Insulin-like growth factor binding protein 3 are associated with endometrial cancer risk
1158. Increased plasma transforming growth factor beta1 (TGFβ1) level in lung cancer patients may be due to the loss of mannose 6-phosphate/Insulin like growth factor 2 …
1159. Increased serum Insulin associated with increased risk of prostate cancer recurrence
1160. Increased serum Insulin‐like growth factor‐1 levels are associated with prolonged response to dasatinib‐based regimens in metastatic prostate cancer
1161. Individual Insulin use and the risk of breast cancer: An international clinical epidemiology study.
1162. Inducible expression of dominant negative Insulin-like growth factor I receptor in MCF-7 breast cancer cells
1163. Inducible knockdown of Insulin receptor substrate I desensitizes ER alpha response to both agonist (estradiol) and antagonist (fulvestrant) in MCF-7L breast cancer …
1164. Induction of anterior gradient 2 (AGR2) plays a key role in Insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration
1165. Induction of Apoptosis in Human cancer Cells by Human Eb-or Rainbow Trout Ea4-Peptide of Pro-Insulin-Like Growth Factor-I (Pro-IGF-I)
1166. Induction of apoptosis in human prostate cancer cells by Insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-α
1167. Induction of fascin spikes in breast cancer cells by activation of the Insulin-like growth factor-I receptor
1168. Induction of Insulin‐like growth factor binding protein expression by ICI 182,780 in a tamoxifen‐resistant human breast cancer cell line
1169. Induction of interleukin-6 by adjuvant breast cancer treatment in mice promotes loss of lean body mass via down-regulation of Insulin-like growth factor I: the role of …
1170. Induction of myasthenia gravis, myositis, and Insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
1171. Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by Insulin-like growth factor II
1172. Inflammatory, Insulin resistance metabolic markers and pancreatic cancer: quo vadis?
1173. Influence of bicalutamide with or without tamoxifen or anastrozole on Insulin-like growth factor 1 and binding proteins in prostate cancer patients
1174. Influence of dietary Insulin scores on survival in colorectal cancer patients
1175. Influence of early enteral nutrition (EEN) on Insulin resistance in gastric cancer patients after surgery
1176. Influence of hormones on tumor growth, cell kinetics, estrogen receptor and Insulin-like growth factor-I-related protein of human breast cancer (MCF-7) cells …
1177. Influence of Inflammation, Insulin Resistance and Excess Body Size on Breast cancer Risk: A Nested Case-Control Study
1178. INFLUENCE OF Insulin AND METFORMIN ON PROSTATE cancer
1179. Influence of Insulin resistance on adiponectin receptor expression in breast cancer
1180. Influence of Insulin therapy for type 2 diabetes mellitus on cancer incidence.
1181. Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast cancer: A Systematic Review
1182. Influence of pituitary stalk section on growth hormone, Insulin and TSH secretion in women with metastatic breast cancer
1183. Influence of remifentanil combined with propofol on sober and Insulin resistance in patients after esophageal cancer radical surgery
1184. Influence of tamoxifen on plasma levels of Insulin-like growth factor I and Insulin-like growth factor binding protein I in breast cancer patients
1185. Influences of Maixiansan on Insulin-like growth factor hinding protein7 and apoptosis in rats with ulcerative colitis-related colorectal cancer
1186. Infusion therapy in sessions of general artificial hyperthermia using large doses of Insulin in cancer patients
1187. Inhibition of apoptosis by amphiregulin via an Insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines
1188. Inhibition of Apoptosis by Amphiregulin via an Insulin‐like Growth Factor‐1 Receptor—Dependent Pathway in Non‐Small Cell Lung cancer Cell Lines
1189. Inhibition of cancer cell proliferation and metastasis by Insulin receptor downregulation
1190. Inhibition of colon cancer cell growth by dietary components: role of the Insulin-like growth factor (IGF) system.
1191. Inhibition of growth and increased expression of Insulin-like growth factor-binding protein-3 (IGFBP-3) and-6 in prostate cancer cells stably transfected with antisense …
1192. Inhibition of growth of prostatic cancer cell lines by peptide analogues of Insulin-like growth factor 1
1193. Inhibition of growth, production of Insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth …
1194. Inhibition of human MCF-7 breast cancer cells and HT-29 colon cancer cells by rice-produced recombinant human Insulin-like growth binding protein-3 …
1195. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I Insulin like growth factor receptor (IGF-IR) mRNA acting through a specific …
1196. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I Insulin-like growth factor receptor mRNA involves inactivation of ErbBs …
1197. Inhibition of Insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells
1198. Inhibition of Insulin-and Insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1, 25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089
1199. Inhibition of Insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non–small cell lung cancer cells
1200. Inhibition of Insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for Insulin-like growth factor binding …
1201. Inhibition of Insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate …
1202. Inhibition of Insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer …
1203. Inhibition of Insulin-like growth factor-1 receptor signaling impairs proliferation of head and neck, lung, prostate and breast cancer cells
1204. Inhibition of Insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer
1205. Inhibition of Insulin-like Growth Factor–Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast cancer Cells to EGF Receptor …
1206. Inhibition of Insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells
1207. Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced Insulin‐like growth factor‐1 secretion by prostate stromal cells
1208. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced Insulin-like growth factor I …
1209. Inhibition of mTOR and targeting Insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in estrogen receptor positive breast cancer cells.
1210. Inhibition of Src and Insulin/Insulin-like growth factor-1 receptor (IR/IGF-1R) on tumors and bone turnover in prostate cancer (PCa) models in vivo compared with …
1211. Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, Insulin, and EGF
1212. Inhibition of the biologic response to Insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the Insulin-like growth factor-I receptor …
1213. Inhibition of the Insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach
1214. Inhibition of the Insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone
1215. Inhibition of the Insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone
1216. Inhibition of tumor cell kinetics and serum Insulin growth factor I levels by octreotide in colorectal cancer patients
1217. Inhibition of type I Insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis
1218. Inhibitors of Insulin-like growth factor signaling: a therapeutic approach for breast cancer
1219. Inhibitors of Insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells
1220. Inhibitory effect of exogenous Insulin-like growth factor binding protein 7 on proliferation of human breast cancer cell line MDA-MB-453 and its mechanism
1221. Inhibitory effect of small interfering RNA targeting Insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells
1222. Insight into the growth hormone–Insulin-like growth factor-I axis in cancer cachexia
1223. Insights into Insulin resistance, lifestyle, and anthropometric measures of patients with prior colorectal cancer compared to controls: a National Health and Nutrition …
1224. Insights into the pharmacologic inhibition of Insulin receptor tyrosine kinase in cancer: avoiding severe metabolic toxicity
1225. Insulin action and metabolism in patients with head and neck cancer
1226. Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of Insulin.
1227. Insulin allergy and immunologic Insulin resistance caused by interleukin-6 in a patient with lung cancer
1228. Insulin analog linked to breast cancer risk
1229. Insulin analogs and cancer
1230. Insulin analogs and cancer: a note of caution
1231. Insulin analogues and cancer risk: cause for concern or cause célèbre?
1232. Insulin analogues and cancer risk: the emergence of second-generation studies
1233. Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activities in cultured cancer cells
1234. Insulin analogues to stimulate cell growth in human cancer initiating cells (CICs).
1235. Insulin and Breast cancer Risk
1236. Insulin and C-peptide response to oral glucose in patients with breast cancer
1237. Insulin and cancer
1238. Insulin and cancer: Should one worry?
1239. Insulin and colon cancer
1240. Insulin and Diazoxide for treatment of cancer
1241. Insulin and endometrial cancer
1242. Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells
1243. Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study.
1244. Insulin and hybrid Insulin/IGF receptors are major regulators of breast cancer cells
1245. Insulin and hypoxia-inducible factor-1 cooperate in pancreatic cancer cells to increase cell viability
1246. Insulin and IGF-1 in Breast cancer Patients are Associated with Tumor Cell Proliferation (Ki67) in their Breast Tumors
1247. Insulin and IGF-I as determinants of low ‘Western’cancer rates in the rural third world
1248. Insulin and IGFs in obesity-related breast cancer
1249. Insulin and Insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line
1250. Insulin and Insulin-like growth factors act as renal cell cancer intratumoral regulators
1251. Insulin and leptin levels in obese patients with and without breast cancer
1252. Insulin and Metformin Control Cell Proliferation by Regulating TDG-Mediated DNA Demethylation in Liver and Breast cancer Cells
1253. Insulin and Metformin Control Cell Proliferation by Regulating Thymine DNA Glycosylase-Mediated DNA Demethylation in Liver and Breast cancer Cells
1254. Insulin and NADPH-generating enzymes as molecular targets to repress colon cancer cell proliferation
1255. Insulin and related factors in breast-cancer mortality
1256. Insulin and related factors in premenopausal breast cancer risk
1257. Insulin and risk of pancreatic cancer
1258. Insulin binding by a cell line (HT 29) derived from human colonic cancer
1259. Insulin breast cancer connection: confirmatory data set the stage for better care
1260. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29
1261. Insulin clearance in normal and cancer involved human kidneys
1262. Insulin controls key steps of carbohydrate metabolism in cultured HT29 colon cancer cells
1263. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway
1264. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells
1265. Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2
1266. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2
1267. Insulin enhances migration and invasion in prostate cancer cells by up-regulation of FOXC2
1268. Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling …
1269. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4
1270. Insulin glargine (Lantus) and cancer risk
1271. Insulin glargine and cancer
1272. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis
1273. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
1274. Insulin glargine and cancer–Authors’ reply
1275. Insulin glargine and cancer—an unsubstantiated allegation
1276. Insulin glargine and cancer: a storm in a glass of water?
1277. Insulin glargine and cancer: another side to the story?
1278. Insulin Glargine and Incidence of cancer—An Ongoing Debate
1279. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
1280. Insulin glargine and risk of cancer: a meta-analysis
1281. Insulin glargine and the risk of cancer
1282. Insulin glargine use and breast cancer risk: associations with cumulative exposure
1283. Insulin glargine use and breast cancer: a systematic review and meta-analysis.
1284. Insulin glargine use and short-term incidence of breast cancer—a four-year population-based observation
1285. Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: a systematic review and meta-analysis
1286. Insulin growth factor binding protein 7 (IGFBP7)-related cancer and IGFBP3 and IGFBP7 crosstalk
1287. Insulin growth factor enhances colon cancer risk
1288. Insulin Growth Factor Receptor as a Prognostic Marker in Operable Squamous-Cell Laryngeal cancer
1289. Insulin growth factor receptor‐1 expression and loss of PTEN protein predict early recurrence in triple‐negative breast cancer
1290. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer
1291. Insulin growth factor-1 pathway in cervical carcinoma cancer stem cells
1292. Insulin growth factor-1 receptor (IGF-1R) expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study
1293. Insulin growth factor-1 receptor (IGF-1R) expression in small cell lung cancer (SCLC).
1294. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer
1295. Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen
1296. Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation
1297. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?
1298. Insulin increases apoptotic resistance in prostate cancer cells, but are sensitised by metformin
1299. Insulin increases de novo steroidogenesis in prostate cancer cells
1300. Insulin induces anticancer cytotoxicity of 5-Fu to two human colon cancer cell lines
1301. Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells
1302. Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China
1303. Insulin levels and Body Mass Index in non-diabetic pre-and post-menopausal women with breast cancer
1304. Insulin like growth factor (IGF) and IGF binding proteins in growth hormone dysregulation and abnormal glucose tolerance in small cell lung cancer patients
1305. Insulin like growth factor 2 regulation of aryl hydrocarbon receptor in MCF-7 breast cancer cells
1306. Insulin like growth factor and its association with lung, breast, and prostate cancer: a brief review
1307. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors
1308. Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth
1309. Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast cancer
1310. Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast cancer. Addendum
1311. Insulin like growth factor in breast cancer subtypes.
1312. Insulin mediates hypoxia-inducible factor-1α in human pancreatic cancer ASPC-1 cells
1313. Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect
1314. Insulin prevents leptin inhibition of RM1 prostate cancer cell growth
1315. Insulin priming effect on estradiol-induced breast cancer metabolism and growth
1316. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors
1317. Insulin promotes progression of colon cancer by upregulation of ACAT1
1318. Insulin promotes proliferation and migration of breast cancer cells through the extracellular regulated kinase pathway
1319. Insulin promotes proliferative vitality and invasive capability of pancreatic cancer cells via hypoxia-inducible factor 1α pathway
1320. Insulin Promotes Proliferative Vitality and Invasive Capability of Pancreatic cancer Cells via Hypoxia-inducible Factor 1α Pathway
1321. Insulin protects against hepatic bioenergetic deterioration induced by cancer cachexia: an in vivo 31P magnetic resonance spectroscopy study
1322. Insulin receptor (IR) and Insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer
1323. Insulin receptor alternative splicing during development and cancer
1324. Insulin receptor and cancer
1325. Insulin receptor and GPCR crosstalk stimulates YAP via PI3K and PKD in pancreatic cancer cells
1326. Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells
1327. Insulin receptor compensates for IGF1R inhibition and induces mitogenic activity in prostate cancer cell lines
1328. Insulin receptor expression and clinical outcome in node-negative breast cancer.
1329. Insulin receptor expression and function in human breast cancer cell lines
1330. Insulin receptor expression and survival of patients with non-small cell lung cancer
1331. Insulin receptor H1085H C> T and Insulin receptor substrate 1 G972R polymorphisms and prostate cancer risk: a pilot study
1332. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
1333. Insulin receptor isoform A modulates metabolic reprogramming of breast cancer cells in response to IGF2 and Insulin stimulation
1334. Insulin receptor isoform A, a newly recognized, high-affinity Insulin-like growth factor II receptor in fetal and cancer cells
1335. Insulin receptor isoform B is downregulated in intestinal stem cells and tumors, limits colon cancer cell growth, and promotes differentiation
1336. Insulin receptor isoform expression in ovarian cancer in African American women
1337. Insulin receptor isoform variations in prostate cancer cells
1338. Insulin receptor isoforms A and B as well as Insulin receptor substrates-1 and-2 are differentially expressed in prostate cancer
1339. Insulin receptor isoforms and Insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid
1340. Insulin receptor isoforms in cancer
1341. Insulin receptor kinase inhibition is better tolerated than hypoInsulinemia and more effective than metformin in treating breast cancer
1342. Insulin receptor signaling activated by penta-O-galloyl-α-D-glucopyranose induces p53 and apoptosis in cancer cells
1343. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
1344. Insulin receptor substrate 1 may play divergent roles in human colorectal cancer development and progression
1345. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells
1346. Insulin Receptor Substrate 1 modulates the transcriptional activity and turnover of Androgen Receptor in breast cancer cells.
1347. Insulin receptor substrate 1, a novel oncogene target in breast cancer
1348. Insulin receptor substrate adaptor proteins mediate prognostic gene expression profiles in breast cancer
1349. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells
1350. Insulin receptor substrate suppression by the tyrphostin NT157 inhibits responses to Insulin-like growth factor-I and Insulin in breast cancer cells
1351. Insulin receptor substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)
1352. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer
1353. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line
1354. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid
1355. Insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human mammary cancer cells
1356. Insulin Receptor Substrate-2 (IRS-2): A Novel Hypoxia-Responsive Gene in Breast cancer: A Dissertation
1357. Insulin receptor substrate-2 gene polymorphism: is it associated with endometrial cancer?
1358. Insulin receptor substrate-4 is overexpressed in colorectal cancer and promotes retinoblastoma–cyclin-dependent kinase activation
1359. Insulin Receptor Substrate-4 Regulates HepG2 cancer Cells Motility Stimulated by EGF in A FAK/AKT-dependent Mechanism
1360. Insulin receptor substrates mediate distinct biological responses to Insulin-like growth factor receptor activation in breast cancer cells
1361. Insulin Receptor Substrates-1 And-2 Regulate cancer Cell Proliferation
1362. Insulin receptor targeting in breast cancer through yeast surface display
1363. Insulin receptor: what role in breast cancer?
1364. Insulin receptors in breast cancer
1365. Insulin receptors in breast cancer: biological and clinical role
1366. Insulin receptors in human cancer.
1367. Insulin resistance (IR) and prognosis of metastatic breast cancer (MBC) patients
1368. Insulin Resistance and Abnormal Glucose Tolerance After Paediatric Hematopoietic Stem Cell Transplantation in Blood cancer Survivors
1369. Insulin resistance and body composition in cancer patients
1370. Insulin Resistance and Breast cancer in Postmenopausal Women
1371. Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative
1372. Insulin resistance and breast‐cancer risk
1373. Insulin resistance and cachexia development in patients with metastatic upper gastrointestinal cancer
1374. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms
1375. Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: the Women’s Health Initiative
1376. Insulin resistance and cancer: epidemiological evidence
1377. Insulin Resistance and cancer: Epidemiology, Cellular and Molecular Mechanisms and Clinical Implications
1378. Insulin resistance and cancer: the role of Insulin and IGFs
1379. Insulin resistance and cancer.
1380. Insulin resistance and colon cancer in African Americans and Caucasians
1381. Insulin resistance and colon cancer promotion in rats on diets differing in fat, energy, and starch
1382. Insulin resistance and colorectal cancer risk: the role of elevated plasma resistin levels
1383. Insulin resistance and endometrial cancer (GI, G2) in postmenopausal women
1384. Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis
1385. Insulin Resistance and Endometrial cancer: Emerging Role for microRNA
1386. Insulin resistance and familial history of breast cancer
1387. Insulin resistance and hyperInsulinaemia in the development and progression of cancer
1388. Insulin resistance and hyperInsulinemia correlate with colorectal cancer promotion
1389. Insulin resistance and inflammation in black women with and without breast cancer: Cause for concern
1390. Insulin Resistance and Insulin Receptor Isoform A in cancer [J]
1391. Insulin resistance and long-term cancer-specific and all-cause mortality: The Women’s Health Initiative (WHI)
1392. Insulin resistance and prostate cancer risk
1393. Insulin resistance and risk of renal cell cancer: a case-control study
1394. Insulin Resistance and Thyroid cancer
1395. Insulin resistance as a predictor of venous thromboembolism in breast cancer
1396. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
1397. Insulin resistance in breast cancer: relevance and clinical implications
1398. Insulin resistance in cancer cachexia and metabolic syndrome
1399. Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-α expression in skeletal muscle
1400. Insulin resistance in pancreatic cancer
1401. Insulin resistance in patients with advanced prostate cancer undergoing intermittent or continuous androgen blockade.
1402. Insulin resistance in patients with advanced prostate cancer who received surgical castration
1403. Insulin resistance in patients with cancer
1404. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure
1405. Insulin resistance in patients with colorectal cancer
1406. Insulin resistance in prostate cancer patients and predisposing them to acute ischemic heart disease
1407. Insulin Resistance Is a Common Core Tethered to Diabetes and Pancreatic cancer Risk
1408. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer
1409. Insulin resistance is associated with early gastric cancer: a prospective multicenter case control study
1410. Insulin resistance is associated with elevated circulating androgens in postmenopausal women: A potential pathway for breast cancer etiology
1411. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden
1412. Insulin resistance was connected with the alterations of substrate utilization in patients with cancer
1413. Insulin resistance-related biomarker clustering and subclinical inflammation as predictors of cancer mortality during 21.5 years of follow-up
1414. Insulin Resistance–Related Gene Polymorphisms and Risk of Prostate cancer
1415. Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy
1416. Insulin Resistance, IGFs and Energy Balance on the Risk of Breast cancer
1417. Insulin resistance, Insulin‐like growth factor I and breast cancer: a hypothesis
1418. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer
1419. Insulin Resistance, Metabolic Syndrome and Diabetes in Women at High Risk for Breast cancer
1420. Insulin resistance, obesity and breast cancer risk
1421. Insulin resistance, obesity, and liver cancer
1422. Insulin Resistance: A Hidden Risk Factor for Gastric cancer?
1423. Insulin resistance: a significant risk factor of endometrial cancer
1424. Insulin resistance: an independent risk factor for lung cancer?
1425. Insulin resistance: any role in the changing epidemiology of thyroid cancer?
1426. Insulin Resistance: Clinical Implications for cancer Treatment and Prevention
1427. Insulin resistance: Influence on cancer risk and cancer prognosis
1428. Insulin resistance/hyperInsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up
1429. Insulin reversal of cancer cachexia in rats
1430. Insulin reverses ammonia‐induced anorexia and experimental cancer anorexia
1431. Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients
1432. Insulin secretion and action in patients with pancreatic cancer
1433. Insulin secretion as a determinant of pancreatic cancer risk
1434. Insulin secretion, glucose production, and Insulin sensitivity in underweight and normal-weight volunteers, and in underweight and normal-weight cancer patients: a …
1435. Insulin sensitivity during combined androgen blockade for prostate cancer
1436. Insulin Sensitivity in Septic cancer‐Bearing Patients
1437. Insulin Signaling & Hypoxic Response in Brain cancer
1438. Insulin signaling in Insulin resistance states and cancer: a modeling analysis
1439. Insulin signaling network in cancer
1440. Insulin stimulated MCF7 breast cancer cells: Proteome dataset
1441. Insulin Stimulation of Fatty Acid Synthesis in Human Breast cancer Cells: Brief Communication
1442. Insulin stimulation of fatty acid synthesis in human breast cancer in long term tissue culture
1443. Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression
1444. Insulin suppresses the expression and function of breast cancer resistance protein in primary cultures of rat brain microvessel endothelial cells
1445. Insulin Therapy and Breast cancer Risk
1446. Insulin therapy and cancer
1447. Insulin therapy and cancer in type 2 diabetes
1448. Insulin therapy and cancer risk in diabetes mellitus
1449. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
1450. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis
1451. Insulin therapy and risk of colorectal cancer: an updated meta-analysis of epidemiological studies
1452. Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies
1453. Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: a meta‐analysis of observational studies
1454. Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis
1455. Insulin therapy in diabetes and cancer risk: current understanding and implications for future study
1456. Insulin therapy, duration of diabetes linked to cancer risk
1457. Insulin treatment and breast cancer risk; A systematic review of in vitro, animal and epidemiological evidence
1458. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning
1459. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies
1460. Insulin use and cancer risk: the effect of choices in study design on risk estimates
1461. Insulin use and smoking jointly increase the risk of bladder cancer mortality in patients with type 2 diabetes
1462. Insulin use is not significantly predictive for prostate cancer mortality in diabetic patients: a 12‐year follow‐up study
1463. Insulin use, adipokine profiles and breast cancer prognosis
1464. Insulin use, hormone receptor status and hematopoietic cytokines׳ circulation in women with diabetes mellitus and breast cancer
1465. Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations
1466. Insulin–cancer relationships: possible dietary implication
1467. Insulin-dependent leptin expression in breast cancer cells
1468. Insulin-increasing diabetes therapies raise risk of death from cancer
1469. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients
1470. Insulin-induced enhancement of MCF-7 breast cancer cell response to 5-fluorouracil and cyclophosphamide
1471. Insulin-induced gene 2 expression is associated with breast cancer metastasis
1472. Insulin-induced GPX4 Expression in Breast cancer Cells
1473. Insulin-like factor binding protein-3 promotes the G1 cell cycle arrest in several cancer cell lines
1474. Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia
1475. Insulin-like growth factor (IGF) and IGF binding proteins in growth hormone dysregulation and abnormal glucose tolerance in small cell lung cancer patients
1476. Insulin-Like Growth Factor (IGF) family and prostate cancer
1477. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 …
1478. Insulin-like growth factor (IGF) pathway targeting in cancer: role of the IGF axis and opportunities for future combination studies
1479. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance
1480. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers
1481. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells
1482. Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms
1483. Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells
1484. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size
1485. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on
1486. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
1487. Insulin-like growth factor (IgF)-I, IgF binding protein-3, and prostate cancer: correlation with gleason score
1488. Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and breast cancer (BC) risk: A synthetic case-control study
1489. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
1490. Insulin-like Growth Factor (IGF)-I, IGF-II, IGF Binding Protein-3, and Risk of Colorectal cancer: a Nested Case-control Study in the JACC Study
1491. Insulin-like Growth Factor (IGF)-I, IGF-II, IGF Binding Protein-3, and Risk of Colorectal cancer: A Nested Casecontrol Study in the JACC Study
1492. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
1493. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk
1494. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
1495. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue
1496. Insulin-like growth factor 1 (IGF-1) pathway targeting in the treat-ment of cancer
1497. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection
1498. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
1499. Insulin-like growth factor 1 activates methionine adenosyltransferase 2A transcription by multiple pathways in human colon cancer cells
1500. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer
1501. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects
1502. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study
1503. Insulin-like growth factor 1 and protein kinase B signalling in prostate cancer progression.
1504. Insulin-like growth factor 1 attenuates antiestrogen-and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro …
1505. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer …
1506. Insulin-like growth factor 1 effects on mitochondrial dynamics and mitophagy in cancer
1507. Insulin-like growth factor 1 gene polymorphism and breast cancer risk
1508. Insulin-like growth factor 1 gene polymorphism and breast cancer risk among arab omani women: a case-control study
1509. Insulin-like growth factor 1 gene polymorphism in women with breast cancer
1510. Insulin-like growth factor 1 genotype, phenotype and breast cancer risk, by racial/ethnic group.
1511. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
1512. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia-reply to the letter from Cohen, Peehl and Rosenfeld
1513. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
1514. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by α v β 3 integrin …
1515. Insulin-like growth factor 1 pathway mutations and protein expression in resected non–small cell lung cancer
1516. Insulin-like growth factor 1 polymorphism and breast cancer risk in Jewish women
1517. Insulin-like growth factor 1 promotes cancer cell growth via RAC1 activation in ovarian epithelial cancer cells
1518. Insulin-like growth factor 1 promotes cancer progression via GTPase RAC activation in epithelial ovarian cancer cells
1519. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer
1520. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer
1521. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro.
1522. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status
1523. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-xL pathway
1524. Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival
1525. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer
1526. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine
1527. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors
1528. Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression
1529. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells
1530. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells
1531. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer
1532. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls
1533. Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal cancer—From Basic Research to Potential Clinical Applications
1534. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer
1535. Insulin-Like Growth Factor 2 in Physiology, cancer, and cancer Treatment
1536. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer
1537. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer
1538. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?
1539. Insulin-like growth factor 2 promotes ovarian cancer growth and resistance to traditional chemotherapy.
1540. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer
1541. Insulin-like growth factor and breast cancer risk: evidence from observational studies
1542. Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease
1543. Insulin-like growth factor and lung cancer
1544. Insulin-like Growth Factor Axis Elements in Breast cancer Progression
1545. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer
1546. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer
1547. Insulin-Like Growth Factor Binding Protein (IGFBP) 3 Suppresses HIF1a Expression in cancer Cells through Reactivating mTOR/Tln Pathway
1548. Insulin-like growth factor binding protein (IGFBP)-3 levels in conditioned media of Hs578T human breast cancer cells are post-transcriptionally regulated.
1549. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction
1550. Insulin-like growth factor binding protein 1 expression inhibits Insulin-like growth factor I action in MCF-7 breast cancer cells.
1551. Insulin-like growth factor binding protein 2 (IGFBP2) expression is associated with radiation resistance and worse prognosis in rectal cancer
1552. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator
1553. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion
1554. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival
1555. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation
1556. Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor β2-induced growth inhibition in human breast cancer cells
1557. Insulin-like growth factor binding protein expression in human small cell lung cancer cell lines
1558. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility
1559. Insulin-like growth factor binding protein-1 (IGFBP-1) targets both the Insulin-like growth factor (IGF) and integrin pathways for the inhibition of breast cancer cell …
1560. Insulin-like growth factor binding protein-1 (IGFBP-1) upregulated by Helicobacter pylori and is associated with gastric cancer cells migration
1561. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma
1562. Insulin-Like Growth Factor Binding Protein-1 Interacts with Integrins to Inhibit Insulin-Like Growth Factor-Induced Breast cancer Growth and Migration
1563. Insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker in lung cancer
1564. Insulin-like growth factor binding protein-2 (IGFBP2), CEA and Ca19-9 in monitoring colon cancer patients
1565. Insulin-like growth factor binding protein-2 alters the sensitivity of breast cancer cells to chemotherapy
1566. Insulin-like growth factor binding protein-2 expression by ER+ ve breast cancer cells is regulated by PI-3 kinase pathway signaling
1567. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer
1568. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival
1569. Insulin-like growth factor binding protein-3 (IGFBP-3) facilitates the response to DNA-damaging chemotherapy in triple-negative breast cancer cells.
1570. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2′-deoxycytidine (AZA) in breast cancer cells
1571. Insulin-like growth factor binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: A possible early prognostic factor of metastatic progression
1572. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) regulates mitochondrial dynamics, EMT and angiogenesis in progression of prostate cancer
1573. Insulin-like growth factor binding protein-3 and Insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.
1574. Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-κB activity in gastric cancer cells
1575. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth …
1576. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells
1577. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells
1578. Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells
1579. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer
1580. Insulin-like growth factor binding protein-3 is secreted as a phosphoprotein by human breast cancer cells
1581. Insulin-like growth factor binding protein-3 links obesity and breast cancer progression
1582. Insulin-LIKE GROWTH FACTOR BINDING PROTEIN-3 MEDIATES 1α,25-DIHYDROXYVITAMIN D3 GROWTH INHIBITION IN THE LNCaP PROSTATE cancer …
1583. Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer
1584. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells
1585. Insulin-like Growth Factor Binding Protein-3 Suppresses VEGF Expression and Inhibits Head and Neck Squamous cancer Cell Angiogenesis
1586. Insulin-like growth factor binding protein-3, induced by hypoxia inducible factor-1α, determines esophageal cancer cell adaptation to the microenvironment
1587. Insulin-like growth factor binding protein-4 (IGFBP-4) tumor and serum levels are increased across all stages of epithelial ovarian cancer
1588. Insulin-like growth factor binding protein-4 and-5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner
1589. Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer
1590. Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth
1591. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells
1592. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has a tumor-suppressive activity in human lung cancer
1593. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer
1594. Insulin-like growth factor binding protein-related protein 1 and cancer
1595. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism
1596. Insulin-like growth factor binding proteins (IGFBPs) in breast cancer
1597. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes
1598. Insulin-like growth factor binding proteins and angiogenesis: from cancer to cardiovascular disease
1599. Insulin-like growth factor binding proteins and breast cancer
1600. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation
1601. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer
1602. Insulin-like growth factor binding proteins in human breast cancer tissue
1603. Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) …
1604. Insulin-like growth factor expression in breast cancer epithelium and stroma
1605. Insulin-like growth factor expression in human cancer cell lines
1606. Insulin-like growth factor gene polymorphisms and risk of pancreatic cancer
1607. Insulin-like growth factor genetic variation, colorectal cancer and diabetes
1608. Insulin-like growth factor I (Igf-1) gene polymorphism in patients with non-metastatic breast cancer
1609. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer
1610. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer
1611. Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells
1612. Insulin-like growth factor I and prostate cancer
1613. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
1614. Insulin-like growth factor I and transforming growth factor α as autocrine growth factors in human pancreatic cancer cell growth
1615. Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells
1616. Insulin-like growth factor I in pregnancy and maternal risk of breast cancer
1617. Insulin-like growth factor I induces tumor hexokinase RNA expression in cancer cells
1618. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
1619. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles
1620. Insulin-Like Growth Factor I Polymorphisms in Breast cancer
1621. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia
1622. Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells
1623. Insulin-like growth factor I receptor (IGF-IR) inhibition in trastuzumab (T) resistant HER2+ breast cancer (BrCa) cells
1624. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells
1625. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts
1626. Insulin-like growth factor I regulates the expression of isoforms of Wilms’ tumor 1 gene in breast cancer
1627. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer
1628. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells
1629. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling
1630. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells
1631. Insulin-Like Growth Factor I, IGF-Binding Protein 3, and Lung cancer Risk in a Prospective Study of Men in
1632. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China
1633. Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer: relationship with the most important morphological and biochemical prognostic parameters
1634. Insulin-like growth factor II (IGF-II) regulates differential expression of Bcl-2, Bcl-XL and Survivin in African-American (AA) and Caucasian breast cancer cells
1635. Insulin-like growth factor II activates mitogenic signaling in pancreatic cancer cells via IRS-1
1636. Insulin-like growth factor II and colorectal cancer risk in women
1637. Insulin-Like Growth Factor II as a Prognostic Indicator in Breast cancer.
1638. Insulin-like growth factor II differential activation of the IGF-1 and Insulin receptors in African-American and Caucasian breast cancer tissues
1639. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells
1640. Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breast cancer cells
1641. Insulin-like growth factor II modulates the routing of cathepsin D in MCF-7 breast cancer cells
1642. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores
1643. Insulin-like growth factor Ⅱ mRNA binding protein 3 expression in the non-muscle invasive bladder cancer and its relationships with the prognosis
1644. Insulin-like growth factor II mRNA binding protein 3 regulates proliferation, invasion and migration of neuroendocrine cancer cells
1645. Insulin-like growth factor II mRNA expression in human breast cancer
1646. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer
1647. Insulin-like growth factor II-producing metastatic colon cancer with recurrent hypoglycemia
1648. Insulin-like growth factor levels in cord blood, birth weight and breast cancer risk
1649. Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer
1650. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials
1651. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival
1652. Insulin-Like Growth Factor Pathway–Targeted Therapy in Breast cancer
1653. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), Insulin resistance, and disease progression in patients with prostate cancer?
1654. Insulin-like growth factor physiology and cancer risk
1655. Insulin-like growth factor polymorphisms and colorectal cancer risk
1656. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
1657. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis
1658. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients
1659. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non–small-cell lung cancer: a comparison between …
1660. Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC)
1661. Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib
1662. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
1663. Insulin-like growth factor receptor 1 as a therapeutic target in head and neck cancer
1664. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer
1665. Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer
1666. Insulin-like growth factor receptor activity in cancer biology & therapy responses
1667. Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer
1668. Insulin-like growth factor receptor and sphingosine kinase co-expression has prognostic and therapeutic potential in breast cancer
1669. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer
1670. Insulin-like growth factor receptor expression and function in human breast cancer
1671. Insulin-like growth factor receptor I signaling in a breast cancer cell line
1672. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer
1673. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells
1674. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen
1675. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
1676. Insulin-like growth factor receptor signaling pathways and resistance to tarceva (erlotinib) in non-small cell lung cancer cells
1677. Insulin-like growth factor receptor type I as a target for cancer therapy
1678. Insulin-like growth factor receptor type I as a target for cancer therapy
1679. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy
1680. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis
1681. Insulin-like growth factor receptors in colorectal cancer.
1682. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer
1683. Insulin-like growth factor signaling in normal mammary gland development and breast cancer progression
1684. Insulin-like growth factor signalling in oestrogen nonresponsive breast cancer cells
1685. Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer
1686. Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer
1687. Insulin-like growth factor system in cancer: novel targeted therapies
1688. Insulin-like growth factor type I and Insulin-like growth factor type II stimulate oestradiol-17β hydroxysteroid dehydrogenase (reductive) activity in breast cancer cells
1689. Insulin-like growth factor type I receptor: a new target in the treatment of non-small cell lung cancer patients
1690. Insulin-like growth factor-1 (IGF-1) receptor-induced resistance to trastuzumab (Herceptin) in breast cancer (BC) xenografts in athymic mice can be measured using …
1691. Insulin-like growth factor-1 (IGF-1), Insulin-like growth factor-binding protein-3 (IGFBP-3) and breast cancer risk: observational and Mendelian randomization analyses
1692. Insulin-like growth factor-1 alters apoptotic signalling in prostate cancer.
1693. Insulin-like growth factor-1 and 17β-estradiol down-regulate prostate apoptosis response-4 expression in MCF-7 breast cancer cells
1694. Insulin-LIKE GROWTH FACTOR-1 AND BREAST cancer RISK IN KURDISH WOMEN
1695. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women.
1696. Insulin-like growth factor-1 and childhood cancer risk
1697. Insulin-like growth factor-1 and Insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy
1698. Insulin-like growth factor-1 and risk of breast cancer
1699. Insulin-like growth factor-1 attenuates cisplatin-induced γH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer
1700. Insulin-like growth factor-1 enhances mortality risk in women with breast cancer through epithelial-mesenchymal transition initiation
1701. Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
1702. Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer
1703. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells
1704. Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a …
1705. Insulin-like growth factor-1 modulates polycomb Cbx8 expression and inhibits colon cancer cell apoptosis
1706. Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach
1707. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer
1708. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial
1709. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives
1710. Insulin-like Growth Factor-1 Receptor as a Prognostic Factor for Breast cancer: A Systematic Review and Meta-Analysis
1711. Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein …
1712. Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7–H4 expression through the MEK/ERK signaling pathway
1713. Insulin-Like Growth Factor-1 Receptor Inhibitors: A Potential cancer Treatment: Patent Highlight
1714. Insulin-like growth factor-1 receptor signaling increases the invasive potential of HER2-overexpressing breast cancer cells via Src-FAK and FoxM1
1715. Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast cancer Cells …
1716. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSA™) in DU 145 human prostate cancer cells
1717. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review
1718. Insulin-like growth factor-1 receptors in head and neck cancer
1719. Insulin-like growth factor-1 regulates oestrogen production in breast cancer tissue.
1720. Insulin-like growth factor-1 signaling promotes mitochondrial turnover and protection in cancer cells
1721. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line
1722. Insulin-like growth factor-1 upregulates cyclooxygenase-2 expression in human ovarian cancer cells
1723. Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study
1724. Insulin-like growth factor-1, IGF-binding protein-3, C-peptide and colorectal cancer: a case-control study
1725. Insulin-like growth factor-1, Insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with∼ …
1726. Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant …
1727. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and-β via the IGF-1 and the Insulin receptors in breast cancer cells
1728. Insulin-like Growth Factor-2 (IGF-2) Activates Estrogen Receptor-α and-β via the IGF-1 and the Insulin Receptors in Breast cancer Cells.
1729. Insulin-like growth factor-2 is induced following 5-aminolevulinic acid-mediated photodynamic therapy in SW620 human colon cancer cell line
1730. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to
1731. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types
1732. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells
1733. Insulin-like growth factor-binding protein-1 and prostate cancer
1734. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or-independent mechanisms and reduces the efficacy of …
1735. Insulin-like growth factor-binding protein-3 gene-202 A/C polymorphism is correlated with advanced disease status in prostate cancer
1736. Insulin-like growth factor-binding protein-3 in breast cancer: analysis with tissue microarray
1737. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis
1738. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells
1739. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential …
1740. Insulin-like growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation
1741. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo
1742. Insulin-like growth factor-binding protein-6 and cancer
1743. Insulin-like growth factor-binding protein-6 produced by human PC-3 prostate cancer cells: isolation, characterization and its biological action
1744. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy
1745. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741
1746. Insulin-like growth factor-I (IGF-I) and all-cancer mortality in older men: The Rancho Bernardo study
1747. Insulin-like growth factor-I (IGF-I) and chosen parameters of hormonal condition in women with breast cancer
1748. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer
1749. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer
1750. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early-and late-stage breast cancer: mutual relationship and possible …
1751. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis
1752. Insulin-like growth factor-I activates NFκB and NLRP3 inflammatory signalling via ROS in cancer cells
1753. Insulin-like growth factor-I and binding protein-3 and risk of cancer
1754. Insulin-like growth factor-I and breast cancer therapy
1755. Insulin-like growth factor-I and breast cancer: epidemiological and clinical data
1756. Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case–control study
1757. Insulin-like growth factor-I and cancer mortality in older men
1758. Insulin-like growth factor-I and cancer risk
1759. Insulin-like growth factor-I and estrogen interactions in breast cancer
1760. Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture
1761. Insulin-like growth factor-I and new opportunities for cancer prevention
1762. Insulin-like growth factor-I and prostate cancer: a meta-analysis
1763. Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition
1764. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells
1765. Insulin-like growth factor-I as a risk factor for breast cancer among Ugandan women in Mulago National Referral Hospital
1766. Insulin-like growth factor-I axis as a pathway for cancer chemoprevention
1767. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.
1768. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into cancer and Nutrition
1769. Insulin-like growth factor-I dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells: Tisheeka R. Graham, Haiyen …
1770. Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer
1771. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth
1772. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells
1773. Insulin-like growth factor-I induces epithelial to mesenchymal transition via GSK-3β and ZEB2 in the BGC-823 gastric cancer cell line
1774. Insulin-like growth factor-I induces MAPK and JAK/STAT signaling and protects breast cancer cells from hormonally-induced cytostasis and cell death
1775. Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line
1776. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin …
1777. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the αvβ3 integrin and PI3-K/Akt signaling
1778. Insulin-like Growth Factor-I Protects Colon cancer Cells from
1779. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor α-induced mitogen-activated protein …
1780. Insulin-like growth factor-I receptor (IGF-IR) dowregulation in cisplatin-resistant human ovarian cancer cells
1781. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells
1782. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells
1783. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol
1784. Insulin-like growth factor-I receptor in human oral cancer
1785. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer
1786. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines
1787. Insulin-like growth factor-I receptor is a candidate molecular target for human esophageal squamous cell cancer.
1788. Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in …
1789. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
1790. Insulin-like growth factor-I receptor signaling and resistance in breast cancer
1791. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor
1792. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
1793. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
1794. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
1795. Insulin-like growth factor-I regulates GPER expression and function in cancer cells
1796. Insulin-like growth factor-i signalling in tamoxifen sensitive and tamoxifen resistant breast cancer cells
1797. Insulin-like growth factor-I–dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells
1798. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays
1799. Insulin-like growth factor-I, interleukin-1 α and β in pancreatic cancer: role in tumor invasiveness and associated diabetes
1800. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II
1801. Insulin-like growth factor-I, soy protein intake, and breast cancer risk
1802. Insulin-like growth factor-I: a key regulator of human cancer risk?
1803. Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration
1804. Insulin-like growth factor-II imprinting in cancer.
1805. Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort
1806. Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth
1807. Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in …
1808. Insulin-like growth factor-l and risk of breast cancer
1809. Insulin-like growth factor-ll (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
1810. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study
1811. Insulin-like growth factor-related signaling and cancer development
1812. Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast cancer
1813. Insulin-Like Growth Factor–Binding Protein-3, Breast cancer Risk, and Different Serum Assays
1814. Insulin-like growth factor–type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells
1815. Insulin-like growth factor: current concepts and new developments in cancer therapy
1816. Insulin-like growth factorⅠregulates the type IGF receptor in A549 non-small cell lung cancer and Lymphocytic cells
1817. Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer
1818. Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study
1819. Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells
1820. Insulin-like growth factors and breast cancer
1821. Insulin-like growth factors and breast cancer risk in Chinese women
1822. Insulin-like growth factors and breast cancer therapy
1823. Insulin-like growth factors and cancer
1824. Insulin-like growth factors and cancer: from basic biology to therapeutics.
1825. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies
1826. Insulin-like growth factors and cancer.
1827. Insulin-like growth factors and cytokines in pediatric cancer
1828. Insulin-like growth factors and Insulin control a multifunctional signalling network of significant importance in cancer
1829. Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate cancer Risk: Results from the Prostate cancer Prevention Trial
1830. Insulin-like growth factors and its binding proteins in serum in colon cancer
1831. Insulin-like growth factors and kidney cancer risk in men
1832. Insulin-like growth factors and liver cancer risk in male smokers
1833. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts
1834. Insulin-like growth factors and prostate cancer
1835. Insulin-like growth factors and prostate cancer: a population-based case-control study in China
1836. Insulin-like growth factors and risk of kidney cancer in men
1837. Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence?☆
1838. Insulin-like growth factors and their binding proteins in tumors and ascites of ovarian cancer patients: association with response to neoadjuvant chemotherapy
1839. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase …
1840. Insulin-like growth factors as targets for cancer treatment
1841. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African–American women
1842. Insulin-like growth factors in breast and prostatic cancer
1843. Insulin-like growth factors in breast cancer
1844. Insulin-like growth factors in human breast cancer
1845. Insulin-like growth factors in lung cancer cell lines
1846. Insulin-like growth factors stimulate the release of Insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell …
1847. Insulin-like growth factors, Insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a US case-control study
1848. Insulin-like growth factors, Insulin, and growth hormone signaling in breast cancer: implications for targeted therapy
1849. Insulin-like growth factors, sex hormones, C-reactive protein, and risk of epithelial ovarian cancer.
1850. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies
1851. Insulin-like-growth factor-binding-protein 7: an antagonist to breast cancer
1852. Insulin-lowering effects of metformin in women with early breast cancer
1853. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes
1854. Insulin-RB heterodimer: potential involvement in the linkage between aging and cancer
1855. Insulin-Regulated Aminopeptidase in Women with Breast cancer: A Role beyond the Regulation of Oxytocin and Vasopressin
1856. Insulin-regulated aminopeptidase/placental leucil Aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer …
1857. Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity.
1858. Insulin-sensitizers, polycystic ovary syndrome and gynaecological cancer risk
1859. Insulin‐induced gene 2 expression correlates with colorectal cancer metastasis and disease outcome
1860. Insulin‐induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system
1861. Insulin‐like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β‐hCG and cancer treatment
1862. Insulin‐like growth factor (IGF) system components in human prostatic cancer cell‐lines: LNCaP, DU145, and PC‐3 cells
1863. Insulin‐like growth factor (IGF)‐I and IGF‐binding protein 3 and the risk of premenopausal breast cancer: a meta‐analysis of literature
1864. Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death–proliferative and anti‐apoptotic effects
1865. Insulin‐like growth factor (IGF)–binding protein‐3 (IGFBP‐3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the …
1866. Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
1867. Insulin‐like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men
1868. Insulin‐like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the STAT3 pathway
1869. Insulin‑like growth factor 1 receptor expression in breast cancer tissue and mammographic density
1870. Insulin‐like growth factor 2 expression in prostate cancer is regulated by promoter‐specific methylation
1871. Insulin‐like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk
1872. Insulin‐like growth factor axis targeting in cancer and tumour angiogenesis–the missing link
1873. Insulin‐like growth factor binding protein‐3 (IGFBP‐3) in the prostate and in prostate cancer: Local production, distribution and secretion pattern indicate a role in …
1874. Insulin‐like growth factor binding protein‐3 (IGFBP‐3) potentiates paclitaxel‐induced apoptosis in human breast cancer cells
1875. Insulin‐like growth factor binding protein‐3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo
1876. Insulin‐like growth factor binding protein‐4 inhibits cell growth, migration and invasion, and downregulates COX‐2 expression in A549 lung cancer cells
1877. Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1) has potential tumour‐suppressive activity in human lung cancer
1878. Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1/mac 25) is reduced in human prostate cancer and is inversely related to tumor volume and …
1879. Insulin‐like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort
1880. Insulin‐like growth factor I and risk of incident cancer in elderly men–results from MrOS (Osteoporotic Fractures in Men) in Sweden
1881. Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines
1882. Insulin‐like growth factor ligands, receptors, and binding proteins in cancer
1883. Insulin‐like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate cancer Cohort …
1884. Insulin‐like growth factor stimulation increases radiosensitivity of a pancreatic cancer cell line through endoplasmic reticulum stress under hypoxic conditions
1885. Insulin‐like growth factor‐1 receptors and Insulin‐like growth factor‐1‐like activity in human primary breast cancer
1886. Insulin‐like growth factor‐1 signaling is responsible for cathepsin G‐induced aggregation of breast cancer MCF‐7 cells
1887. Insulin‐like growth factor‐2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer
1888. Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women
1889. Insulin‐like growth factor‐I promotes multidrug resistance in MCLM colon cancer cells
1890. Insulin‐like growth factor‐I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45
1891. Insulin‐like growth factor‐I receptor correlates with connexin 26 and Bcl‐xL expression in human colorectal cancer
1892. Insulin‐like growth factor‐I, Insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
1893. Insulin‐like growth factor–binding protein‐3 and breast cancer survival
1894. Insulin‐like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells
1895. Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells
1896. Insulin‐like growth‐factor‐binding protein 3 is decreased in early‐stage operable pre‐menopausal breast cancer
1897. Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in …
1898. Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
1899. Insulin—carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research
1900. Insulin, carbohydrate restriction, metabolic syndrome and cancer
1901. Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11β-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell …
1902. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer
1903. Insulin, estradiol levels and body mass index in pre-and post-menopausal women with breast cancer
1904. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes
1905. Insulin, glucose, Insulin resistance, and incident colorectal cancer in male smokers
1906. Insulin, glucose, Insulin resistance, and pancreatic cancer in male smokers
1907. Insulin, growth factors, and cancer cell energy metabolism: an hypothesis on oncogene action
1908. Insulin, IGFs, and energy balance: Relevance to cancer risk.
1909. Insulin, Insulin receptors, and cancer
1910. Insulin, Insulin resistance, and cancer associations
1911. Insulin, Insulin resistance, obesity, and cancer
1912. Insulin, Insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer
1913. Insulin, Insulin-like growth factor-I and breast cancer risk in Japanese women
1914. Insulin, Insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
1915. Insulin, Insulin-like growth factor-I, endogenous estradiol and risk of colorectal cancer in postmenopausal women
1916. Insulin, Insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women
1917. Insulin, Insulin-like growth factors and colon cancer: a review of the evidence
1918. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth
1919. Insulin, macronutrient intake, and physical activity: are potential indicators of Insulin resistance associated with mortality from breast cancer?
1920. Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications
1921. Insulin, the Insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
1922. Insulin: a novel agent in the pathogenesis of prostate cancer
1923. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors
1924. Insulin/IGF Axis in Breast cancer: Clinical Evidence and Translational Insights
1925. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention
1926. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer
1927. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer
1928. Insulin/Insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells …
1929. Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies
1930. Insulin/PI3K signalling pathway regulates the expression of survivin in liver cancer HepG2 cells
1931. Intact and total Insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study
1932. Integrating Insulin-like growth factor-1 (IGF-1) score into Barcelona Clinic Liver cancer (BCLC) and cancer of the Liver Italian Program (CLIP) scores.
1933. Integration of downstream signals of Insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer …
1934. Intensive versus conventional Insulin therapy in nondiabetic patients receiving parenteral nutrition after D2 gastrectomy for gastric cancer: a randomized controlled …
1935. Intensive versus conventional Insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial
1936. Interaction between cyclooxygenase-2 and Insulin-like growth factor in breast cancer: A new field for prevention and treatment
1937. Interaction between estrogen receptor alpha and Insulin/IGF signaling in breast cancer.
1938. Interaction between nuclear Insulin receptor substrate-2 and NF-κB in IGF-1 induces response in breast cancer cells
1939. Interaction of breast cancer and Insulin resistance on PD1 and TIM3 expression in peripheral blood CD8 T cells
1940. Interaction of Insulin-like growth factor-I and Insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk
1941. Interaction of Insulin-like growth factor-I and Insulin resistance-related genetic variants with obesity and lifestyle factors on postmenopausal breast cancer risk
1942. Interactions between Insulin-like growth factor-I, estrogen receptor-α (ERα) and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells
1943. Interactions between plasma levels of 25-hydroxyvitamin D, Insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer
1944. Interactions of the Insulin-like growth factor axis and vitamin D in prostate cancer risk in the prostate cancer prevention trial
1945. Interleukin-1 blocks Insulin and Insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity
1946. Interleukin-1beta (IL-1beta) and IL-6 modulate Insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells
1947. Interrelationships between plasma testosterone, SHBG, IGF-I, Insulin and leptin in prostate cancer cases and controls
1948. Interventions to improve Insulin resistance for the prevention of endometrial cancer
1949. Intestinal Insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer
1950. Intra-Pancreatic Insulin Nourishes cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?
1951. Intracellular presence of Insulin and its phosphorylated receptor in non‐small cell lung cancer
1952. Introduction of Insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential
1953. Inverse relation between prostate-specific antigen and Insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer
1954. Investigating the Insulin-like growth factor axis in head and neck cancer
1955. Investigation of Insulin resistance gene polymorphisms in patients with differentiated thyroid cancer
1956. Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms’ Tumor 1 (WT1) Expression Levels in the Colon Polyp Subtypes in Colon cancer
1957. Involvement of alternative splicing of the Insulin and androgen receptors in prostate cancer: role of the Insulin like growth factor axis
1958. Involvement of Insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth
1959. Involvement of Insulin-Like Growth Factor-1 in Receptor Activator of Nuclear Factor Kappa-B Ligand-Targeted Therapy in Mouse Model of Lung cancer Bone …
1960. Involvement of p53 in Insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage
1961. Involvement of the Insulin-like growth factor binding proteins in the cancer cell response to DNA damage
1962. IRS-1 and SOCS2 are key regulators of Insulin-like growth factor signaling in intestinal cancer
1963. Is elevated serum Insulin a marker of increased risk of colorectal cancer?
1964. Is Insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
1965. Is Insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?
1966. Is maternal variability in the Insulin-like growth factor I pathway associated with testicular cancer risk? A case-parent triad study.
1967. Is profound peripheral Insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?
1968. Is the mannose-6-phosphate/Insulin-like growth factor 2 receptor coded by a breast cancer suppressor gene?
1969. Is the type I Insulin-like growth factor receptor a therapeutic target in endometrial cancer?
1970. Is there an association between variants in candidate Insulin pathway genes IGF-I, IGFBP-3, INSR, and IRS2 and risk of colorectal cancer in the Iranian population?
1971. Is there any association between Insulin resistance and thyroid cancer?: a case control study
1972. Isoflavone effects on Insulin like growth factors and breast cancer.
1973. Isolated isoflavones do not affect the circulating Insulin-like growth factor system in men at increased colorectal cancer risk
1974. Isolation of a cDNA for a Growth Factor of Vascular Endothelial Cells from Human Lung cancer Cells: Its Identity with Insulin‐like Growth Factor II
1975. James Forsythe, MD, HMD: The Success of Integrative cancer Therapy Based on Chemosensitivity Testing and Insulin Potentiation Therapy
1976. Joint effect of Insulin-like growth factors and mutagen sensitivity in lung cancer risk
1977. Joint effect of Insulin-like growth factors and sex steroids on breast cancer risk
1978. Judicious toggling of mTOR activity to combat Insulin resistance and cancer: current evidence and perspectives
1979. Kaempferol downregulates Insulin-like growth factor-I receptor and ErbB3 signaling in HT-29 human colon cancer cells
1980. Kallikrein 11 expressed in human breast cancer cells releases Insulin-like growth factor through degradation of IGFBP-3
1981. Kernel density estimation as a measure of environmental exposure related to Insulin resistance in breast cancer survivors
1982. Key protein expressions in the Insulin-like growth factor-1 signal pathway involved in the resistance of ovarian cancer to cisplatin
1983. Klotho expression in epithelial ovarian cancer and its association with Insulin-like growth factors and disease progression
1984. Knockdown of Insulin-like growth factor I receptor inhibits the growth and enhances chemo-sensitivity of liver cancer cells
1985. Knockdown of type I Insulin-like growth factor receptor inhibits human colorectal cancer cell growth and downstream PI3K/Akt, WNT/β-catenin signal pathways
1986. Knotwood extract from Norway spruce (Picea abies) as treatment for androgen-independent prostate cancer: In vitro study of Insulin signaling and proliferation in PC-3 …
1987. Lack of any prognostic role of Insulin-like growth factor-1 receptor in non-small cell lung cancer
1988. Lack of association between Insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis
1989. Lack of Association between Risk of Biliary Tract cancer and Circulating IGF (Insulin-like Growth Factor)-I, IGF-II or IGFBP-3 (IGF-binding Protein 3): A Nested …
1990. Lack of interaction between ErbB2 and Insulin receptor substrate signaling in breast cancer
1991. Lack of prognostic value of Insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray
1992. Laminin-5 and Insulin-like growth factor-II mRNA binding protein-3 (IMP3) expression in preoperative biopsy specimens from oral cancer patients: Their role in neural …
1993. Laparoscopic surgery improves blood glucose homeostasis and Insulin resistance following distal gastrectomy for cancer
1994. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on Insulin-like growth factor I signaling
1995. Lead identification to generate isoquinolinedione inhibitors of Insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment
1996. Lean mass is inversely associated with breast cancer, while abdominal adiposity and Insulin resistance increases the chances of developing the cancer
1997. Leptin and Insulin growth factor I in relation to breast cancer (Greece)
1998. Leptin and Insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells
1999. Leptin in Breast cancer: Its Relationship with Insulin, Estrogens and Oxidative Stress
2000. Leptin, Insulin and body composition changes during adjuvant taxane based chemotherapy in patients with breast cancer, preliminary study
2001. let-7a and its target, Insulin-like growth factor 1 receptor, are differentially expressed in recurrent prostate cancer
2002. Let-7a regulation of Insulin-like growth factors in breast cancer
2003. Let‐7e enhances the radiosensitivity of colorectal cancer cells by directly targeting Insulin‐like growth factor 1 receptor
2004. Letter regarding article,“Associations of obesity and circulating Insulin and glucose with breast cancer risk: a Mendelian randomization analysis”
2005. Leucinostatin A inhibits prostate cancer growth through reduction of Insulin‐like growth factor‐I expression in prostate stromal cells
2006. Levels of Insulin-like growth factor during pregnancy and maternal cancer risk: a nested case–control study
2007. Levels of Insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
2008. Lin28b promotes head and neck cancer progression via modulation of the Insulin-like growth factor survival pathway
2009. Link between Insulin and metabolic disorders in cancer: does leptin play a key role?
2010. Linoleic acid induces an increased response to Insulin in MDA‐MB‐231 breast cancer cells
2011. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced Insulin resistance
2012. Lipopolysaccharide, TNFα, IL-6, dexamethasone, and Insulin increase the expression of GPR54 in the MCF7 breasr cancer cell line
2013. Liposomal Insulin promoter–thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice
2014. Local expression of Insulin-like growth factor-I affects angiogenesis in colorectal cancer
2015. Local expression of Insulin-like growth factor-I, Insulin-like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer
2016. Localization of Insulin Receptor Substrate-2 in Breast cancer: A Dissertation
2017. Long-acting Insulin analogs and cancer
2018. Long-acting Insulin analogs exposure and cancer specific mortality in patients with diabetes mellitus
2019. Long-Acting Insulin Analogues and Risk of Breast cancer—Meta-analysis
2020. Long-term effects of fenretinide, a retinoic acid derivative, on the Insulin-like growth factor system in women with early breast cancer
2021. Long-term effects of Insulin glargine on the risk of breast cancer
2022. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without Insulin treatment: a nationwide cohort study
2023. Long-term use of basal Insulin and the risk of breast cancer
2024. Long-term use of Insulin glargine might increase the risk of breast cancer
2025. Long-term use of long-acting Insulin analogs and breast cancer incidence in women with type 2 diabetes
2026. Long‐term metformin use reduces gastric cancer risk in type 2 diabetics without Insulin treatment: a nationwide cohort study
2027. Longitudinal associations of blood biomarkers of Insulin and glucose metabolism and colorectal cancer risk in the Framingham Heart Study Offspring population (1971 …
2028. Longitudinal associations of blood markers of Insulin and glucose concentrations and cancer mortality in the Third National Health and Nutrition Examination …
2029. Longitudinal associations of blood markers of Insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey
2030. Loss of imprinting and abnormal expression of Insulin-like growth factor II in gastric cancer
2031. Loss of imprinting and abnormal expression of the Insulin‐like growth factor 2 gene in gastric cancer
2032. Loss of imprinting of Insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer
2033. Loss of imprinting of Insulin-like growth factor 2 is associated with increased risk of primary lung cancer in the central China region
2034. Loss of imprinting of Insulin-like growth factor II is associated with increased risk of proximal colon cancer
2035. Loss of imprinting of the Insulin-like growth factor 2 gene and risk of colorectal cancer
2036. Loss of imprinting of the Insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer
2037. Loss of Insulin Receptor Substrates 1 and 2 Suppresses Kras-Driven Non-Small Cell Lung cancer
2038. Loss of Insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells
2039. Loss of Insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and Insulin receptors
2040. Low levels of Insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes’ C human colorectal cancers
2041. Low serum Insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
2042. Low-dose chemotherapy with Insulin (Insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer
2043. LOW-PENETRANCE SUSCEPTIBILITY GENES FOR COLORECTAL cancer IN THE Insulin/Insulin GROWTH FACTOR 1 AXIS
2044. Lower Concentrations of Glucose or Insulin Decrease the Risk of Various Types of cancer in the Long-Lived Ames Dwarf Mouse by Increasing the Expression …
2045. Lung cancer–Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) …
2046. Lupeol, a novel diet-based triterpene modulates Insulin growth factor receptor 1 and β-catenin signaling in human prostate cancer cells
2047. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the Insulin-like growth factor system in androgen-independent prostate cancer …
2048. Luteolin decreases IGF-II production and downregulates Insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells
2049. Luteolin inhibits Insulin-like growth factor 1 receptor signaling in prostate cancer cells
2050. Lycopene enhances docetaxel’s effect in castration-resistant prostate cancer associated with Insulin-like growth factor I receptor levels
2051. Lycopene interferes with cell cycle progression and Insulin-like growth factor I signaling in mammary cancer cells
2052. Lycopene supplementation elevates circulating Insulin-like growth factor–binding protein-1 and-2 concentrations in persons at greater risk of colorectal cancer
2053. Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs Insulin secretion function of β-cell
2054. Mammary cancer in transgenic mice expressing Insulin-like growth factor II (IGF-II)
2055. Marginal effects of glucose, Insulin and Insulin‑like growth factor on chemotherapy response in endothelial and colorectal cancer cells
2056. Markers of Insulin resistance and colorectal cancer mortality
2057. Markers of Insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and …
2058. Material-induced Senescence (MIS): Fluidity induces senescent type cell death of lung cancer cells via Insulin-like growth factor binding protein 5
2059. Matrix metalloproteinase 9 promotes breast cancer through regulation of Insulin-like growth factor-binding proteins
2060. Measurement of Insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening
2061. Mechanism involved in genistein activation of Insulin-like growth factor 1 receptor expression in human breast cancer cells
2062. Mechanism of protein kinase B activation by Insulin IGF1 revealed by specific inhibitors of the phosphoinositide 3-kinase. Significance for diabetes and cancer
2063. Mechanisms linking diet and colorectal cancer: the possible role of Insulin resistance
2064. Mechanisms of acquired resistance to Insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line
2065. Mechanisms of antibody-mediated Insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.
2066. Mechanisms of disease: signaling of the Insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer
2067. Mechanisms of Insulin resistance in cancer associated malnutrition
2068. Mechanisms of regulation of cell adhesion and motility by Insulin receptor substrate-1 in prostate cancer cells
2069. Mechanisms underlying lack of Insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer
2070. Mechanistic links between obesity, Insulin, and cancer
2071. Mechanistic target of rapamycin (mTOR): a point of convergence in the action of Insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer …
2072. Medically managed hypercholesterolemia and Insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer
2073. Meeting Report: 3 rd International Workshop on Insulin & cancer Heidelberg, Germany, October 30-31, 2010
2074. Megestrol acetate may stimulate the production of Insulin-like growth factor 1 in breast tissues of women with breast cancer
2075. MEK1 and MEK2 differentially regulate human Insulin-and Insulin glargine-induced human bladder cancer T24 cell proliferation
2076. Membrane localization of Insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer
2077. Mendelian Randomization Analysis Identifies Body Mass Index and Fasting Insulin as Potential Causal Risk Factors for Pancreatic cancer Risk
2078. Meta-analysis of cancer risk among users of Insulin glargine.
2079. Meta-analysis of Insulin glargine and cancer risk.
2080. Meta-analysis of the association between Insulin-like growth factor binding protein 3 genetic polymorphisms and colorectal cancer susceptibility
2081. Metabolic disturbance and Insulin resistance in patients with colorectal cancer
2082. Metabolic health, Insulin, and breast cancer: Why oncologists should care about Insulin
2083. Metabolic modification by Insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells
2084. Metabolic syndrome and colon cancer: Is hyperInsulinemia/Insulin receptor-mediated angiogenesis a critical process?
2085. Metabolic syndrome and colorectal cancer: is hyperInsulinemia/Insulin receptor-mediated angiogenesis a critical process?
2086. Metabolic syndrome and Insulin resistance in patients with prostate cancer treated with androgen deprivation hormone
2087. Metabolic syndrome and Insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China
2088. Metabolic syndrome, central obesity and Insulin resistance are associated with adverse pathological features in postmenopausal breast cancer
2089. Metabolic syndrome, Insulin resistance, and inflammation in breast cancer: impact on prognosis and adjuvant interventions
2090. METABOLIC SYNDROME, Insulin RESISTANCE, AND SEDENTARY BEHAVIOR AMONG OVERWEIGHT AND OBESE BREAST cancer SURVIVORS
2091. Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of Insulin-growth factor binding protein-3 in breast cancer
2092. Metformin affects breast cancer cell growth and disturbs an IGF1/Insulin related gene network that correlates with breast cancer progression
2093. Metformin and an Insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer
2094. Metformin and cancer occurrence in Insulin-treated type 2 diabetic patients
2095. Metformin and energy metabolism in breast cancer: from Insulin physiology to tumour-initiating stem cells
2096. Metformin disrupts crosstalk between G protein–coupled receptor and Insulin receptor signaling systems and inhibits pancreatic cancer growth
2097. Metformin inhibits the androgen mediated up-regulation of Insulin Growth Factor-I Receptor in prostate cancer cells
2098. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of Insulin-like growth factor 1 receptor
2099. Metformin revert Insulin‐induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells
2100. Metformin, Insulin, breast cancer and more…
2101. Methylation of the Insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
2102. Methylation status of Insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer
2103. Methylation status of Insulin‐like growth factor‐binding protein‐3 promoter in prostate cancer tissues
2104. MHC-restricted phosphopeptides from Insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer
2105. Micro RNA 145 targets the Insulin receptor substrate-1 and inhibits the growth of colon cancer cells
2106. Microarray Identifies Cyclo-oxygenase-2–Dependent Modulation of Insulin-like Growth Factor Binding Protein-3 in Non-small Cell Lung cancer Cells
2107. MicroRNA-10b inhibits proliferation, migration and invasion in cervical cancer cells via direct targeting of Insulin-like growth factor-1 receptor
2108. MicroRNA-126 inhibits the migration and invasion of endometrial cancer cells by targeting Insulin receptor substrate 1
2109. MicroRNA-139-5p inhibits cell proliferation and invasion by targeting Insulin-like growth factor 1 receptor in human non-small cell lung cancer
2110. MicroRNA-140-5p targets Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) to suppress cervical cancer growth and metastasis
2111. microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting Insulin receptor substrate 2
2112. MicroRNA-145 directly targets the Insulin-like growth factor receptor I in human bladder cancer cells
2113. MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting Insulin receptor substrate 2
2114. MicroRNA-30a inhibits colorectal cancer metastasis through down-regulation of type I Insulin-like growth factor receptor
2115. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the Insulin-like growth factor 1 receptor
2116. MicroRNA-497 targets Insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer
2117. MicroRNA-503 inhibits the proliferation and invasion of breast cancer cells via targeting Insulin-like growth factor 1 receptor
2118. MicroRNA-664 targets Insulin receptor substrate 1 to suppress cell proliferation and invasion in breast cancer
2119. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting Insulin-like growth factor-1 receptor
2120. MicroRNA-7 functions as antimetastic microRNA in gastric cancer by targeting Insulin-like growth factor 1 receptor
2121. MicroRNA‑30a‑5p inhibits the proliferation and invasion of gastric cancer cells by targeting Insulin‑like growth factor 1 receptor
2122. MicroRNA‑320a is downregulated in non‑small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting Insulin‑like growth factor …
2123. MicroRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting Insulin‑like growth factor 1 receptor
2124. MicroRNA‑454‑3p inhibits cell proliferation and invasion in esophageal cancer by targeting Insulin‑like growth factor 2 mRNA‑binding protein 1
2125. MicroRNA‑455 is downregulated in gastric cancer and inhibits cell proliferation, migration and invasion via targeting Insulin‑like growth factor 1 receptor
2126. MicroRNA‑497 inhibits tumor growth through targeting Insulin receptor substrate 1 in colorectal cancer
2127. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting Insulin receptor substrate 2 and regulating the PI3K/Akt pathway
2128. Milk intake, circulating levels of Insulin-like growth factor-I, and risk of colorectal cancer in men
2129. Minireview: IGF, Insulin, and cancer
2130. miR-133a suppresses ovarian cancer cell proliferation by directly targeting Insulin-like growth factor 1 receptor
2131. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I Insulin-like growth factor receptor
2132. miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting Insulin-like growth factor 1 receptor
2133. MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting Insulin-like growth factor receptor 1 in human cervical cancer
2134. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the Insulin-like growth factor-1 receptor
2135. miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the Insulin signaling pathway
2136. miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the Insulin-like growth factor-1 receptor
2137. MiR-99a suppress proliferation, migration and invasion through regulating Insulin-like growth factor 1 receptor in breast cancer
2138. miR‑197 promotes the invasion and migration of colorectal cancer by targeting Insulin‑like growth factor‑binding protein 3
2139. miRNAs in Insulin resistance and diabetes-associated pancreatic cancer: the ‘minute and miracle’molecule moving as a monitor in the ‘genomic galaxy’
2140. Mitogenic and anti-apoptotic effects of Insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent
2141. Mitogenic signaling of Insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen …
2142. Mitogenic stimulation of human breast cancer cells in a growth factor‐defined medium: synergistic action of Insulin and estrogen
2143. Modulation of both Insulin resistance and cancer growth by inositol
2144. Modulation of Insulin degrading enzyme activity: A link between T2DM and liver cancer?
2145. Modulation of Insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol
2146. Modulation of Insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives
2147. Modulation of Insulin-like growth factors (IGF I-II) and IGF binding-protein 3 (IGFBP-3) through exercise training in women with breast cancer: A systematic review and …
2148. Modulation of Insulin-like growth factors following exercise in breast cancer: A meta-analysis of randomized controlled trials.
2149. Modulation of response to radiation of human lung cancer cells following Insulin-like growth factor 1 receptor inactivation
2150. Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and Insulin
2151. Modulation of the Insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines
2152. Molecular analysis of non–small cell lung cancer identifies subsets with different sensitivity to Insulin-like growth factor I receptor inhibition
2153. Molecular and circulatory expression of Insulin growth factors in Indian females with advanced cervical cancer
2154. Molecular aspects of the link between obesity, Insulin resistance and breast cancer.
2155. Molecular forms of the Insulin-like growth factor-binding protein-2 in patients with colorectal cancer
2156. Molecular imaging of Insulin-like growth factor 1 receptor in cancer
2157. Molecular Interactions Between Insulin-like Growth Factor Signal Transduction and Retinoids in Breast cancer Cells
2158. Molecular links between energy balance and colorectal cancer risk: A key role for methylation of Insulin-like growth factor binding protein genes.
2159. Molecular pathology of lung cancer and Insulin-like growth factors
2160. Molecular predictors of response to a humanized anti–Insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
2161. Molecular Profiling of Breast cancer Susceptibility of Obese or Insulin-Resistant and Pre-Diabetic Patients Using ITLN1 and CD295 SNPs
2162. Monoallelic expression of the Insulin-like growth factor-2 gene in ovarian cancer.
2163. More about: prospective study of colorectal cancer risk in men and plasma levels of Insulin-like growth factor (IGF)-I and IGF-binding protein-3
2164. Mouse Models Used to Study the Effects of Diabetes, Insulin, and IGFs on cancer
2165. MP37-12 Insulin-LIKE GROWTH FACTOR-I INDUCES CLU EXPRESSION THROUGH TWIST1 TO PROMOTE PROSTATE cancer GROWTH
2166. MP39-10 SERUM Insulin-LIKE GROWTH FACTOR-1 (IGF-1) WAS A VALUABLE BIOMARKER TO PREDICT THE HIGH GRADE PROSTATE cancer IN FINAL …
2167. MP46-08 THE TYRPHOSTIN, NT157, SUPPRESSES Insulin RECEPTOR SUBSTRATES AND AUGMENTS THERAPEUTIC RESPONSE OF PROSTATE cancer
2168. MP46-10 UTILIZING Insulin IN THE TREATMENT OF PROSTATE cancer WITH BKM120 ABROGATES THE THERAPEUTIC EFFECT OF PI3K PATHWAY …
2169. MP68-09 Insulin RECEPTOR IS OVEREXPRESSED IN TUMOR BLOOD VESSELS AND PREDICTS WORSE OUTCOME IN BLADDER cancer
2170. mRNA expression of components of the Insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells.
2171. Multifunctional roles of Insulin-like growth factor binding protein 5 in breast cancer
2172. Multihormonal regulation of Insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells
2173. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among Insulin/Insulin-like growth factor-I, serum, and …
2174. Multiple roles for the mannose-6-phosphate/Insulin-like growth factor II receptor in prostate cancer growth.
2175. Multiple signaling pathways are activated during Insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration
2176. Mutational analysis of the Insulin‑like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients
2177. Myotubularin-related protein 7 inhibits Insulin signaling in colorectal cancer
2178. Nanog regulates self‐renewal of cancer stem cells through the Insulin‐like growth factor pathway in human hepatocellular carcinoma
2179. Naproxen, clenbuterol and Insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats
2180. Neuroendocrine cancer-specific up-regulating mechanism of Insulin-like growth factor binding protein-2 in small cell lung cancer
2181. New advances on the functional cross-talk between Insulin-like growth factor-I and estrogen signaling in cancer
2182. New doctorial cancer research: novel animal models to study the role of the growth hormone Insulin-like growth factor I axis in prostate cancer
2183. New metformin derivative HL 156A prevents oral cancer progression by inhibiting the Insulin‐like growth factor/AKT/mammalian target of rapamycin pathways
2184. New players for advanced prostate cancer and the rationalisation of Insulin-sensitising medication
2185. Newly diagnosed Insulin resistance in patients with esophageal cancer
2186. Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of Insulin receptor substrate-1 protein
2187. No association between genetic polymorphisms in Insulin and Insulin receptor substrate-1 and prostate cancer
2188. No association between serum Insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk
2189. No association of Insulin-like growth factor gene polymorphisms with survival in patients with colorectal cancer
2190. No effect of red clover–derived isoflavone intervention on the Insulin-like growth factor system in women at increased risk of colorectal cancer
2191. No Increased Risk of Breast cancer in Patients Exposed to Insulin Glargine Compared with Human NPH Insulin
2192. Non-metabolisable Insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes
2193. Non-receptor mediated, post-transcriptional regulation of Insulin-like growth factor binding protein (IGFBP)-3 in Hs578T human breast cancer cells
2194. Non-small cell lung cancer cell survival crucially depends on functional Insulin receptors
2195. Nonsecreted Insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms …
2196. Nordihydroguaiaretic acid, a cytotoxic Insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
2197. Normal protein anabolic response to hyperaminoacidemia in Insulin-resistant patients with lung cancer cachexia
2198. Normal protein anabolic response to hyperaminoacidemia in Insulin‐resistant patients with lung cancer cachexia
2199. Novel aspects concerning the functional cross-talk between the Insulin/IGF-I system and estrogen signaling in cancer cells
2200. Novel Insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
2201. Novel multiplex method to assess Insulin, leptin and adiponectin regulation of inflammatory cytokines associated with colon cancer
2202. Novel stimulatory role for Insulin‐like growth factor binding protein‐2 in prostate cancer cells
2203. Novel Targets for the Treatment of Pancreatic cancer I: Insulin-like Growth Factor Receptor
2204. Novel therapeutic targets in advanced gastric cancer: $$ b the Insulin-like growth factor signal transduction pathway
2205. NR2F2 plays a major role in Insulin-induced epithelial-mesenchymal transition in breast cancer cells
2206. Nuclear expression of Insulin receptor (InsR) adds prognostic information in primary breast cancer patients with high BMI
2207. Nuclear Insulin-like growth factor binding protein-3 as a biomarker in triple-negative breast cancer xenograft tumors: effect of targeted therapy and comparison …
2208. Nuclear localization of Insulin-like growth factor binding protein 3 in a lung cancer cell line
2209. Null association between Insulin-like growth factors, Insulin-like growth factor-binding proteins, and prostate cancer in a prospective study
2210. Nutrition and breast cancer risk: can an effect via Insulin resistance be demonstrated?
2211. Nutrition, energy balance and colon cancer risk: the role of Insulin and Insulin-like growth factor-I.
2212. Nutrition, hormones, and breast cancer: is Insulin the missing link?
2213. Nutrition, Insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence
2214. Nutrition, Insulin, Insulin-like growth factors and cancer
2215. Nutrition, physical activity and cancer risks: the role of Insulin and Insulin-like growth factor-1
2216. Nutritional predictors of Insulin-like growth factor I and their relationships to cancer in men
2217. O4-4.3 cancer incidence and Insulin therapy in a cohort of diabetic patients
2218. Obesity and cancer risk: the role of the Insulin–IGF axis
2219. Obesity and cancer, a case for Insulin signaling
2220. Obesity and Insulin resistance in breast cancer–chemoprevention strategies with a focus on metformin
2221. Obesity, adipocytokines, and Insulin resistance in breast cancer
2222. Obesity, Dyslipidemia and Insulin Resistance in Survivors of Childhood cancer
2223. OBESITY, HYPERInsulinEMIA, THE Insulin AND Insulin-LIKE GROWTH FACTOR 1 RECEPTORS, AND RISK OF COLORECTAL cancer
2224. Obesity, Insulin and chemoresistance in colon cancer
2225. Obesity, Insulin resistance and breast cancer outcomes
2226. Obesity, Insulin resistance and cancer risk
2227. Obesity, Insulin Resistance and cancer: The PI3K connection
2228. Obesity, Insulin resistance and endometrial cancer risk
2229. Obesity, Insulin resistance and lifestyle factors: implications for prostate cancer screening
2230. Obesity, Insulin resistance and type 2 diabetes: risk factors for breast cancer
2231. Obesity, Insulin Resistance Pathway Factors, and Colon cancer
2232. Obesity, Insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets
2233. Obesity, Insulin resistance, and cancer prognosis: implications for practice for providing care among cancer survivors
2234. Obesity, Insulin resistance, and colorectal cancer: could miRNA dysregulation play a role?
2235. Obesity, Insulin, and colon cancer.
2236. Obesity, type 2 diabetes, and cancer: the Insulin and IGF connection
2237. Obesity, Type 2 Diabetes, and cancer: The Insulin and Insulin-Like Growth Factor Connection.
2238. Obesity, weight change, fasting Insulin, proInsulin, C-peptide, and Insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo …
2239. Observation of application mode of Insulin in perioperative colon cancer patients with diabetes mellitus
2240. Observation of different infusion methods of Insulin in TPN in gastric cancer patients with diabetes after operation
2241. Observations on the effects of suppressor of cytokine signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin like growth factor I (IGF-I)
2242. Oestrogen/Insulin-like growth factor-I receptor interaction in early breast cancer: clinical implications
2243. Omega-3 free fatty acids attenuate Insulin-promoted breast cancer cell proliferation
2244. On the status of β-cell dysfunction and Insulin resistance of breast cancer patient without history of diabetes after systemic treatment
2245. Oncogene activation induces metabolic transformation resulting in Insulin-independence in human breast cancer cells
2246. Oncogenes and Human cancer Blood Groups in cancer Copper and Inflammation Human Insulin
2247. Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-Insulin growth factor-binding protein 3 axis in human gastric cancer
2248. Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-Insulin growth factor-binding protein 3 axis in human gastric cancer.
2249. Oncogenic ras causes resistance to the growth inhibitor Insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells
2250. Oral consumption of green tea polyphenols inhibits Insulin-like growth factor-I–induced signaling in an autochthonous mouse model of prostate cancer
2251. Oral Insulin Secretagogues and cancer Risk in Type 2 Diabetes Mellitus: An Updated Review
2252. Oral Insulin secretagogues, Insulin, and cancer risk in type 2 diabetes mellitus
2253. Osthole inhibits Insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells
2254. Over-expression of Insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a …
2255. Overexpression of Insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation …
2256. Overexpression of Insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients
2257. Overexpression of Insulin-like growth factor II alters serum sensitivity of breast cancer cells
2258. Overexpression of Insulin-like growth factor-1 receptor is associated with penile cancer progression
2259. Overexpression of Insulin‐like Growth Factor Binding Protein 1 (IGFBP1) Generates Tamoxifen Resistance in Breast cancer Cells
2260. Overexpression of Insulin‐like growth factor II (IGFII) in ZR‐75‐1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative …
2261. Overexpression of mature Insulin-like growth factor (IGF)-II leads to growth arrest in Caco-2 human colon cancer cells
2262. Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of Insulin receptor tyrosine kinase activity.
2263. Overexpression of the Insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells
2264. Overlaps Between the Insulin and IGF-I Receptor and cancer
2265. P-10 Mitogenic activity and signaling pathways elicited by long-acting Insulin analogues Glargine and Detemir in colon cancer derived cell lines
2266. P-cadherin cooperates with Insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via …
2267. P10 Circulating Insulin-like growth factor-I (IGF-I) concentrations and incidence of cancer at 26 sites: prospective analyses in UK Biobank
2268. P3-016: In vitro activity of picropodophyllin in lung cancer cell lines and association to the Insulin-like Growth Factor-1 receptor
2269. P4-02-09: Estrogen-Related Receptor a Mediates Insulin-Like Growth Factor-I Dependent Migration in Breast cancer Cells.
2270. P4-02-11: Insulin-Like Growth Factor I Promotes Estrogen Receptor Positive Breast cancer Cell Proliferation, in Part, through CYP1A1 Signaling.
2271. P4-07-15: Insulin-Like Growth Factor Receptor I (IGFIR) Expression in Circulating Tumor Cells (CTCs) of Patients with Early and Metastatic Breast cancer (BC).
2272. P5-06-04: Mechanisms of Acquired Resistance to Insulin-Like Growth Factor 1 Receptor Inhibitor in MCF-7 Breast cancer Cell Line.
2273. Paclitaxel and trastuzumab treatment affects Insulin growth factor I expression in breast cancer cell lines
2274. Pamidronate and Clodronate Inhibit Insulin-like Growth Factor-1 (IGF-I)-Induced HIF-1α Protein Accumulation and VEGF Expression in Human Breast cancer Cells
2275. Pancreatic cancer and factors associated with the Insulin resistance syndrome in the Korean cancer prevention study
2276. Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the Insulin-like growth factor-I pathway
2277. Pancreatic Insulin secretion in exocrine pancreatic cancer
2278. Paracrine/autocrine regulation of breast cancer by the Insulin-like growth factors
2279. Paradoxical effects of overexpression of the type I Insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol
2280. Patient concerns about Insulin and cancer
2281. Patients with both cognitive impairment and solid cancer present increased Insulin resistance
2282. Patterns of Intravenous Glucose Tolerance and Insulin Response Before and After Treatment with Streptozotocin (NSC-85998) in Patients with cancer 1, 2, 3
2283. PD33-04 INVERSE RELATIONSHIP BETWEEN Insulin RECEPTOR EXPRESSION AND cancer PROGRESSION IN RENAL CELL CARCINOMA: CLINICAL AND …
2284. Peptide as potential imaging agent of breast cancer by phage display for Insulin receptor
2285. Permissive role of polyamines in the cooperative action of estrogens and Insulin or Insulin-like growth factor I on human breast cancer cell growth
2286. Perturbation by Insulin of human breast cancer cell cycle kinetics
2287. Pharmacological Strategies for Insulin Sensitivity in Obesity and cancer: Thiazolidinediones and Metformin
2288. Phenformin increases Insulin binding to human cultured breast cancer cells
2289. Phenotypes and genotypes of Insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies
2290. Phloroglucinol induces apoptosis through the regulation of Insulin-like growth factor 1 receptor signaling pathways in human colon cancer HT-29 cells
2291. Phosphatidylinositol 3-kinase signaling regulates Insulin-like growth factor binding protein-3 expression in endometrial cancer cell lines
2292. Phosphorylated Insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer
2293. Phosphorylated Insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells
2294. Phosphorylated Insulin-like growth factor-1 receptor expression predicts poor prognosis of Chinese patients with gastric cancer
2295. Phosphorylation of Insulin-like growth factor (IGF) binding protein-3 by breast cancer cell membranes enhances IGF-I binding
2296. Physical activity and breast cancer: Quantitative risk assessment and investigation of Insulin-like growth factor proteins as a potential molecular pathway
2297. Physical activity, Insulin-like growth factor 1, Insulin-like growth factor binding protein 3, and survival from colorectal cancer
2298. Physiological concentrations of Insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT …
2299. Plasma and tissue Insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for …
2300. Plasma C‐peptide, Insulin‐like growth factor‐I, Insulin‐like growth factor binding proteins and risk of colorectal cancer in a nested case‐control study: The Japan …
2301. Plasma Insulin-like growth factor 1, Insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden
2302. Plasma Insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer
2303. Plasma Insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy
2304. Plasma Insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer
2305. Plasma Insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, and the risk of prostate cancer: a Matched Case-Control Study in a Korean population
2306. Plasma Insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era
2307. Plasma Insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer
2308. Plasma Insulin-like growth factor-I and prostate cancer risk: a prospective study
2309. Plasma Insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the …
2310. Plasma Insulin-like growth factor-I, Insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
2311. Plasma Insulin-like growth factors, Insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
2312. Plasma Insulin‐like growth factor 1 is positively associated with low‐grade prostate cancer in the Health Professionals Follow‐up Study 1993–2004
2313. Plasma Insulin‐like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen
2314. Plasma Insulin, C‐peptide and blood glucose and the risk of gastric cancer: The J apan P ublic H ealth C enter‐based prospective study
2315. Plasma Insulin, IGF-I and breast cancer
2316. Plasma Insulin, IGF‐binding proteins‐1 and‐2 and risk of colorectal cancer: a prospective study in northern Sweden
2317. Plasma levels of acid-labile subunit, free Insulin-like growth factor-I, and prostate cancer risk: a prospective study
2318. Plasma levels of Insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk
2319. Plasma levels of Insulin-like growth factor-I and lung cancer risk: a case-control analysis
2320. Polyethylene glycol conjugated Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice
2321. Polymorphic CA repeat length in Insulin-like growth factor 1 and risk of breast cancer in Iranian women
2322. Polymorphic markers associated with genes responsible for lipid and carbohydrate metabolism disorders and Insulin resistance in cancer patients
2323. Polymorphism of genes related to Insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case–control study in Shanghai, China
2324. Polymorphism of gnes rlated to Insulin sensitivity and the risk or biliary tract cancer and biliary stones: a population-based case-control study in Shanghai, China
2325. Polymorphism of the Insulin gene is associated with increased prostate cancer risk
2326. Polymorphism-23HPhI in the promoter of Insulin gene and pancreatic cancer: a pilot study
2327. Polymorphisms and circulating levels in the Insulin-like growth factor system and risk of breast cancer: a systematic review
2328. Polymorphisms in Insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer
2329. Polymorphisms in the Insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer
2330. Polymorphisms in the Insulin-like growth factor axis are associated with gastrointestinal cancer
2331. Polymorphisms of Insulin-like growth factor 1 pathway genes and breast cancer risk
2332. Positive expression of Insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer
2333. Positive expression of Insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer
2334. Possible Involvement of Insulin Resistance in the Progression of cancer Cachexia in Mice.
2335. Possible roles of Insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer
2336. Post genome-wide gene-environment interaction study: The effect of genetically driven Insulin resistance on breast cancer risk using Mendelian …
2337. Post Genome-Wide Gene–Environment Interaction Study Using Random Survival Forest: Insulin Resistance, Lifestyle Factors, and Colorectal cancer Risk
2338. Post-diagnosis serum Insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial
2339. Post‐hypophysectomy Insulin response in patients with advanced breast cancer
2340. Postdiagnostic Dietary Glycemic Index, Glycemic Load, Dietary Insulin Index, and Insulin Load and Breast cancer Survival
2341. Postsynthetic regulation of Insulin-like growth factor-binding protein-3 by MCF-7 human breast cancer cells in culture
2342. Potential crosstalk between Insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer
2343. Potential impact on breast cancer risk of circulating Insulin–like growth factor I modifications induced by oral HRT in menopause
2344. Potential Mechanisms Linking Insulin to cancer
2345. Potential molecular mechanisms of Insulin like growth factor-1 (IGF-1)/Insulin like growth factor-1 receptor (IGF-1R) interaction in prostate cancer invasion
2346. Potential therapeutic strategies to interrupt Insulin-like growth factor signaling in breast cancer
2347. Potential use of serum Insulin‐like growth factor 1 and E‐cadherin as biomarkers of colorectal cancer
2348. PPAR γ and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and Insulin-related genes (United States)
2349. PPARγ induces growth inhibition and apoptosis through upregulation of Insulin-like growth factor-binding protein-3 in gastric cancer cells
2350. PRAS40 as a mediator of Insulin-like growth factor-1 receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer
2351. Pre-diagnosis Insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: a collaborative re-analysis from the Ovarian cancer …
2352. Pre‐diagnostic circulating Insulin‐like growth factor‐I and bladder cancer risk in the European Prospective Investigation into cancer and Nutrition
2353. Preclinical evaluation of a small molecule inhibitor of the IGF-1/Insulin receptor kinases in prostate cancer
2354. Preclinical evidence supporting cotargeting Insulin-like growth factor receptor (IGF-1R) and Src in non-small cell lung cancer.
2355. Prediagnosis circulating Insulin-like growth factors and pancreatic cancer survival
2356. Prediagnosis smoking, obesity, Insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study
2357. Prediction the Risk of Breast cancer from Body Mass Index (BMI), Glucose and Insulin
2358. Predictors of fasting serum Insulin and glucose and the risk of pancreatic cancer in smokers
2359. Premenopausal breast cancer and the association between estrogen receptor status, Insulin-like growth factor-I (IGF-I), Insulin-like growth factor binding protein-3 …
2360. Premenopausal Levels of Circulating Insulin-Like Growth Factor I and the Risk of Post-Menopausal Breast cancer: A Population-Based, Nested Case-Control Study
2361. Premenopausal levels of circulating Insulin-like growth factor I and the risk of postmenopausal breast cancer: A population-based, nested case-control study.
2362. Premenopausal levels of circulating Insulin‐like growth factor I and the risk of postmenopausal breast cancer
2363. Preoperative serum levels of Insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients
2364. Prepubertal exposure to cow’s milk reduces expression of Insulin like growth factor-1 in the rat mammary gland and susceptibility to breast cancer
2365. Presence of Insulin-like growth factor binding proteins correlates with tumor-promoting effects of matrix metalloproteinase 9 in breast cancer
2366. Present research on the status and the prospect of Insulin-like growth factor-I in head and neck cancer
2367. Pretreatment Insulin levels as a prognostic factor for breast cancer progression
2368. Pretreatment with Insulin enhances anticancer functions of 5‐fluorou‐racil in human esophageal and colonic cancer cells
2369. Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current Insulin use among US adults with diagnosed diabetes: findings from the …
2370. Prevalence of Obesity, Dyslipidemia, and Insulin Resistance in Childhood cancer Survivors
2371. Preventive effect of 8 weeks moderate training on susceptible colon cancer factor (Insulin Growth Factor I and Insulin Growth Factor Binding Protein 3 in rats)
2372. Primary and Permissive Actions of Insulin in Breast cancer
2373. Processing of Insulin-like growth factor-II (IGF-II) by human breast cancer cells
2374. Production of immunoreactive Insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines
2375. Production of Insulin-like growth factor binding proteins by small-cell lung cancer cell lines
2376. Profiling the Roles of Insulin Receptor Substrate Isoforms 1 and 2 in Breast cancer
2377. Progesterone crosstalks with Insulin-like growth factor signaling in breast cancer cells via induction of Insulin receptor substrate-2
2378. Progesterone receptor-B regulation of Insulin-like growth factor–stimulated cell migration in breast cancer cells via Insulin receptor substrate-2
2379. Progesterone Regulation of Insulin Receptor Substrates Mediates Focal Adhesion Formation in Breast cancer Cells
2380. Progesterone-induced secretion of growth hormone, Insulin-like growth factor I and prolactin by human breast cancer explants
2381. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by Insulin
2382. Progestin regulation of Insulin and Insulin-like growth factor I receptors in cultured human breast cancer cells
2383. Progestins induce down-regulation of Insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II
2384. Prognostic impact of Insulin receptor expression on survival of patients with nonsmall cell lung cancer
2385. Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non–Small-Cell Lung cancer
2386. Prognostic role of Insulin-like growth factor receptor-1 (IGFR-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) expression in small cell lung cancer
2387. Prognostic role of Insulin‐like growth factor receptor‐1 expression in small cell lung cancer
2388. Prognostic role of plasma Insulin-like growth factor (IGF) and IGF-binding protein 3 in metastatic colorectal cancer
2389. Prognostic significance of Insulin growth factor-I receptor and Insulin growth factor binding protein-3 expression in primary breast cancer
2390. Prognostic significance of Insulin-like growth factor 1 receptors in human breast cancer
2391. Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast cancer
2392. Prognostic significance of Insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer
2393. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular cancer Patients: A Validation Study
2394. Prognostic significance of serum levels of vascular endothelial growth factor and Insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX …
2395. Prognostic value of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 blood levels in breast cancer
2396. Prognostic value of Insulin-like growth factor-1 receptors in patients with colon/rectal cancer: correlation with plasma prolactin
2397. Prognostic value of receptors for Insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer
2398. Prognostic value of vitamin D receptor and Insulin-like growth factor receptor 1 expression in triple-negative breast cancer
2399. Progress in the Research of Insulin-like Growth Factor Family in Gastric cancer
2400. Progress in the research of Insulin-like growth factor family in lung cancer
2401. Progress in the Research of Insulin-Like Growth Factor in Non-Small Cell Lung cancer [J]
2402. Progress of Insulin-like Growth Factor-1 in Colorectal cancer
2403. Prolactin does not require Insulin-like growth factor intermediates but synergizes with Insulin-like growth factor I in human breast cancer cells
2404. Proliferation of cultured human prostate cancer cells is inhibited by Insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop
2405. Proliferation of DU145 prostate cancer cells is inhibited by suppressing Insulin‐like growth factor binding protein‐2
2406. Proliferative and signaling activities of Insulin analogues in endometrial cancer cells
2407. Prolonged use of human Insulin increases breast cancer risk in Taiwanese women with type 2 diabetes
2408. Promoter-202 A/C polymorphism of Insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk
2409. Promoter-specific transcription of Insulin-like growth factor-II in epithelial ovarian cancer
2410. Promoter− 202 A/C polymorphism of Insulin‐like growth factor binding protein‐3 gene and non‐small cell lung cancer risk
2411. Promotion of cancer cell migration: an Insulin-like growth factor (IGF)-independent action of IGF-binding protein-6
2412. Prospective evaluation of abnormal glucose metabolism and Insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer
2413. Prospective Evaluation of Glucose Tolerance and Insulin Resistance Among Patients with Endometrial cancer and Atypical Endometrial Hyperplasia
2414. Prospective evaluation of Insulin resistance among endometrial cancer patients
2415. Prospective study of colorectal cancer risk in men and plasma levels of Insulin-like growth factor (IGF)-I and IGF-binding protein-3
2416. Prospective study of prostate cancer in relation to serum concentrations of Insulin-like growth factor-1 and Insulin-like growth factor binding protein-3.
2417. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or Insulin use in men
2418. PROSTATE cancer AND DIABETES LINK: ROLE OF Insulin AND Insulin LIKE GROWTH FACTORS
2419. Prostate cancer patients with unmanaged diabetes or on Insulin have worse outcomes and toxicities after treatment with radiation therapy
2420. Prostate cancer patients with unmanaged diabetes or receiving Insulin experience inferior outcomes and toxicities after treatment with radiation therapy
2421. Prostate cancer risk and serum levels of Insulin and leptin: a population-based study
2422. Prostate cancer risk in relation to a single nucleotide polymorphism in the Insulin-like growth factor-binding protein-3 (IGFBP3) gene: a meta-analysis
2423. Prostate cancer risk in relation to Insulin-like growth factor (IGF)-I and IGF-binding protein-3: A Nested Case-Control Study in Large Scale Cohort Study in …
2424. Prostate cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Nested Case-Control Study in Large Scale Cohort Study in …
2425. Prostate cancer risk in relation to Insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study
2426. Prostate cancer Risk is associated with Polymorphism of Insulin gene
2427. Prostate cancer, Insulin, and androgen deprivation therapy
2428. Prostate cancer: another aspect of the Insulin‐resistance syndrome?
2429. Prostate-specific antigen and Insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer
2430. Prostatic cancer, hypogonadism, and Insulin resistance: A case report
2431. Prostatic fluid‐free Insulin‐like growth factor‐1 in relation to prostate cancer
2432. Protein anabolism is resistant to Insulin action in lung cancer cachexia
2433. Protein expression of PTEN, Insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study
2434. Protein of type 1 binding Insulin-like growth factors in blood serum in cancer and prostatic adenoma
2435. Protein-tyrosine phosphatase 1B antagonized signaling by Insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells
2436. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor …
2437. Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancer cells through Insulin-like growth factor-binding protein-3 …
2438. PS 1587; Lung cancer: MicroRNA-146a Inhibits Epithelial Mesenchymal Transition in Non Small Cell Lung cancer by Targeting Insulin Receptor Substrate 2
2439. PTEN inhibits Insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer …
2440. PTEN, Insulin resistance and cancer
2441. Purification of a colon cancer cell growth inhibitor and its identification as an Insulin-like growth factor binding protein
2442. Putative role of serum Insulin-like growth factor–1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men
2443. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/Insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer
2444. Quality and quantity of visceral fat tissue are associated with Insulin resistance and survival outcomes after chemotherapy in patients with breast cancer
2445. Quantification of Insulin receptor mRNA splice variants as a diagnostic tumor marker in breast cancer
2446. Quantifying mediating effects of endogenous estrogen and Insulin in the relation between obesity, alcohol consumption, and breast cancer
2447. Quantitative determination of Insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer
2448. Rab GTPases Accelerates GLUT4 Translocation in Colorectal cancer Progression by Insulin/IGF System
2449. Racial differences in Insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer
2450. Randomized controlled trial of aerobic exercise on Insulin and Insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study
2451. Re: Insulin resistance and prostate cancer risk
2452. Re: Insulin, Insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
2453. Re: plasma Insulin-like growth factor-I, Insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
2454. Re: Prospective study of colorectal cancer risk in men and plasma levels of Insulin-like growth factor (IGF)-I and IGF-binding protein-3
2455. Re: Re: Role of the Insulin-like growth factors in cancer development and progression
2456. RE:“SERUM Insulin AND GLUCOSE LEVELS AND BREAST cancer INCIDENCE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY”
2457. Reactive oxygen species regulate Insulin-induced VEGF and HIF-1α expression through the activation of p70S6K1 in human prostate cancer cells
2458. Realationship of Insulin-like growth factor-Ⅰ and breast cancer
2459. Recent advances in the research on the relationship between Insulin resistance and endometrial cancer
2460. Recent advances on the role of microRNAs in both Insulin resistance and cancer
2461. Receptor binding and growth-promoting activity of Insulin-like growth factors in human breast cancer cells (T-47D) in culture
2462. Receptors for epidermal growth factor and Insulin-like growth factor I and their relation to steroid receptors in human breast cancer
2463. Receptors for Insulin-like growth factor-2 and androgens as therapeutic targets in triple-negative breast cancer
2464. Recombinant adenoviruses expressing dominant negative Insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer
2465. Recombinant human Insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
2466. Recombinant Insulin‐like growth factor binding protein‐1 inhibits IGF‐I, serum, and estrogen‐dependent growth of MCF‐7 human breast cancer cells
2467. Recombinant PAPP-A resistant Insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer
2468. Recruitment of Insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells
2469. Reduced expression of Insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype
2470. Reduced Insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH
2471. Reduction of the type I Insulin-like growth factor receptor expression in DU145 human prostate cancer cell line by antisense RNA
2472. Regarding the article’Does the negative correlation found in breast cancer patients between plasma melatonin and Insulin-like growth factor-1 concentrations imply …
2473. Regulation of breast cancer cell motility by Insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines
2474. Regulation of breast cancer growth by Insulin-like growth factors
2475. Regulation of DUI45 human prostate cancer cell proliferation by Insulin‐like growth factors and its interaction with the epidermal growth factor autocrine loop
2476. Regulation of endometrial cancer cell growth by Insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75
2477. Regulation of Insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1, 25 (OH) 2D3 …
2478. Regulation of Insulin-like growth factor binding protein-4 in Ah responsive and Ah nonresponsive human breast cancer cells by 17 B-estradiol and 2, 3, 7, 8 …
2479. Regulation of Insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen
2480. Regulation of Insulin-like growth factor receptor activity and its therapeutic targeting in cancer
2481. Regulation of Insulin-like growth factor type 1 receptor expression in A549 non-small cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells and its …
2482. Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast cancer Cells: Use of IGFBP-1 as as Inhibitor of Insulin-like Growth Factor …
2483. Regulation of Insulin-like growth factors and NF-kappaB by proteasome system in endometrial cancer
2484. Regulation of Insulin-like growth NF-κB proteasome system in endometrial cancer
2485. Regulation of Insulin‑like growth factor signaling by metformin in endometrial cancer cells
2486. Regulation of interleukin-8 expression in human prostate cancer cells by Insulin-like growth factor-I and inflammatory cytokines
2487. Regulation of the Insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer
2488. Regulation of vascular endothelial growth factor expression in human colon cancer by Insulin-like growth factor-I
2489. Regulatory Mechanism of Insulin-Like Growth Factor Binding Protein-3 in Non-Small Cell Lung cancer
2490. Relation between duration of androgen deprivation therapy and degree of Insulin resistance in men with prostate cancer
2491. Relation between Insulin resistance and breast cancer among Chilean women
2492. Relation between Insulin resistance and serum concentrations of IL-6 and TNF-α in overweight or obese women with early stage breast cancer
2493. Relation of blood lipids and Insulin to body fat content, body surface area and state of the subcutaneous fatty tissue in patients with breast and lung cancer
2494. Relation of serum Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)
2495. Relations of Insulin Resistance and Serum Concentrations of Estradiol and Sex Hormone‐binding Globulin to Potential Breast cancer Risk Factors
2496. Relationship Between ABO Blood Groups and Insulin Resistance in Patients with Colon and Gastric cancer
2497. Relationship between aerobic capacity of African American males, serum concentration of Insulin‐like growth factor‐1 and growth of prostate cancer cells
2498. Relationship between exogenous Insulin therapy and colorectal cancer in diabetic patients: a meta-analysis
2499. Relationship between Insulin Receptor (INSR rs 1799817) and Colorectal cancer (CRC)
2500. Relationship between Insulin resistance related factors and colon cancer stem cells
2501. Relationship between Insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
2502. Relationship between Insulin-like growth factor II and prognosis of colorectal cancer
2503. Relationship between Insulin-like growth factor-1 and human testicular cancer
2504. Relationship between Insulin‐like growth factor‐1 receptor and human papillomavirus in patients with oropharyngeal cancer
2505. Relationship between Prostate Sspecific Antigen and Testosterone, Insulin, Adeponectin on Prostate cancer Patients with Metabolic Syndrome
2506. Relationship between serum levels of Insulin-like growth factors and subsequent risk of cancer mortality: Findings from a nested case–control study within the Japan …
2507. Relationship of dyslipidemia, Insulin resistance, and prostate‑specific antigen with prostate cancer
2508. Relationship of Insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer
2509. Relationship of obesity and physical activity with C-peptide, leptin, and Insulin-like growth factors in breast cancer survivors
2510. Relationship of Serum Insulin-Like Growth Factor I and Parameters in Patients with Prostate cancer
2511. Relationship of serum isoflavone, Insulin and adiponectin levels with breast cancer risk
2512. Relationships between critical period of estrogen exposure and circulating levels of Insulin‐like growth factor‐I (IGF‐I) in breast cancer: evidence from a case‐control …
2513. Relationships between Insulin-like growth factor i and selected clinico-morphological parameters in colorectal cancer patients.
2514. Relationships between plasma Insulin-like growth factor-I and Insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of …
2515. Relationships of Insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer
2516. Relaxation of imprinting of the Insulin-like growth factor II gene in colorectal cancer
2517. Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate cancer Development
2518. Relaxation of Insulin‐like growth factor 2 gene imprinting in esophageal cancer
2519. Relevance of Insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer
2520. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the Insulin-like growth factor axis
2521. Repeated measures of serum glucose and Insulin in relation to postmenopausal breast cancer
2522. Reply: Prostate cancer, Insulin and androgen deprivation therapy
2523. Repression of the Insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer
2524. Research advances in Insulin-like growth factor 1 receptor and its pathway in diagnosis and treatment of primary liver cancer
2525. Research advances in Insulin-like growth factor-1 receptor in pancreatic cancer
2526. Research Article Adipokines and Insulin Resistance in Young Adult Survivors of Childhood cancer
2527. Research progress in the relationship between Insulin like growth factor binding protein-2 (IGFBP-2) and lung cancer
2528. Resistance exercise reduces body fat and Insulin during androgen-deprivation therapy for prostate cancer
2529. Response of extensive breast cancer skin metastases to rechallenge with trastuzumab together with low-dose chemotherapy and Insulin
2530. Response of the Insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and …
2531. Response to Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident cancer: A Retrospective Cohort Study of Older …
2532. Response: More About: Prospective Study of Colorectal cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3
2533. Response: re: plasma Insulin-like growth factor-i, Insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
2534. Responses of human pancreatic cancer cells to treatment with Insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor NVP-AEW541 alone and in …
2535. Restoration of Insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer
2536. Resveratrol attenuates prostate cancer growth by inhibiting Insulin-like growth factor-1 receptor signaling.
2537. Resveratrol inhibits Insulin-like growth factor-1 mediated migration and invasion of human breast cancer cells
2538. Resveratrol Phenocopies the Suppressive Effects of Insulin‐like Growth Factor Receptor‐1 siRNA on IGF‐1 Promoted Colon cancer Cell Proliferation
2539. Resveratrol regulates Insulin-like growth factor-II in breast cancer cells
2540. Rethinking the Relationship between Insulin and cancer
2541. Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is meditated by the Insulin growth factor-I/phosphatidylinositol 3-kinase and p38 …
2542. Retinoic acid suppresses Insulin-induced cell growth and cyclin D1 gene expression in human breast cancer cells.
2543. Retnoic Acid-Induced Insulin-Like Growth Factor (IGF)-I and Insulin-Like Growth Factor Binding Protein-3 Secretion in Breast cancer Cell Involves in Selective …
2544. RETRACTED ARTICLE: Insulin-like growth factor 1 promotes growth of gastric cancer by inhibiting foxo1 nuclear retention
2545. RETRACTED: Quercetin suppresses Insulin receptor signaling through inhibition of the Insulin ligand-receptor binding and therefore impairs cancer cell proliferation.
2546. Retraction Notice to: The cancer-Associated FGFR4-G388R Polymorphism Enhances Pancreatic Insulin Secretion and Modifies the Risk of Diabetes
2547. Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate cancer Cells by Activating mTOR Signaling
2548. RETRACTION: Quercetin suppresses Insulin receptor signaling through inhibition of the Insulin ligand–receptor binding and therefore impairs cancer cell proliferation
2549. Retraction: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast cancer Cells
2550. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-Insulin-dependent diabetes (NIDDM).
2551. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense Insulin-like growth factor II (IGF-II)
2552. Reversal of enhanced pancreatic cancer growth in diabetes by Insulin
2553. Review of: Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I Insulin-like growth factor receptor mRNA involves inactivation of …
2554. Review: Milk and milk products, Insulin-like growth factor-1 and cancer
2555. Ripk2 dictates blood Insulin and glucose responses to cancer drug and microbial xenobiotics
2556. Rising thyroid cancer incidence in the world might be related to Insulin resistance
2557. Risk factors for breast cancer and expression of Insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China
2558. Risk of breast cancer by individual Insulin use: an international multicenter study
2559. Risk of breast cancer in patients exposed to Insulin glargine compared to human NPH Insulin.
2560. Risk of breast cancer in patients on long-acting Insulin analogues in comparison with those on human Insulin
2561. Risk of cancer in patients on Insulin glargine and other Insulin analogues in comparison with those on human Insulin: results from a large population-based …
2562. Risk of cancer in patients receiving Insulin glargine
2563. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, Insulin-like growth factor binding proteins-1 and-2 (USA, Sweden, Italy)
2564. RNAi‐mediated silencing of Insulin receptor substrate 1 (IRS‐1) enhances tamoxifen‐induced cell death in MCF‐7 breast cancer cells
2565. RNAi‐mediated silencing of Insulin receptor substrate‐4 enhances actinomycin D‐and tumor necrosis factor‐α‐induced cell death in hepatocarcinoma cancer cell …
2566. Role of cyclic AMP response element–binding protein in Insulin-like growth factor-I receptor up-regulation by sex steroids in prostate cancer cells
2567. Role of estrogen receptor (ER) α in Insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells
2568. Role of estrogen receptor α (ERα) in Insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells
2569. Role of estrogen-induced Insulin-like growth factors in the proliferation of human breast cancer cells
2570. Role of Inflammation and Insulin Resistance in Mouse Models of Breast cancer
2571. Role of Insulin and IGF-1 receptors in bronchial epithelial cancer cells
2572. Role of Insulin dysregulation in the development of yoshida sarcoma-induced cancer cachexia
2573. Role of Insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting.
2574. Role of Insulin like growth factor binding proteins and tamoxifen resistance in breast cancer epithelial cells
2575. Role of Insulin receptor isoform A in breast cancer
2576. Role of Insulin receptor substrates and protein kinase C-ζ in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer …
2577. Role of Insulin-like growth factor (IGF) axis in the development of tamoxifen resistance in breast cancer epithelial cells
2578. Role of Insulin-like growth factor 1 receptor in pancreatic cancer pathogenesis
2579. Role of Insulin-like growth factor 1 receptor signalling in cancer
2580. Role of Insulin-like growth factor 1 receptor signalling in cancer.
2581. Role of Insulin-like growth factor binding protein-3 in 1, 25-dihydroxyvitamin-D3-induced breast cancer cell apoptosis
2582. Role of Insulin-like growth factor binding protein-4 in prevention of colon cancer
2583. Role of Insulin-like growth factor binding protein-5 in pancreatic cancer cell survival
2584. Role of Insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis
2585. Role of Insulin-Like Growth Factor Receptors in cancer Signaling
2586. Role of Insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells
2587. Role of Insulin-like growth factor-2 in colorectal cancer.
2588. Role of Insulin-like growth factor-type 1 receptor (IGF-IR) signalling in tamoxifen-resistant breast cancer
2589. Role of Insulin-like growth factor, Insulin-like growth factor receptors, and Insulin-like growth factor-binding proteins in ovarian cancer
2590. Role of Insulin-like growth factors and the type I Insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.
2591. Role Of Insulin-Like Growth Factors Binding Protien 2 (IGFBP2) In Breast cancer
2592. Role of Insulin‐like growth factor binding protein‐3 in breast cancer cell growth
2593. Role of Insulin‐like growth factor binding proteins in 1α,25‐dihydroxyvitamin D3‐induced growth inhibition of human prostate cancer cells
2594. Role of Insulin like growth factors family in endometrial cancer
2595. Role of IRS-1 signaling in Insulin-induced modulation of estrogen receptors in breast cancer cells
2596. Role of PRAS40 in mammalian target of rapamycin (mTOR) modulation in cancer and Insulin resistance
2597. Role of testosterone, estradiol, and Insulin in diet-and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro
2598. Role of the Insulin-like growth factor family in cancer development and progression
2599. Role of the Insulin-like growth factor signaling system on post-confluent growth by MCF-7 breast cancer cells
2600. Role of the Insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line
2601. Role of tumor necrosis factor system in pregnancy induced Insulin resistance and in the pathogenesis of cancer of the uterine cervix
2602. Roles of the Insulin-like growth factor system and nutrition in cancer
2603. Roles of transforming growth factor-beta, Insulin-like growth factors and proteases in human breast cancer
2604. Rye whole grain and bran intake compared with refined wheat decreases urinary C-peptide, plasma Insulin, and prostate specific antigen in men with prostate cancer
2605. S961, a biosynthetic Insulin receptor antagonist, downregulates Insulin receptor expression & suppresses the growth of breast cancer cells
2606. Sa1444 Does Insulin Influence the Risk of Colon Adenomas and Colorectal cancer? a Multicenter Look At a Minority Population
2607. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, Insulin, and Insulin-like growth factor axis proteins
2608. Sam68 mediates the activation of Insulin and leptin signalling in breast cancer cells
2609. Saturated free fatty acids activate a c-Src-JNK1 axis within lipid rafts: Implications for the development of Insulin resistance, obesity, and obesity-associated cancer
2610. Screen‐detected prostate cancer and the Insulin‐like growth factor axis: results of a population‐based case‐control study
2611. Search for breast cancer susceptibility genes in the growth hormone/Insulin-like growth factor-1 axis
2612. Secretion of an Insulin-like growth factor-I-related protein by human breast cancer cells
2613. Selective Effects of Glucose, Insulin and Leptin by Molecular Breast cancer Subtype.
2614. Selective tyrosine kinase inhibition of Insulin‐like growth factor‐1 receptor inhibits human and mouse breast cancer–induced bone cell activity, bone remodeling, and …
2615. Self reported non-Insulin dependent diabetes, family history, and risk of prevalent colorectal cancer: population based, cross sectional study
2616. Sensitivity of breast cancer cell lines to the novel Insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression
2617. Sequencing of type I Insulin-like growth factor receptor inhibition with chemotherapy in breast cancer cells.
2618. Serum adiponectin and Insulin-like growth factor 1 in predominantly female patients with thyroid cancer: association with the histologic characteristics of the tumor
2619. Serum and Insulin inhibit cell death induced by cycloheximide in the human breast cancer cell line MCF-7
2620. Serum and tissue level of Insulin‐like growth factor‐I (IGF‐I) and IGF‐I binding proteins as an index of pancreatitis and pancreatic cancer
2621. Serum and tissue levels of Insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer
2622. Serum C-peptide, Insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women
2623. Serum changes of adiponectin, Insulin resistance and their correlation in endometrial cancer patients
2624. Serum concentration of Insulin, C-peptide and Insulin-like growth factor I in patients with colon adenomas and colorectal cancer
2625. Serum concentrations of Insulin, Insulin-like growth factor I, vascular endothelial growth factor and gastrin in patients with colon adenomas and colorectal cancer
2626. SERUM GROWTH HORMONE IN PATIENTS WITH BREAST cancer AND Insulin-LIKE GROWTH FACTOR-I LEVELS AND THEIR CLINICAL SIGNIFICANCE [J]
2627. Serum human glandular kallikrein (hK2) and Insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia …
2628. Serum Insulin and C-peptide concentration and breast cancer: a meta-analysis
2629. Serum Insulin and fructosamine levels and pancreatic cancer risk: A nested case-control study in Japan
2630. Serum Insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study
2631. Serum Insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
2632. Serum Insulin level, HOMA-IR and prostate cancer risk: A systematic review and meta-analysis
2633. Serum Insulin levels in patients with colorectal cancer
2634. Serum Insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa).
2635. Serum Insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the β-Carotene and Retinol Efficacy Trial …
2636. Serum Insulin-like Growth Factor (IGF) and IGF-binding Protein Levels and Risk of Lung cancer: A Case-Control Study Nested in the-Carotene and Retinol …
2637. Serum Insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest
2638. Serum Insulin-like Growth Factor (IGF)-l and in Lung cancer Patients
2639. Serum Insulin-like growth factor 1 (IGF-I) and prostatic cancer risk a retrospective study
2640. Serum Insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer
2641. Serum Insulin-like growth factor axis and the risk of pancreatic cancer: Systematic review and meta-analysis
2642. Serum Insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men
2643. Serum Insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men
2644. Serum Insulin-like growth factor-1 is not a useful marker of prostate cancer.
2645. Serum Insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer.
2646. Serum Insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate …
2647. Serum Insulin-like growth factor-I and Insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia
2648. Serum Insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis
2649. Serum Insulin-like growth factor-I and tumor size in patients with metastatic liver cancer
2650. Serum Insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer
2651. Serum Insulin-like growth factor-I levels and prostate cancer risk—interpreting the evidence
2652. Serum Insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk
2653. Serum Insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery
2654. Serum Insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer
2655. Serum Insulin-like Growth Factors I and II, Insulin-like Growth Factor Binding Protein-3 and Risk of Breast cancer in the JACC Study
2656. Serum Insulin-like growth factors, Insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women
2657. Serum Insulin‐like growth factor (IGF)‐1 and IGF‐binding protein‐3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples
2658. Serum Insulin‐like growth factor binding protein‐3/prostate‐specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer
2659. Serum Insulin‐like growth factor I/free prostate specific antigen (IGF‐I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0–10.0 ng/ml
2660. Serum Insulin‐like growth factor‐I and breast cancer
2661. Serum Insulin‐like growth factor‐I, Insulin‐like growth factor binding protein‐3, and the risk of pancreatic cancer death
2662. Serum Insulin‐like Growth Factors, Insulin‐like Growth Factor‐binding Protein‐3, and Risk of Lung cancer Death: A Case‐control Study Nested in the Japan …
2663. Serum Insulin‐like, growth factor binding protein‐related protein 1 (IGFBP‐rP1) and endometrial cancer risk in Chinese women
2664. Serum Insulin, glucose, indices of Insulin resistance, and risk of lung cancer
2665. Serum Insulin, glucose, indices of Insulin resistance, and risk of prostate cancer
2666. Serum interleukin-8 and Insulin like growth factor-1 in Egyptian bladder cancer patients
2667. Serum leptin levels in gastric cancer patients and the relationship with Insulin resistance
2668. Serum Levels of Gastrin, and Insulin-like Growth Factor (IGF-1) in Patients with Gastro-Esophageal cancer
2669. Serum levels of Insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer
2670. Serum levels of Insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
2671. Serum levels of Insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of …
2672. Serum levels of Insulin-like growth factor-I, IGF-binding protein 1 and 3, and Insulin and endometrial cancer risk
2673. Serum levels of Insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer
2674. Serum levels of Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs),-1,-2,-3, in oral cancer
2675. SERUM LEVELS OF Insulin, IGF-1 AND PSA IN PROSTATE cancer PATIENTS IN LOCAL POPULATION
2676. Serum levels of leptin, Insulin, and lipids in relation to breast cancer in china
2677. Serum prolactin contributes to enhancing prolactin receptor and pJAK2 in type I endometrial cancer cells in young women without Insulin resistance
2678. Serum tumour necrosis factor alpha and Insulin resistance in gastrointestinal cancer
2679. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to Insulin-like growth factor II (IGF-II), IGF …
2680. Session 4: CVD, diabetes and cancer Diet, Insulin resistance and diabetes: the right (pro) portions: Symposium on ‘Dietary management of disease’
2681. Severe hypoglycaemia caused by raised Insulin-like growth factor II in disseminated breast cancer.
2682. Sex hormone, Insulin, and Insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology …
2683. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and Insulin resistance
2684. Short-term effects of anastrozole treatment on Insulin-like growth factor system in postmenopausal advanced breast cancer patients
2685. Signal relay by retinoic acid receptors α and β in the retinoic acid-induced expression of Insulin-like growth factor-binding protein-3 in breast cancer cells
2686. Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast cancer Cells: RELATIONSHIP TO TRANSFORMING GROWTH …
2687. Significance and expression of Insulin-like growth factor 1 and IGF binding protein 3 in serum of patients with lung cancer
2688. Significance and expression of serum Insulin-like growth factor-Ⅱ levels in prostatic cancer [J]
2689. Significance of determination of serum Insulin-like growth factor-1 in prostate cancer and benign prostate hypertrophy [J]
2690. Significance of Determination of Serum Insulin-like Growth Factor-I (IGF-I) in Prostate cancer and Benign Prostate Hypertrophy [J]
2691. Significance of Insulin-Like Growth Factor-1 (IGF-1) in the Ascites of the Ovaran cancer
2692. Significance of serum c-erbB-2 oncoprotein, Insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
2693. Significance of serum vascular endothelial growth factor, Insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients
2694. Silencing Insulin‑like growth factor‑1 receptor expression inhibits gastric cancer cell proliferation and invasion
2695. Silibinin up-regulates Insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells
2696. Simultaneous blockade of both the epidermal growth factor receptor and the Insulin-like growth factor receptor signaling pathways in cancer cells with a fully …
2697. SIMULTANEOUS OVEREXPRESSION OF Insulin-LIKE GROWTH FACTOR Ⅱ (IGF-Ⅱ) AND IGF Ⅱ RECEPTOR GENES IN HUMAN PRIMARY HEPATIC cancer
2698. Simvastatin induces apoptosis and suppresses Insulin-like growth factor 1 receptor in bile duct cancer cells
2699. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the Insulin-like growth factor 1 receptor
2700. siRNA mediated the type 1 Insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells
2701. siRNA‐mediated type 1 Insulin‐like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53
2702. Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer
2703. Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated Insulin-like growth factor receptor activation
2704. Smoking, green tea consumption, genetic polymorphisms in the Insulin-like growth factors and lung cancer risk
2705. SNPs in the Insulin-like growth factor gene and obesity impact on colorectal cancer in Egyptians
2706. Somatic mutations in the Insulin-like growth factor-1 and Insulin receptors found in cancer genomes result in constitutive activation of the receptor kinases
2707. Somatomedin-C/Insulin-like growth factor-I is a mitogen for human small cell lung cancer.
2708. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on Insulin-like growth factor-I (IGF-I) levels.
2709. Specific binding and growth-promoting activity of Insulin in endometrial cancer cells in culture
2710. Specific binding sites for Insulin and Insulin-like growth factor I in human endometrial cancer
2711. Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat Insulin promoter
2712. Specific targeting of Insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine …
2713. Sporadic amplification of the Insulin receptor gene in human breast cancer
2714. Statin induces apoptosis of human colon cancer cells and downregulation of Insulin-like growth factor 1 receptor via proapoptotic ERK activation
2715. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased Insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and …
2716. Stimulation of TPA-responsive element activity by a cooperative action of Insulin and estrogen in human breast cancer cells
2717. Stop the Insulin Hazardous Abbreviation for “Intranasal” cancer Patients Deserve the Safest Practices Regardless of Where They are Treated
2718. Stromal cells promote anti-estrogen resistance of breast cancer cells through an Insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia …
2719. Structural and functional studies of Insulin receptors in human breast cancer
2720. Structural commonality of C1q TNF‐related proteins and their potential to activate relaxin/Insulin‐like family peptide receptor 1 signalling pathways in cancer cells
2721. Study of Effect of Dyslipidemia And Insulin Resistance on Colorectal cancer risk patients in A Teaching Hospital of India
2722. Study of Insulin resistance and antioxidant vitamin status in prostate cancer patients
2723. Study of serum IGF-1, IGFBP-3 and Insulin levels in patients with type 2 diabetes mellitus and their relationship with colorectal cancer
2724. Study on the correlation between expression of Insulin-like growth factor-1 receptor and loco-regional recurrence of breast cancer after postoperative irradiation
2725. Study on the relations between serum Insulin-like growth factor-1, Insulin-like growth factor binding protein-3 and colorectal cancer: a meta-analysis
2726. Study on the relationship between Insulin-like growth factor binding protein 5 and anti-proliferating effect of tetrandrine on human colon cancer cells
2727. Study on the relationship between Insulin-like growth factor I receptor and the cisplatin resistance in epithelial ovarian cancer
2728. Study Protocol: Insulin and its role in cancer
2729. Substrate contribution to endogenous glucose production, Insulin resistance and protein metablism in non-small cell lung cancer cachexia
2730. Sugar pills for pancreatic cancer: The benefits of becoming (Insulin) sensitive
2731. Summary Insulin-Like Activity of the Blood Serum in Breast cancer and in Specific Age-Related Pathology
2732. SUN-131 The Roles of Two Insulin Receptor Isoforms in Triple Negative Breast cancer Growth
2733. Suppressed expression of Insulin‐like growth factor binding protein‐1 mRNA in the endometrium: A molecular mechanism associating endometrial cancer with its risk …
2734. Suppressing Insulin feedback to improve efficacy of cancer therapeutics
2735. Suppression of homologous recombination by Insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
2736. Suppression of serum Insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy
2737. Suppression of Type 1 Insulin-like Growth Factor Receptor Expression by Small Interfering RNA Inhibits A549 Human Lung cancer Cell Invasion in vitro and …
2738. Suppressor of cytokine signaling-2 (SOCS2) and epidermal growth factor (EGF) modulate Insulin-like growth factor-I receptor (IGF-IR) signaling in intestinal cancer
2739. Suramin and serum Insulin-like growth factor levels in metastatic cancer patients.
2740. Suramin interferes with auto/paracrine Insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines
2741. Survival time in pancreatic cancer patients with metabolic syndrome varies by use of Insulin and statins
2742. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by Insulin-like growth factor-1, interferon-γ and a novel NF-κB inhibitor
2743. Synthesis of novel inhibitors that target the Insulin growth factor-1 receptor (IGF-1R):(potential anti-breast cancer compounds)
2744. Systematic review and meta-analysis of Insulin therapy and risk of cancer
2745. SYSTEMIC RISK FACTORS FOR FACTORS FOR ORAL cancer: ESTROGEN DEFICIENCY AND Insulin RESISTANCE
2746. Systems analysis of Insulin and IGF1 receptors networks in breast cancer cells identifies commonalities and divergences in expression patterns
2747. T-helper I immunity, specific for the breast cancer antigen Insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity
2748. Tamoxifen alters levels of serum Insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study
2749. Tamoxifen interferes with the Insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
2750. Targeted therapy of the Insulin-like growth factor-1 receptor in cancer
2751. Targeting 3-phosphoinoside-dependent kinase-1 to inhibit Insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells
2752. Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with Insulin resistance and breast cancer …
2753. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-Insulin receptor substrate and STAT3 signaling
2754. Targeting Downstream Effectors of IGF/Insulin Signaling System in Human Breast cancer
2755. Targeting Heat Shock Protein 90 in Pancreatic cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and …
2756. Targeting heat shock protein 90 in pancreatic cancer impairs Insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of …
2757. Targeting Insulin and Insulin-like growth factor pathways in epithelial ovarian cancer
2758. Targeting Insulin and Insulin-like growth factor signaling in breast cancer
2759. Targeting Insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients
2760. Targeting Insulin receptor in breast cancer using small engineered protein scaffolds
2761. Targeting Insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis
2762. Targeting Insulin-like growth factor binding protein-3 signaling in triple-negative breast cancer
2763. Targeting Insulin-like growth factor in breast cancer therapeutics
2764. Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in cancer
2765. Targeting Insulin-like growth factor type 1 receptor in cancer therapy
2766. Targeting Insulin-like growth factor-1 receptor in cancer
2767. TARGETING Insulin-LIKE GROWTH FACTOR-1 RECEPTOR WITH ANTISENSE OLIGONUCLEOTIDES IN PROSTATE cancer
2768. Targeting Insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer
2769. Targeting Insulin-like growth factors in the treatment of cancer
2770. Targeting IRS‐1/mPGES‐1/NOX2 to inhibit the inflammatory response caused by Insulin‐like growth factor‐I‐induced activation of NF‐κB and NLRP3 in cancer cells
2771. Targeting non-small cell lung cancer cells by dual inhibition of the Insulin receptor and the Insulin-like growth factor-1 receptor
2772. Targeting of bone-derived Insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment
2773. Targeting STAT1 in both cancer and Insulin resistance diseases
2774. Targeting the Anaplastic Lymphoma Kinase (ALK) and the Insulin-like Growth Factor Receptor 1 (IGF1R) in crizotinib resistant lung cancer cells
2775. Targeting the Insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer
2776. Targeting the Insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse …
2777. Targeting the Insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy
2778. Targeting the Insulin-like growth factor axis as a cancer therapy
2779. Targeting the Insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti …
2780. Targeting the Insulin-like growth factor network in cancer therapy
2781. Targeting the Insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer
2782. Targeting the Insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls
2783. Targeting the Insulin-like growth factor receptor-1R pathway for cancer therapy
2784. Targeting the Insulin-like growth factor receptor/Insulin receptor and Src signaling network for the treatment of non-small cell lung cancer
2785. Targeting the Insulin-like growth factor-1 receptor in human cancer
2786. Targeting the Insulin-like growth factor-I receptor in cancer therapy
2787. Targeting the Insulin‐like growth factor‐1 receptor by picropodophyllin for lung cancer chemoprevention
2788. Targeting the type 1 Insulin-like growth factor receptor as a treatment for cancer
2789. Targeting the type 1 Insulin-like growth factor receptor as anti-cancer treatment
2790. Targeting the type I Insulin-like growth factor system for breast cancer therapy
2791. Telephone-based nutrition coaching decreases Insulin resistance in patients undergoing breast cancer treatment.
2792. TET1-GPER-PI3K/AKT pathway is involved in Insulin-driven endometrial cancer cell proliferation
2793. TGFβ activates Insulin‐like growth factor 1‐mediated signaling pathway in human liver cancer cells (144.9)
2794. TH1 and TH2 cytokine data in Insulin secretagogues users newly diagnosed with breast cancer
2795. TH1 and TH2 cytokines dataset in Insulin users with diabetes mellitus and newly diagnosed breast cancer
2796. The “Cross Talk” between the receptors of Insulin, estrogen and progesterone in neutrophils in the synthesis of maspin through nitric oxide in breast cancer
2797. The “Cross Talk” between the Receptors of Insulin, Estrogen and Progesterone in Neutrophils in the Synthesis of Maspin through Nitric Oxide in Breast cancer
2798. The “Cross Talk” between the receptors of Insulin, estrogen and progesterone in neutrophils in the synthesis of maspin through nitric oxide in breast cancer
2799. The “Cross Talk” between the Receptors of Insulin, Estrogen and Progesterone in Neutrophils in the Synthesis of Maspin through Nitric Oxide in Breast cancer
2800. The A− 336C Insulin-Like Growth Factor Binding Protein-3 Promoter Polymorphism Is Not a Modulator of Breast cancer Risk in Caucasian Women
2801. The activation of ERK1/2 and JNK MAPK signaling by Insulin/IGF-1 is responsible for the development of colon cancer with type 2 diabetes mellitus
2802. The aging suppressor klotho interacts with the Insulin-like growth factor-1 receptor, inhibits it activation and reduces growth of breast cancer cells.
2803. The apoptotic effect of HIF-1α inhibition combined with glucose plus Insulin treatment on gastric cancer under hypoxic conditions
2804. The aromatase inhibitor letrozole in advanced breast cancer: effects on serum Insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels
2805. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene
2806. The association between diabetes, Insulin use, and colorectal cancer among Whites and African Americans
2807. The association between plasma Insulin-like-growth factor (IGF)-I and colorectal cancer is modified by BMI or C-peptide.
2808. The association between polymorphismsin Insulin and obesity related genesand risk of colorectal cancer
2809. The association between thyroid cancer and Insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis
2810. The association of hyperInsulinemia with cardiovascular risk and cancer poses new challenges in the treatment of the Insulin resistance type 2 diabetes patient
2811. The association of serum ghrelin, GIP, Insulin, and leptin levels with sleep quality and cancer-related fatigue in cancer survivors.
2812. The association of serum Insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study
2813. The association of tissue and serum adiponectin levels with the parameters of Insulin-resistance in breast cancer patients
2814. The biological and clinical roles of increased Insulin receptors in human breast cancer
2815. The cancer-associated FGFR4-G388R polymorphism enhances pancreatic Insulin secretion and modifies the risk of diabetes
2816. The cellular and molecular mechanisms by which Insulin influences breast cancer risk and progression
2817. The Change of Serum Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) in the Diagnosis and Management of Prostate cancer
2818. The Clinical Application of Insulin-like Growth Factor-I Receptor (IGF-IR) and Insulin Receptor Substrate-1 (IRS-1) Expression in Breast cancer
2819. The Clinical Research on the Dynamic Change of Insulin Resistance during the Therapy of Prostate cancer
2820. The clinical significance of the Insulin-like growth factor-1 receptor polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation
2821. The colonic protein fermentation and Insulin resistance hypotheses for colon cancer etiology: experimental tests using precursor lesions
2822. The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of Insulin-like growth factor binding …
2823. The combination treatment with inhibitors targeting the type I Insulin-like growth factor receptor and the epidermal growth factor receptor in human colon cancer.
2824. The consequences of Insulin-like growth factors/receptors dysfunction in lung cancer
2825. The Correlation between Circulating Insulin-like Growth Factor-Ⅰ in Blood and Clinicopathological Parameters in Non-Small Cell Lung cancer
2826. The correlation between zinc and Insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer
2827. The development of the metabolic syndrome and Insulin resistance after adjuvant treatment for breast cancer
2828. The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?
2829. The dietary glycemic index and its implications in cancer risk, Insulin-like growth factors and oxidative stress
2830. The dog as a naturally-occurring model for Insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study
2831. The Effect and Mechanism of Action of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 in Human Breast cancer; A Systematic Review.
2832. The effect of a single nucleotide polymorphism in the Insulin-like growth factor I regulatory region on breast cancer risk is modified by body mass index
2833. The effect of droloxifene on the Insulin-like growth factor-I-stimulated growth of breast cancer cells.
2834. THE EFFECT OF EIGHT WEEKS AEROBIC ACTIVITY ON CA15-3 MARKER, GROWTH HORMONE AND Insulin OF WOMEN WITH BREAST cancer
2835. The effect of exercise intensity on Insulin levels in postmenopausal breast cancer survivors
2836. The effect of graded doses of Insulin on peripheral glucose uptake and lactate release in cancer cachexia.
2837. The effect of green tea extract compounds on regulation of glucose homoeostasis in Insulin-sensitive and breast cancer cells
2838. The effect of Insulin analogues only or combined with metformin on the prolifeation of breast cancer cell line (MCF-7)
2839. The effect of Insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells
2840. The effect of Insulin on glucose and protein metabolism in the forearm of cancer patients
2841. The effect of Insulin on human breast cancer cell line in vitro [J]
2842. The effect of Insulin on INSR receptor and Bax and Bcl-2 protein expression in drug resistance situation on MCF-7 breast cancer cells line
2843. The effect of Insulin resistance on breast cancer risk in Latinas of Mexican origin
2844. The effect of serum Insulin like factor Ⅰ on mouse cancer
2845. The effect of the preoperative oral carbohydrate treatment on immediate postoperative Insulin resistance in patients after colorectal cancer resection
2846. The Effects of Ellagic Acid on Insulin-Like Growth Factor Binding Protein-2 in Human Prostate cancer Cells
2847. The effects of exercise on Insulin, glucose, IGF‐axis and CRP in cancer survivors: Meta‐analysis and meta‐regression of randomised controlled trials
2848. The Effects of Exercise Training on Insulin Supply and Demand in Breast cancer Survivors
2849. The Effects of Fructose Injection on the Levels of Blood Glucose, Insulin in cancer by Chemotherapy [J]
2850. The effects of genetic variants related to Insulin metabolism pathways and the interactions with lifestyles on colorectal cancer risk
2851. The effects of Insulin and Insulin-like growth factors on tumor vascularization: new insights of Insulin-like growth factor family in cancer
2852. The effects of Insulin receptor substrate-1 regulation on cell cycle progression in non-small cell lung cancer
2853. The effects of Insulin-like growth factor binding protein-3 (IGFBP-3) on T47D breast cancer cells enriched for IGFBP-3 binding sites
2854. The Effects of Insulin-like Growth Factor-I (IGF-I) in Mouse Lung cancer Cells
2855. The effects of pioglitazone treatment on pancreatic cancer-related Insulin resistance.
2856. The Effects of Recombinant Synucleins and Insulin-like Growth Factor 1 on cancer Cell Migration
2857. The emerging role of Insulin and Insulin-like growth factor signaling in cancer stem cells
2858. The emerging role of Insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives
2859. The emerging role of the Insulin‐like growth factor pathway as a therapeutic target in cancer
2860. The estrogen receptor α: Insulin receptor substrate 1 complex in breast cancer: structure–function relationships
2861. The expression and imprinting status of Insulin-like growth factor 2 gene in colorectal cancer
2862. The expression and significance of Insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors
2863. The expression of ADAM-9 and-10 in prostate cancer and their regulation by dihydrotestosterone, Insulin-like growth factor-1 and epidermal growth factor
2864. The expression of Insulin receptor substrate 1 and estrogen receptor as prognostic factor on breast cancer patient
2865. The expression of Insulin-like growth factor (IGF), IGF-binding protein (IGFBP) and the role of IGFBP-3 in the Korean gastric cancer cell lines
2866. The Expression of Insulin-like Growth Factor I and its Receptor in Colorectal Polypus and Colorectal cancer [J]
2867. The expression of Insulin-like growth factor Ⅱ (IGF-Ⅱ) in serum and tissues of patients with breast cancer
2868. The Expression of Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Early Breast cancer.
2869. The expression of Insulin-like growth factor-1 receptor on breast cancer and normal breast tissue
2870. The expression of Insulin-like growth factor-1 receptor on LN (-) breast cancer, LN (+) breast cancer and normal breast tissue
2871. The expression of Insulin‐like growth factor and its binding protein mRNA in the endometrium of postmenopausal patients with breast cancer receiving tamoxifen
2872. The expression of the Insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
2873. The expression of VEGF in colon cancer tissue was affected by the serum levels of Insulin–like Growth Factor I
2874. The glucose tolerance test and Insulin secretion test as risk factors in liver cancer surgery
2875. The growth hormone-Insulin-like growth factor axis and colorectal cancer
2876. The growth hormone–Insulin-like growth factor-I axis and colorectal cancer
2877. The growth hormone/Insulin-like growth factor axis and breast cancer risk
2878. The human Insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21. 1 and is close to the gene for hereditary breast-ovarian cancer
2879. The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in cancer: Actionable Perspectives
2880. The Impact of Insulin Exposure on Colorectal cancer Metabolism
2881. The impact of Insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28
2882. The impact of obesity and Insulin resistance on thyroid cancer: a systematic review
2883. The importance of serum Insulin-like growth factor-I level determination in the follow-up of patients with epithelial ovarian cancer.
2884. The Importance of the Insulin-like Growth Factor Signaling Pathway in Lung cancer and the Potential of its Components as Therapeutic Targets
2885. The influence of exercise intensity on Insulin sensitivity and the Insulin-like growth factor axis in colorectal cancer survivors
2886. The influence of oral administration of glucose before surgery on Insulin resistance and oxidative stress in castric cancer patients undergoing surgery
2887. The influence of overweight and Insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study
2888. The influence of overweight and Insulin resistance on localised and advanced breast cancer risk: A prospective study
2889. The inhibition of Insulin‐like growth factor 1 receptor pathway targets putative cancer stem cells in human malignant mesothelioma
2890. The Insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy
2891. The Insulin receptor isoform exon 11-(IR-A) in cancer and other diseases: a review
2892. The Insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer
2893. The Insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer
2894. The Insulin receptor substrate-1: a biomarker for cancer?
2895. The Insulin receptor: a new target for cancer therapy
2896. The Insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression
2897. The Insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer
2898. The Insulin-like growth factor (IGF) axis is involved in normal prostate differentiation and downregulated in local prostate cancer
2899. The Insulin-like growth factor (IGF) family and breast cancer
2900. The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in cancer Treatment
2901. The Insulin-like growth factor 1 (IGF1) is differentially expressed in metastatic breast cancer, both in metastases to the brain and to the lymph nodes.
2902. The Insulin-like growth factor 1 axis in prognosis and treatment of breast cancer
2903. The Insulin-like growth factor 1 receptor in cancer: old focus, new future
2904. The Insulin-like growth factor 2 mRNA binding protein IMP2/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic cancer
2905. The Insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
2906. The Insulin-like growth factor axis, adipokines, physical activity, and obesity in relation to breast cancer incidence and recurrence
2907. The Insulin-like growth factor axis: A biological mechanism linking physical activity to colorectal cancer survival
2908. The Insulin-like growth factor axis: a potential link between glycemic index and cancer,
2909. The Insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells
2910. The Insulin-like growth factor binding proteins (IGFBPs) in human breast cancer
2911. The Insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis
2912. The Insulin-like growth factor family and breast cancer prognosis: a prospective cohort study among postmenopausal women in Denmark
2913. The Insulin-like growth factor II/mannose 6-phosphate receptor: implications for IGF action in breast cancer
2914. The Insulin-like growth factor network and breast cancer
2915. The Insulin-like growth factor pathway as a target for cancer therapy
2916. The Insulin-like growth factor pathway in lung cancer
2917. The Insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt-and MAPK-dependent activation of paxillin
2918. The Insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt-and mitogen-activated protein kinase-dependent …
2919. The Insulin-like growth factor receptor is a promising target for innovative treatment approaches of hepatocellular cancer
2920. The Insulin-like growth factor system and cancer
2921. The Insulin-like growth factor system and cancer: what are the implications?
2922. The Insulin-like growth factor system and colorectal cancer: clinical and experimental evidence
2923. The Insulin-like growth factor system as a target in breast cancer
2924. The Insulin-like growth factor system as a therapeutic target in colorectal cancer
2925. The Insulin-like growth factor system as a treatment target in breast cancer
2926. The Insulin-like growth factor system in advanced breast cancer
2927. The Insulin-like growth factor system in cancer
2928. The Insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies
2929. The Insulin-like growth factor system is modulated by exercise in breast cancer survivors: a systematic review and meta-analysis
2930. The Insulin-like growth factor-1 ligand in breast cancer management
2931. The Insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer
2932. The Insulin-like growth factor-2 (IGF-2): A potential therapeutic target for triple-negative breast cancer metastasis
2933. The Insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies
2934. The Insulin-like growth factor-I receptor as a target for cancer therapy
2935. The Insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
2936. The Insulin-like growth factor/Insulin system in epithelial ovarian cancer
2937. The Insulin-like growth factors and breast cancer—revisited
2938. The Insulin-like growth factors and Insulin-signalling systems: an appealing target for breast cancer therapy?
2939. The Insulin-like growth factors, their receptors, and their binding proteins in human breast cancer
2940. The Insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor
2941. The Insulin‐like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer
2942. The Insulin‐like growth factor‐1 elevates urokinase‐type plasminogen activator‐1 in human breast cancer cells: A new avenue for breast cancer therapy
2943. The Insulin/IGF system in colorectal cancer development and resistance to therapy
2944. The integrative role of leptin, oestrogen and the Insulin family in obesity‐associated breast cancer: potential effects of exercise
2945. The interactions between Insulin and androgens in progression to castrate-resistant prostate cancer
2946. The interactions of obesity, inflammation and Insulin resistance in breast cancer
2947. The international study of Insulin and cancer
2948. The International Study of Insulin and cancer
2949. The intracellular mechanism of Insulin resistance in pancreatic cancer patients
2950. The involvement of Insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion
2951. The involvement of Insulin-like growth factor binding protein 2 in promoting prostate cancer progression and metastasis
2952. The involvement of survivin in Insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer
2953. The key role of growth hormone–Insulin–IGF-1 signaling in aging and cancer
2954. The kinetics of methotrexate polyglutamate formation and efflux in a human breast cancer cell line (MDA. MB. 436): the effect of Insulin
2955. The lack of an effect by Insulin or Insulin-like growth factor-1 in attenuating colon-26-mediated cancer cachexia
2956. The level of Insulin-like growth factor-Ⅰ in blood circulation in patients with non-small cell lung cancer after surgery and its clinical significance [J]
2957. The Limited Screening Value of Insulin-Like Growth Factor-I in 610 Very Long Term Adult Survivors of Leukemia and Other Types of Childhood cancer
2958. The limited screening value of Insulin‐like growth factor‐i as a marker for alterations in body composition in very long‐term adult survivors of childhood cancer
2959. The links between Insulin resistance, diabetes, and cancer
2960. The matrix metalloproteinase and Insulin-like growth factor system in oral cancer–a prospective clinical study
2961. The Mechanisms and Impact of Obesity and Insulin Resistance on Breast cancer Incidence
2962. The miRNA let-7a1 inhibits the expression of Insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells
2963. The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with Insulin regarding cancer survival
2964. The neglected Insulin: IGF-II, a metabolic regulator with implications for diabetes, obesity, and cancer
2965. The nuclear receptor coactivator AIB1 mediates Insulin-like growth factor I-induced phenotypic changes in human breast cancer cells
2966. The nuclear translocation of Insulin‐like growth factor receptor and its significance in cancer cell survival
2967. The p53-family members p63 and p73 inhibit Insulin-like growth factor-I receptor gene expression in colon cancer cells
2968. The PI3K/Akt/mTOR signaling pathway mediates Insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells
2969. The possible role of Insulin-like growth factors and matrix metalloproteinases as a diagnostic of colorectal cancer.
2970. The potential clinical applications of Insulin-like growth factor-1 ligand in human breast cancer
2971. The potential role of Insulin (and stress response) pathway components in breast cancer development and progression
2972. The potential role of Insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
2973. The potentiation of estrogen on Insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
2974. The predictive value of Insulin-like growth factor 1 in irradiation-dependent growth hormone deficiency in childhood cancer survivors
2975. THE PRICE OF MEDICINE FOR cancer, Insulin, AND ADDICTION RELATED DRUGS: A CASE OF PERFECT INELASTICITY OF DEMAND
2976. The prognostic significance of the expression of Insulin-like growth factor receptor-I in prostate cancer
2977. The prognostic significance of the Insulin‐like growth factor‐1 ligand and receptor expression in breast cancer tissue
2978. The prognostic value of Insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients
2979. The prognostic value of polymorphisms in the Insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC)
2980. The prognostic values of Insulin-like growth factor binding protein in breast cancer
2981. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian cancer
2982. The proliferating role of Insulin and Insulin-like growth factors in cancer
2983. The proliferative role of Insulin and the mechanism underlying this action in human breast cancer cell line MCF-7
2984. The prospective estimation of blood serum free IGF-1, Insulin concentration, and body mass index as a prognostic factor for breast cancer patients.
2985. The Prospective Estimation of Body Mass Index, Blood Serum Free Igf-1, Insulin Concentration as Prognostic Factor for Colorectal cancer Patients
2986. The Protective Effect of Lycopene on Prostate Growth Inhibitory Efficacy by Decreasing Insulin Growth Factor-1 in Indonesian Human Prostate cancer Cells
2987. The R-Ras GTPase mediates cross talk between estrogen and Insulin signaling in breast cancer cells
2988. The regulation of expression of the Insulin-like growth factor II (IGF2) gene in breast cancer.
2989. The regulation of Insulin-like growth factor binding protein-5 production and secretion by ovarian hormones in human breast cancer cells
2990. The Relation of Cytokines, Serum Insulin and Insulin Resistance with the Progression Free Survival and Overall Survival of Metastatic Breast cancer Patients
2991. The relation of Insulin and IGF-II in human colorectal cancer and its biological significance [J]
2992. The relationship between HPV infection and the expression of Insulin-like growth factor Ⅱ in lung cancer and its clinical significance [J]
2993. The relationship between HPV infection and the expression of Insulin-like growth factor II in lung cancer and its clinical significance.
2994. The Relationship between Insulin PSTI Polymorphism and Prostate cancer in Turkish Population
2995. The relationship between Insulin resistance and colon cancer
2996. The Relationship Between Insulin Resistance and HyperInsulinemia on Mammary cancer Growth and Development
2997. The relationship between serum levels of erythropoietin (EPO) and Insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non …
2998. The relationship between the exposure time of Insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of …
2999. The Relationship Between the Insulin Resistance and cancer [J]
3000. The relationship between the Insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous …
3001. The relationship of circulating Insulin‐like growth factor 1, its binding protein‐3, prostate‐specific antigen and C‐reactive protein with disease stage in prostate cancer
3002. The relationship of Insulin resistance and metabolic syndrome with known breast cancer prognostic factors in postmenopausal breast cancer patients
3003. The Relationship of Type 2 Diabetes, Oral Diabetes Medications, and Insulin Therapy to Risk for Breast cancer
3004. The role of activation of Insulin-like growth factors in colorectal cancer
3005. The Role of Adiponectin, Leptin, Soluble Leptin Receptor and Insulin-like Growth Factor in A Sample of Breast cancer Iraqi woman
3006. The role of early placenta Insulin like growth factor in invasion and metastasis of HER2 positive breast cancer cells in vivo
3007. The role of early placenta Insulin-like growth factor (EPIL) as a potential regulator of cancer progenitor cells
3008. The role of endocrine Insulin-like growth factor-I and Insulin in breast cancer
3009. The role of genetic variation in Insulin-like growth factors in prostate cancer risk: The multiethnic cohort
3010. The role of growth factors in pathogenesis of pancreatic cancer. Part III: Vascular endothelial growth factor (VEGF) and Insulin-like growth factors (IGFs)
3011. The Role of Growth Hormone and Insulin-Like Growth Factor 1 in Human Breast cancer Growth in a Mouse Xenograft Model
3012. The role of Insulin and IGF system in pancreatic cancer
3013. The role of Insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
3014. The role of Insulin and Insulin-like growth factors in the increased risk of cancer in diabetes
3015. The role of Insulin dependent NO synthesis in the impaired production of maspin in human breast cancer
3016. The role of Insulin in advanced prostate cancer
3017. The role of Insulin in cancer malnutrition.
3018. The role of Insulin Receptor in cancer
3019. The role of Insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer
3020. The role of Insulin receptors and IGF-I receptors in cancer and other diseases
3021. The role of Insulin resistance and hyperInsulinemia in cancer causation
3022. The role of Insulin resistance in the development of muscle wasting during cancer cachexia
3023. The Role of Insulin Signaling on c-Myc Expression in Breast cancer Cells
3024. The role of Insulin-like amyloid polypeptide in pancreatic cancer
3025. The role of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 in human esophageal cancer
3026. The role of Insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents
3027. The Role of Insulin-like Growth Factor I (IGF-I), and IGF Binding Protein (IGFBP) in Mouse Lung cancer Cells.
3028. The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in breast cancer cells
3029. The Role of Insulin-Like Growth Factor Signaling in Prostate cancer Development and Progression
3030. The role of Insulin-like growth factor-1 and Insulin like growth factor-1 receptor in obesity and oesophageal cancer
3031. The role of Insulin-like growth factor-1 in the pathogenesis of cancer and inflammatory skin diseases.
3032. The role of Insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models
3033. The Role of Insulin-like Growth Factors in cancer Therapy
3034. The role of Insulin-like growth factors in the development of prostate cancer
3035. The role of Insulin‐like growth factor binding protein‐3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells
3036. The Role of Insulin, IGF-1 and PRAS40 in the Processes of Oncogenesis in Women with Type 2 Diabetes Mellitus and Endometrial cancer
3037. The Role of Legumes in Weight Management, Insulin Resistance and Colon cancer Prevention
3038. The role of Notch signaling pathway in Insulin regulation of endometrial cancer cell growth and apoptosis
3039. The role of somatostatin analog octreotide on gastrointestinal cancer and its influence on the serum level of Insulin-like growth factor 1 (IGF-1)
3040. The role of some ADAM-proteins and activation of the Insulin growth factor-related pathway in colorectal cancer
3041. The role of the Insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
3042. The role of the Insulin-like growth factor system in colorectal cancer: review of current knowledge
3043. The role of the Insulin-like growth factor system in human cancer
3044. The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal cancer
3045. The role of the Insulin-like growth factor-1 system in breast cancer
3046. The role of the Insulin‐like growth factor‐I receptor in cancer
3047. The role of the Insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link
3048. The Role of Type I Insulin-Like Growth Factor Receptor Signaling in Breast cancer Brain Metastasis
3049. The roles of Insulin-like growth factor 2 mRNA-binding protein 2 in cancer and cancer stem cells
3050. The roles of integrins and extracellular matrix proteins in the Insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells
3051. The significance of serum levels of Insulin‐like growth factor‐1 in patients with prostate cancer
3052. The synthetic retinoid fenretinide lowers plasma Insulin-like growth factor I levels in breast cancer patients
3053. The Therapeutic and Preventive Effect of RRR-A-Vitamin E Succinate on Prostate cancer via Induction of Insulin-Like Growth Factor Binding Protein-3
3054. The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of Insulin-like growth factor binding protein-3
3055. The type 1 Insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer
3056. The type 1 Insulin‐like growth factor receptor is over‐expressed in bladder cancer
3057. The type I Insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
3058. The type I Insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
3059. The type-1 Insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance
3060. The tyrphostin NT157 suppresses Insulin receptor substrates and augments therapeutic response of prostate cancer
3061. The use of Insulin and the effect on survival of non-small cell lung cancer patients
3062. The Use of Long-Acting Insulin Analogs and the Risk of Colorectal cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
3063. The value of Insulin-like growth factor in the evaluation of the effect of neoadjuvant chemotherapy in gastric cancer [J]
3064. The Yin and Yang function of microRNAs in Insulin signalling and cancer
3065. Thematic Poster: TP-47; MicroRNA-146a Inhibits Epithelial Mesenchymal Transition in Non Small Cell Lung cancer by Targeting Insulin Receptor Substrate 2
3066. Therapeutic Destruction of Insulin Receptor Substrates for cancer
3067. Therapeutic destruction of Insulin receptor substrates for cancer treatment
3068. Therapeutic Potential of Insulin-sensitizing Drugs in the Treatment of Prostate cancer with Coexisting Obesity
3069. Therapeutic targeting of the Insulin-like growth factor-I receptor (IGF-IR) plus oxaliplatin decreases hepatic growth of human colon cancer
3070. Therapy of Prostate cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR)
3071. Thyroid cancer and Insulin resistance: is it important?
3072. Time course of fenretinide‐induced modulation of circulating Insulin‐like growth factor (IGF)‐i, IGF‐II and IGFBP‐3 in a bladder cancer chemoprevention trial
3073. Tissue distribution and cancer growth inhibition of magnetic lipoplex-delivered type 1 Insulin-like growth factor receptor shRNA in nude mice
3074. Tissue-Type Plasminogen Activator Is Upregulated in Metastatic Breast cancer Cells Exposed to Insulin-Like Growth Factor—I
3075. Tissue‐Specificity and Ethnic Diversity in Obesity‐Related Risk of cancer May Be Explained by Variability in Insulin Response and Insulin Signaling Pathways
3076. TMPRSS2-ERG fusion protein regulates Insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor …
3077. To Study the Dose and Time Dependent Effect of Human Insulin and Metformin on the Growth of Breast cancer Cells
3078. To study the effect of Insulin on advanced androgen-indpendent prostate cancer (pc-3) cells
3079. Tomato and soy polyphenols reduce Insulin-like growth factor-I–stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of …
3080. Tomato lycopene extract supplementation decreases Insulin-like growth factor-I levels in colon cancer patients
3081. Total Insulin-like activity of blood serum in patients with mammary gland cancer and in specific age-associated pathology
3082. trans-10, cis-12 Conjugated Linoleic Acid Reduces Insulin-Like Growth Factor-II Secretion in HT-29 Human Colon cancer Cells
3083. trans-10,cis-12 Conjugated Linoleic Acid Inhibits Insulin-Like Growth Factor-I Receptor Signaling in TSU-Pr1 Human Bladder cancer Cells
3084. Transactivation of CXCR4 by the Insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells
3085. Transcriptional activation of the porcine P450 11A Insulin-like growth factor response element in MCF-7 breast cancer cells
3086. Transcriptional regulation of Insulin-like growth factor-I receptor gene expression in prostate cancer cells
3087. Transcriptional regulation of the Insulin-like growth factor-I receptor gene in breast cancer
3088. Transcriptome analysis of a human colorectal cancer cell line shows molecular targets of Insulin‐like growth factor‐binding protein‐4 overexpression
3089. Transfection of antisense oligonucleotide against the Insulin like growth factor# IOTA# on proliferactio and apoptosis of liver cancer cell
3090. Transfection of human Insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer
3091. Transforming growth factor-α and Insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines
3092. Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through Insulin-like growth factor-binding protein-3 …
3093. Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through Insulin-like growth factor-I
3094. Transforming growth factor‑β, Insulin‑like growth factor I/Insulin‑like growth factor I receptor and vascular endothelial growth factor‑A: Prognostic and predictive …
3095. Treatment of human breast cancer cells with antisense RNA to the type I Insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the …
3096. Treatment of murine breast cancer cells with antisense RNA to the type I Insulin-like growth factor receptor decreases the level of plasminogen activator …
3097. Treatment with growth hormone, somatostatin, and Insulin in combination with hypocaloric parenteral nutrition in gastrointestinal cancer patients after surgery
3098. Treatment with human Insulin does not increase thyroid cancer risk in patients with type 2 diabetes
3099. Treatment with Insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence
3100. Treatment with Insulin (analogues) and breast cancer risk in women with diabetes; a systematic review and meta-analysis of in vitro, animal and human …
3101. Treatment with Insulin analog X10 and IGF-1 increases growth of colon cancer allografts
3102. Treatment with Insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells
3103. Treatment with Insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study
3104. Treatment with Insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer
3105. Trimethylamine N-oxide (TMAO) as a new potential therapeutic target for Insulin resistance and cancer
3106. Troglitazone: from an Insulin sensitizer to a novel class of anti-cancer agent
3107. TTP inhibits Insulin receptor signals in cancer cell
3108. Tumor expression of the type I Insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancer
3109. Tumor Suppressor BRCA1 Is Expressed in Prostate cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor …
3110. Tumor suppressor gene Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) induces senescence-like growth arrest in colorectal cancer cells
3111. Tumor suppressors govern Insulin-like growth factor signaling pathways: implications in metabolism and cancer
3112. Tumour necrosis factor-alpha, interleukin-6, and fasting serum Insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy
3113. Type 1 Insulin-like growth factor receptor inhibition as treatment for urological cancer
3114. Type 1 Insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
3115. Type 1 Insulin-like growth factor receptor targeted therapies in pediatric cancer
3116. Type 2 diabetes and cancer: Should we prefer antihyperglycaemic treatments without unnecessarily increasing Insulin levels?
3117. Type 2 Diabetes Mellitus, Insulin Resistance, Obesity, there is Any Association with Liver cancer?
3118. Type 2 diabetes mellitus, Insulin‐use and risk of bladder cancer in a large cohort study
3119. Type 2 diabetes mellitus, oral diabetic medications, Insulin therapy, and overall breast cancer risk
3120. Type 2 diabetes, but not Insulin (analog) treatment, is associated with more advanced stages of breast cancer: a national linkage of cancer and pharmacy registries
3121. Type 2 diabetes, Insulin treatment and prognosis of breast cancer
3122. Type I Insulin-like growth factor receptor antisense strategies in experimental breast cancer
3123. Type I Insulin-like growth factor receptor as a therapeutic target in cancer
3124. Type I Insulin-like growth factor receptor function in breast cancer
3125. Type I Insulin-like growth factor receptors in human colorectal cancer
3126. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast cancer Cells
3127. Tyrosine kinase of Insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer
3128. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer
3129. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 Insulin-like growth factor receptor
3130. Unbalanced cancer Status May Undermine Results on Insulin and Insulin-like Growth Factor
3131. Understanding the Contribution of Insulin Resistance to the Risk of Pancreatic cancer.
3132. Unravelling the link between diabetes, Insulin treatment and breast cancer
3133. UP-01.024 The Association Between Bladder cancer and a Single Nucleotide Polymorphism (Rs2854744) in the Insulin-Like Growth Factor (IGF) Binding Protein-3 …
3134. UP-02.208 Insulin and Insulin Resistance Are Associated with the Advanced Pathological Stage of Prostate cancer in the Korean Population
3135. UP-02.50: A study of the role of Insulin like growth factor 1 (IGF1) and rapamycin sensitive signaling in an androgen independent prostate cancer cell line
3136. UP-1.089: Prostate cancer Risk in Relation to Serum Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Nested Case-Control Study in Japan
3137. Up-regulation of Insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade
3138. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, Insulin resistance, and cancer program-the ‘PKC …
3139. Upper abdominal obesity, Insulin resistance and breast cancer risk
3140. Upregulated Insulin receptor tyrosine kinase substrate promotes the proliferation of colorectal cancer cells via the bFGF/AKT signaling pathway
3141. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum Insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk.
3142. Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the Insulin-like growth factor-binding protein-3 (IGFBP3) gene
3143. Use of an Insulin Pump in the Elderly Surgical Patient: Tolerance of Total Pancreatectomy After Neoadjuvant Chemotherapy for Multifocal Pancreatic cancer
3144. Use of elevated Insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation …
3145. Use of Insulin and Insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies
3146. Use of Insulin and mortality from breast cancer among Taiwanese women with diabetes
3147. Use of Insulin and Risk of cancer among Patients with Diabetes Mellitus: A Nonconcurrent Prospective Study
3148. Use of Insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
3149. Use of Insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients.
3150. Use of Insulin-like Growth Factor-I Gene Expression to Distinguish Between Breast and Ovarian cancer
3151. Use of statins offsets Insulin‐related cancer risk
3152. Usefullness of serum Insulin-like growth factor (IGF-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis
3153. Usefulness of the Insulin-like growth factors and their binding proteins for the assessment of the treatment results in patients with colorectal cancer
3154. Utility of Insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer
3155. Vaccination Targeting Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Advanced Ovarian cancer: Safety, Immunogenicity, and Surveillance …
3156. Validation of the type 1 Insulin-like growth factor receptor as a therapeutic target in renal cancer
3157. Value of circulating Insulin-like growth factor–associated proteins for the detection of stage I non–small cell lung cancer
3158. Vascular endothelial growth factor and Insulin-like-growth factors in prostate cancer.
3159. Virtual screening of specific Insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National cancer Institute (NCI) molecular database
3160. Visceral adiposity, Insulin resistance and cancer risk
3161. Visceral obesity, metabolic syndrome, Insulin resistance and cancer
3162. Vitamin D receptor gene polymorphisms, dietary promotion of Insulin resistance, and colon and rectal cancer
3163. Vitamin D receptor gene polymorphisms, Insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China
3164. Vitamin D status and its relation with Insulin resistance and VDR-FokI polymorphism in Iranian non-melanoma skin cancer (NMSC) patients: a case-control …
3165. Vitamin D status and its relation with Insulin resistance and VDR-FokI polymorphism in Iranian non-melanoma skin cancer (NMSC) patients: a case-control study
3166. Vitamin D–Binding Protein Enhances Epithelial Ovarian cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor …
3167. Vitamin D3 levels and Insulin resistance in papillary thyroid cancer patients
3168. Weight control and cancer preventive mechanisms: role of Insulin growth factor-1-mediated signaling pathways
3169. Western nutrition and the Insulin resistance syndrome: a link to breast cancer
3170. What is the role of the Insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated?
3171. When “flawed” translates into “flood”: The unproven association between cancer incidence and glargine Insulin therapy
3172. Which hormones promote breast cancer in postmenopause: estrogens, progestins, Insulin and/or adipocytokines?
3173. Whole‐body protein metabolism in cancer‐bearing patients. Effect of total parenteral nutrition and associated serum Insulin response
3174. Window opportunity studies in head and neck cancer to target the Insulin growth factor-1 and the epidermal growth factor receptors: from bed to bench
3175. WITHDRAWN: Significance of serum vascular endothelial growth factor, Insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients
3176. Worse breast cancer prognosis in Insulin treated diabetic patients-A population based registry study in Sweden
3177. WW domain containing E3 ubiquitin protein ligase 1 (WWP1) expression in breast cancer and its correlation with estrogen receptor (ER) and Insulin-like growth factor …
3178. YAP/TAZ regulates the Insulin signaling via IRS1/2 in endometrial cancer
3179. … -01-12: Prevalence of Insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association …
3180. … -02.092 Relationship of Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) Gene Polymorphism with the Susceptibility to Development of Prostate cancer …
3181. … -04: Interactions between plasma levels of 25-hydroxyvitamin D and Insulin-like growth factor (IGF)-1, IGF-binding proteins and C-peptide with risk of colorectal cancer
3182. … -0646 (MK), Insulin growth factor 1 receptor (IGF-1R) antibody combined with pemetrexed (P) and cisplatin (C) in stage IIIb or IV metastatic nonsquamous lung cancer …
3183. … -1 is the predominant signaling molecule activated by Insulin-like growth factor-I, Insulin, and interleukin-4 in estrogen receptor-positive human breast cancer …
3184. … -1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer
3185. … -10, in prostate cancer and its regulation by dihydrotestosterone, Insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP
3186. … -20: Insulin-like growth factor receptor-1 (IGF-1R) expression is highly correlated with HER2 amplification on circulating epithelial tumor cells (CETCs) in breast cancer …
3187. … -536924 is better tolerated than alloxan-induced hypoInsulinemia and more effective than metformin in the treatment of experimental Insulin-responsive breast cancer.
3188. … -7 (MMP7) and phosphorylated Insulin growth factor receptor I (pIGF-IR) as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A …
3189. … -binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer …
3190. … -delivery of Insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer …
3191. … -II (IGF II) and IGF-II receptor (IGF-II R) genes in human primary cancer-implication of autocrine and paracrine mechanism in autonomous growth of hepatic cancer
3192. … -Ⅱ R) GENES IN HUMAN PRIMARY cancer-IMPLICATION OF AUTOCRINE AND PARACRINE MECHANISM IN AUTONOMOUS GROWTH OF HEPATIC cancer
3193. … -induced Insulin growth factor receptor (IGF-IR) activation determines response to combined EM164/chemotherapy treatment in non-small cell lung cancer (NSCLC) …
3194. … -induced upregulation of Insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer.
3195. … –Insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression as a predictive marker of resistance in previously untreated metastatic colorectal cancer …
3196. … –Insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
3197. … -like growth factor 1/mammalian target of rapamycin and AMP-activated protein kinase signaling involved in the effects of metformin in the human endometrial cancer
3198. … -like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer
3199. … -like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer
3200. … -Like Growth Factor I (IGF) Induced Metastasis Signature Correlates with Poor Prognosis and Decreased Distant Metastasis-Free Survival in Human Breast cancer.
3201. … -like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells
3202. … -like growth factor system in human intestinal epithelial cells. Unique apical sorting of Insulin-like growth factor binding protein-6 in differentiated human colon cancer …
3203. … -like growth factor-1 receptor (IGF-1R) expression and the efficacy of trastuzumab (T) monotherapy for hormone-resistant HER2-postitive metastatic breast cancer …
3204. … -like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer
3205. … -like growth factor-binding protein-3 inhibits Insulin-like growth factor-I-induced Insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer …
3206. … -like growth factor-I-induced hypoxia inducible factor 1α protein accumulation and vascular endothelial growth factor expression in human breast cancer cells
3207. … -mediated induction of Insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer …
3208. … -Mediated Insulin-Like Growth Factor 2 (IGF2) Signal Pathway on Immune Function and Invasion and Migration of cancer Cells in Rats with Ovarian cancer
3209. … -regulation of Insulin receptor by antibodies against the type I Insulin-like growth factor receptor: implications for anti–Insulin-like growth factor therapy in breast cancer
3210. … ‐LIKE GROWTH FACTOR‐I AND Insulin‐LIKE GROWTH FACTOR BINDING PROTEIN‐3 FOLLOWING CHEMOTHERAPY FOR ADVANCED BREAST cancer
3211. … ‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced cancer
3212. … , 4‐hydroxyandrostenedione or tamoxifen on plasma concentrations of Insulin‐like growth factor (IGF)‐I, IGF‐II and IGFBP‐1 in women with advanced breast cancer
3213. … , adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer
3214. … , an inhibitor of the Insulin-like growth factor I receptor and Insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell …
3215. … , an Insulin-like growth factor-1 receptor/Insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in …
3216. … , an open access journal ISSN: 1948-593X 12. Mu N, Zhu Y, Wang Y, Zhang H, Xue F (2012) Insulin resistance: A significan t risk factor of endometrial cancer
3217. … , dual IGF‐1R/Insulin receptor (IR) inhibitor: Early pharmacodynamic (PD) and positron emission tomography (PET) imaging results from a daily‐dose study in cancer …
3218. … , estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA. 14 adjuvant breast cancer trial
3219. … , human epidermal growth factor receptor 2, and Insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer …
3220. … , or formestane on Insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer
3221. … : Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast cancer in Korean Women
3222. … : Dual tyrosine kinase inhibitor for focal adhesion kinase and Insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT …
3223. … : Emodin increases expression of Insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer
3224. … : Hydroxyzine-Hydroxyurea Mix-up: Concomitant Use of Entresto and ACE Inhibitors can Lead to Serious Outcomes: More Outpatient Oral cancer Drugs should be in …
3225. … : MK-0646 (Dalotuzumab), Insulin growth factor 1 receptor antibody combined with pemetrexed and cisplatin in stage IV metastatic non-squamous lung cancer
3226. … . Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast cancer …
3227. … (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a …
3228. … (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating …
3229. … (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer …
3230. … (IGF1R) expression in small cell lung cancer and the effect of inhibition of IGF1R expression by RNAi on growth of human small cell lung cancer NCI-H446 cell
3231. … (IGFI), Insulin-like growth factor binding protein 3 (IGFBP3) and transforming growth factor beta1 (TGF-beta1) in patients with locally-advanced and metastatic cancer …
3232. … (Ir) and Pathologic Complete Response (Pcr) to Neoadjuvant Chemotherapy (Nac) Among No Diabetic Women with Localized Infiltrating Breast cancer (Libc …
3233. … (MAb), against the Insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC …
3234. … ) supplementation on antioxidant capacity, DNA single‐strand breaks and levels of Insulin‐like growth factor‐1/IGF‐binding protein 3 in the ferret model of lung cancer
3235. … 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non–small-cell lung cancer
3236. … 1 receptor expression and IGF1R 3129G> T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from …
3237. … 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer …
3238. … 1855: The novel Hsp90 inhibitor NVP-AUY922 reduces Insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative breast cancer …
3239. … abrogates the stimulatory effects of 17β-estradiol and Insulin-like growth factor-1 on proliferation of epithelial and granulosa ovarian cancer cell lines via …
3240. … ACCELERATION OF PROSTATE cancer INHIBITED BY A SMALL MOLECULE INHIBITOR OF Insulin-LIKE GROWTH FACTOR 1 RECEPTOR/Insulin …
3241. … activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2
3242. … activity of BMS-754807, a small molecule inhibitor of Insulin-like growth factor-1 receptor/Insulin receptor, in combination with gemcitabine in pancreatic cancer
3243. … Adipose Tissue Distribution, and Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 in Men and Women. cancer Epidemiol. Biomark. Prev …
3244. … agent N-acetyl-L-cysteine (NAC) decreases Insulin-like growth factor I receptor (IGF-IR) and epidermal growth factor receptor (EGFR) levels on colorectal cancer cell …
3245. … amino‐acid sequence of the Mannose‐6‐phosphate/Insulin‐like growth‐factor‐II receptor in ovarian carcinomas with loss of heterozygosity and in breast‐cancer cell …
3246. … amphiregulin and Insulin-like growth factor-1 inhibits Bax-and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer …
3247. … analog octreotide acetate on circulating Insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a …
3248. … analysis of serum and tumor vascular endothelial growth factor, Insulin-like growth factor 1, matrix metalloproteinase 7 levels in patients with ovarian cancer
3249. … and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of Insulin-like growth factor …
3250. … and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of Insulin-like growth factor (IGF) …
3251. … and hormonal regulation of radioimmunoassayable IGF-I (Insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells.
3252. … and Insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells
3253. … and Insulin-like Growth Factor Binding Protein 1 (IGFBP-1) Are Key Components of Tamoxifen Action and the Development of Tamoxifen Resistance in Breast cancer …
3254. … and Insulin-like growth factor-1 inhibits Bax-and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells
3255. … and is associated with circulating Insulin‐like growth factor‐1 levels: implications for risk of early‐onset breast cancer in young women from hereditary breast cancer …
3256. … and non-secreted forms of intact Insulin-like growth factor binding protein-3 (IGFBP-3) and its 1-97 N-terminal fragment in PC-3 human prostate cancer cells
3257. … AND NOVEL TARGETS: Microrna-146a Inhibits Epithelial Mesenchymal Transition In Non-Small Cell Lung cancer By Targeting Insulin Receptor Substrate 2
3258. … and patterns of phospho Insulin growth factor receptor-1 (pIGF-1R) and matrilysin (MMP7) expression in metastatic colorectal cancer (mCRC), and correlation with …
3259. … AND PHYSIOLOGICAL MATURITY ALONGSIDE Insulin-LIKE ANDROGENIC GLAND (IAG) EXPRESSION AND SIZE IN MALE JONAH CRAB, cancer BOREALIS …
3260. … and predictive significance of Insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 in metastatic colorectal cancer
3261. … and Survival Data in Non-Metastatic Breast cancer Patients in Correlation with Tumour Infiltrating Lymphocytes, Androgen Receptor and Insulin-Like Growth Factor …
3262. … antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized …
3263. … antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase …
3264. … Antigen (CCA-CA) and Insulin-like Growth Factor 1 (IGF-1) in Blood Serum and Bile in Patients with Extrahepatic Bile Duct cancer and Obstructive Jaundice
3265. … antitumor activity of deguelin targeting the Insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer
3266. … are less potent local human growth hormone and Insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the …
3267. … as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer
3268. … B LYMPHOMAS2 ROLE OF MACROPHAGES IN HUMAN B LYMPHOMA PROGRESSION3 INTERACTION OF BREAST cancer WITH FOLLICULAR DENDRITIC …
3269. … between carbohydrate metabolism and serum Insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy …
3270. … between Insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer
3271. … between sex hormones, sex hormone binding globulin, Insulin‐like growth factor‐I and Insulin‐like growth factor binding protein‐I in post‐menopausal breast cancer …
3272. … BINDING PROTEIN-2 (IGFBP-2) ALTERS PTEN ACTIVITY AND REDUCES THE EFFICACY OF DOCETAXEL IN THE TREATMENT OF PROSTATE cancer (PCA)
3273. … blockade inhibits the action of EGF, Insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell …
3274. … blockade of epidermal growth factor receptor (EGFR) and Insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized …
3275. … both epidermal growth factor receptor and Insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer
3276. … by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and Insulin growth factor-1 receptor in BG-1 ovarian cancer cells
3277. … cancer risk in relation to selected genetic polymorphisms in Insulin-like growth factor-I, Insulin-like growth factor binding protein-3, and Insulin-like growth factor-I …
3278. … cancer Society, and Eli Lilly & Company. An assessment of the efficacy and safety of orlistat for the long-term management of obesity-Molecular regulation of Insulin …
3279. … carcinogenesis in the Noble rat: The role of Insulin‐like growth factor‐1 (IGF‐1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer
3280. … cell growth of BG-1 ovarian cancer cells induced by 17-estradiol or bisphenol A through down-regulating cross-talk of estrogen receptor and Insulin-like growth factor …
3281. … cells, of CP-751,871 (C), a monoclonal antibody against the Insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer
3282. … charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and Insulin-like growth factor type …
3283. … Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast cancer
3284. … concentrations of androgens up-regulate Insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer …
3285. … contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer …
3286. … cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of Insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer …
3287. … diabetes mellitus induced by immune checkpoint inhibitor therapy in an Insulinoma-associated antigen-2 autoantibody-positive patient with advanced gastric cancer
3288. … disruption of Insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer …
3289. … effects of calorie restriction and Insulin-like growth factor-1 treatment on body composition and bone mineral density of C57BL/6 mice: implications for cancer …
3290. … enhances Insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer …
3291. … epidermal growth factor receptor (EGFR) heterodimerization and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
3292. … epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan …
3293. … erlotinib in combination with placebo or R1507, a monoclonal antibody to Insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer …
3294. … erlotinib in combination with placebo or R1507, a monoclonal antibody to Insulin-like growth factor-1 receptor, for advanced-stage non–small-cell lung cancer
3295. … estrogen receptor-alpha dependent expression of Insulin-like growth factor-1 receptor and Insulin receptor substrate-1 and proliferation of human breast cancer cells
3296. … et al., A Prospective Study of Plasma Insulin-like Growth Factor-1 and Binding Protein-3 and Risk of Colorectal Neoplasia in Women. cancer Epidemiol. Biomark. Prev …
3297. … et al.: decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on Insulin-like growth factor 1 …
3298. … expression of Insulin-like growth factor-I receptor, Insulin receptor and phospho-Insulin-like growth factor-I receptor/Insulin receptor in primary breast cancer …
3299. … expression of phospho-Insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with …
3300. … factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer
3301. … factor receptor (IGF1R) pathway driven metastasis signature correlates with poor prognosis and decreased distant metastasis-free survival in human breast cancer
3302. … factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer …
3303. … factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer …
3304. … FACTOR-1 RECEPTOR (IGF-1R) SIGNAL TRANSDUCTION PATHWAYS WITH INHIBITORS OF IGF-1R, EGFR, PI3K, MEK, AND MTOR IN BREAST cancer …
3305. … factor-I in the monitoring of growth hormone treatment with respect to efficacy of treatment and side effects: should potential risks of cardiovascular disease and cancer …
3306. … factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro
3307. … factor-Ⅱ, carbohydrate antigen 19-9 and alpha fetoprotein levels after intervention and percutaneons ethanol injection therapy in patients with primary hepatic cancer
3308. … factor‑induced mesenchymal‑epithelial transition factor activation leads to Insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer …
3309. … farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma (Clinical cancer Research (2006) 12 …
3310. … FERMENTED SOYBEAN DREGS ENHANCES GLUCOSE UPTAKE AND MITIGATES Insulin RESISTANCE IN HUMAN LIVER cancer CELL (HEPG2) MODEL …
3311. … Following Intravenous Alimentation-II. Insulin-and growth hormone responses following oral or intravenous alimentation in patient with far advanced gastric cancer
3312. … food frequency questionnaire compared to 24 h recalls and biochemical measurements: pilot phase of Golestan cohort study of esophageal cancer. Eur J Clin …
3313. … for epidermal growth factor and Insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on Insulin …
3314. … for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, Insulin-like growth factor-I, Insulin-like growth factor …
3315. … FOR: Science Writers and Editors on the Journal Press List: Insulin-Like Growth Factor Receptors May Be Involved in Development of Resistance to the Breast cancer …
3316. … from hen’s‐egg yolks against human mannose‐6‐phosphate/Insulin‐like growth‐factor‐II receptor (M6P/IGFII‐R): Characterization and potential use in clinical cancer …
3317. … from human Insulin‐like growth factor‐II mRNA binding protein 3 can induce human leukocyte antigen‐A2‐restricted cytotoxic T lymphocytes reactive to cancer cells
3318. … from Ruiter et al regarding ‘Risk of cancer in patients on Insulin glargine and other Insulin analogues in comparison with those on human Insulin: results from a large …
3319. … fusion protein targeting epidermal growth factor receptor and Insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer
3320. … genetic variation in 61 genes related to steroid hormone and Insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer …
3321. … growth factor (EGF), Insulin-like growth factor-1 (IGF-1), Insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer
3322. … growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer …
3323. … growth factor I receptor/Insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer …
3324. … growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan …
3325. … growth factor receptor (EGFR) or Insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive resistance to NVP-BKM120 in non-small cell lung cancer …
3326. … growth factor receptor and Insulin‐like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells
3327. … growth factor receptor type 1 antibody (h7C10) enhances the antitumor activity of Navelbine® and anti-epidermal growth factor receptor therapy against human cancer …
3328. … growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer …
3329. … growth factor receptor-1 (IGF-1R) and epidermal growth factor receptor (EGFR) correlates with a poor patient prognosis in resected non-small cell lung cancer …
3330. … growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer …
3331. … Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate cancer following Insulin-Like Growth Factor-I Receptor …
3332. … growth of ovarian cancer cells was reversed by a phytoestrogen, genistein, by inhibition of a crosstalk between estrogen receptor and Insulin-like growth factor 1 …
3333. … hepatocyte growth factor (HGF) and Insulin-like growth factor binding protein (IGFBP)-3 with gefitinib resistance in patients with advanced non-small cell lung cancer
3334. … hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by Insulin-like growth factors
3335. … human monoclonal antibody to Insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer …
3336. … hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and Insulin …
3337. … hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an Insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer
3338. … I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen …
3339. … I trial of a DNA plasmid-based vaccine targeting Insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and …
3340. … IGF1 receptor/Insulin receptor dual kinase inhibitor BMS-754807 targets the cancer stem cell population in addition to its synergism with Lapatinib in colorectal cancer …
3341. … II comparative study of metformin plus first-line chemotherapy (CT) versus CT alone in HER2-negative, Insulin-resistant (IR), nondiabetic metastatic breast cancer …
3342. … II study of the anti‐Insulin‐like growth factor receptor type 1 (IGF‐1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer
3343. … importance of Cannabis sativa L. in regulation of Insulin and IL-6R/MAO-A in cancer cell progression and migration of breast cancer patients with diabetes
3344. … in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the Insulin-like growth factor-I …
3345. … in androgens and upregulation of Insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer
3346. … in Human MCF7 ER+ Breast cancer Cells by Nuclease-Resistant IRS1 siRNA Conjugated To a Disulfide-Bridged d-Peptide Analogue of Insulin-Like Growth Factor …
3347. … inactivation implies independent functions for Insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer …
3348. … increased Insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer …
3349. … induced by combination of farnesyl transferase inhibitor SCH66336 and Insulin like-growth factor binding protein-3 in apoptosis of non-small cell lung cancer cell …
3350. … induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and Insulin-like growth factor 1 receptor pathways in the bile duct cancer …
3351. … inhibition of synergistically Insulin-like growth factor-1-and bisphenol A-induced poliferation of estrogen receptor alpha (ERalpha)-positive human breast cancer MCF …
3352. … inhibitor for focal adhesion klinase (FAK) and Insulin like growth factor-I receptor (IGF-IR), exhibits antiproliferative effect in Barrett’s esophageal cancer in vitro and in …
3353. … inhibitor letrozole and inhibitors of Insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
3354. … Insulin growth factor/Insulin growth factor receptor1 (IGF-I, IGF-I-1R) and VEGF-A as prognostic factors and surrogate biomarkers in triple negative breast cancer …
3355. … Insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer …
3356. … Insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into cancer …
3357. … Insulin-like growth factor 1 receptor and estrogen receptor with pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer
3358. … Insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer …
3359. … Insulin-Like Growth Factor I (IGF-I)-Induced Gene, Solute Carrier Family 7 Member 11 (SLC7A11)/xCT, Mediates IGF-I-Induced Biological Behaviors in Breast cancer …
3360. … Insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro …
3361. … Insulin-like Growth Factor Receptor Single Nucleotide Polymorphism (SNP) with Platinum-based Chemotherapy Outcomes in Advanced Non-small Cell Lung cancer.
3362. … Insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer …
3363. … Insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) with E-cadherin (E-CAD) expression and improved survival in breast cancer …
3364. … Insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer …
3365. … Insulin-like growth factor-I, Insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and …
3366. … Insulin-like growth factor-II (proIGF-II) and mature IGF-II differentially mediate resveratrol-induced downregulation of survivin and apoptosis of MCF-7 breast cancer …
3367. … Insulin-using diabetes mellitus patients, non-Insulin-using diabetes mellitus patients and patients without diabetes mellitus after partial gastrectomy for gastric cancer
3368. … Insulin‐like growth factor (IGF)‐independent interactions of IGF binding protein‐3 and IGF binding protein‐5 on apoptosis in human breast cancer cells. Involvement of …
3369. … Insulin/Insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer
3370. … interfering RNAs targeting Insulin-like growth factor 1 receptor and inslin-like growth factor 1 receptor potentiate the cytotoxic effect of chemotherapy in ovarian cancer …
3371. … is better tolerated than alloxan-1 induced hypoInsulinemia and more effective than metformin in the treatment of 2 experimental Insulin responsive breast cancer …
3372. … is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer
3373. … kinase and Insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT‑rich interactive domain 1A in endometrial cancer
3374. … LB-391: Combination of Insulin-like growth factor-1 receptor/Insulin receptor (IGF1R/IR) antagonist with anti-PD-L1 antibody blocks triple-negative breast cancer …
3375. … level of Insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1 (E3R) in vivo and the clonogenic survival of breast cancer …
3376. … Levels and Secretion of Insulin‐Like‐Growth‐Factor‐Binding Proteins in MCF‐7/6, MCF‐7/AZ and MDA‐MB‐231 Breast cancer Cells: Differential Modulation by …
3377. … levels of circulating Insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case …
3378. … levels of Insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer …
3379. … levels of Insulin-like growth factor-I and decreased circulating levels of Insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer
3380. … levels of Insulin-like growth factor-I and-II and Insulinlike growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer
3381. … like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer …
3382. … Lindera obtusiloba extract suppresses growth and attenuates Insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell …
3383. … low-affinity Insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer …
3384. … measurements of testosterone, Insulin‐like growth factor 1, and Insulin‐like growth factor binding protein‐3 in the diagnosis of prostate cancer among Korean men
3385. … metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/Insulin‐like growth factor‐1 …
3386. … METABOLISM IS INFLUENCED DIFFERENTLY BY THE Insulin-LIKE-GROWTH-FACTOR (IGF)/Insulin AXIS IN PROSTATE cancer & BENIGN PROSTATE …
3387. … model assessment to detect Insulin resistance and identify patients at high risk of breast cancer development: National cancer Institute of Naples experience
3388. … module associated with Insulin-like Growth Factor 1 (IGF1) pathway activation predicts poor response to tamoxifen in women with ER+/HER2-early breast cancer (BC) …
3389. … monoclonal antibody against Insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.
3390. … mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and Insulin …
3391. … of a legume-enriched, low-glycemic index diet is associated with biomarkers of Insulin resistance and inflammation among men at risk for colorectal cancer
3392. … OF BG-1 OVARIAN cancer CELLS INDUCED BY 17β-ESTRADIOL OR BISPHENOL A THROUGH DOWNREGULATING ESTROGEN RECEPTOR α AND Insulin …
3393. … of Blood Hemoglobin Concentration in Patients Receiving Androgen Deprivation Therapy (ADT) for Prostate cancer: Impact of ADT on Insulin-Like Growth Factor-1 …
3394. … of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of Insulin-like growth factor binding …
3395. … of Calcitonin Gene-Related Peptide and Insulin-Like Growth Factor: A Potential New Therapeutic Strategy To Reduce Bone Pain in Bone Metastases of Breast cancer …
3396. … of droloxifene on plasma levels of Insulin-like growth factor (IGF)-I, pro-IGF-IIE, Insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer …
3397. … of epidermal growth factor receptor mutations and Insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer
3398. … of estrogen receptor and Insulin-like growth factor 1 receptor signaling pathways is involved in the anticancer effect of genistein on ovarian cancer growth induced by …
3399. … of excess body weight in postmenopausal breast cancer patients, in relation to expression of Insulin‐like growth factor I receptor and Insulin‐like growth factor II genes
3400. … of exercise training on fasting Insulin, Insulin resistance, Insulin-like growth factors, and Insulin-like growth factor binding proteins in postmenopausal breast cancer …
3401. … of genes coding for Insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the …
3402. … of genes involved in the Insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer
3403. … of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and Insulin …
3404. … of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and Insulin
3405. … of Insulin like growth factor 1 and Insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer
3406. … of Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum …
3407. … of Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, and C-peptide predict long-term prostate cancer survival in men without apparent prostate cancer at …
3408. … of Insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer …
3409. … of Insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National cancer Institute Breast and Prostate cancer …
3410. … of Insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to Insulin-like growth factors in vitro …
3411. … of Insulin-like growth factor binding protein-5 potentiates Insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer …
3412. … of Insulin-like growth factor binding proteins-2 and-4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer …
3413. … of Insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer
3414. … of Insulin-like growth factor II and stimulate production of Insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer …
3415. … of Insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer
3416. … of Insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer
3417. … of Insulin-like growth factor-1 receptor/Insulin receptor (IGF1R/IR) and androgen receptor (AR) antagonists with metformins inhibits triple-negative breast cancer …
3418. … of Insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer …
3419. … of Insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis
3420. … of Insulin-like growth factor-II, Insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
3421. … of matrix metalloproteinase-7, Insulin-like growth factor-1, Insulin-like growth factor-2 and Insulin-like growth factor-1 receptor in patients with colorectal cancer: Insulin …
3422. … of PKB/Akt Kinase Activity by the Vacuolar-ATPase in the Canonical Insulin Signaling Pathway: Implications for the Targeted Pharmacotherapy of cancer
3423. … of polymorphic variants in steroid hormone and Insulin‐like growth factor‐1 metabolism and risk of in situ breast cancer: Results from the Breast and Prostate cancer …
3424. … of polymorphisms in genes of Insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 …
3425. … of preoperative plasma levels of Insulin-like growth factor I and Insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and …
3426. … of protein kinase B activation by Insulin/Insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase—significance for diabetes and cancer
3427. … of protumorigenic pathways by Insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis
3428. … of radiation and docetaxel on anti-tumor effects of Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) in hormone-refractory human prostate cancer …
3429. … of radioimmuno and carbon nanotube field-effect transistor assays for measuring Insulin-like growth factor-1 in a preclinical model of human breast cancer
3430. … of raloxifene on Insulin-like growth factor-I, Insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer
3431. … of sense and antisense Insulin-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) …
3432. … OF SERUM Insulin-LIKE GROWTH FACTOR IS INDEPENDENTLY ASSOCIATED WITH INCREASED RISK OF HIGH GRADE PROSTATE cancer
3433. … of serum Insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer …
3434. … of short-acting intravenous Insulin therapy in preparation of F-18 fluorodeoxyglucose positron emission tomography computed tomography scan in cancer …
3435. … of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer
3436. … of the role of Insulin-like and vascular endothelial growth factors in development, prognosis and targeted therapy in patients with ovarian cancer
3437. … of type I Insulin-like growth factor receptor (IGF1R) in tamoxifen-resistant cells: Implications for cotargeting of IGF1R and estrogen receptor (ER) in breast cancer.
3438. … of vitamin D deficiency, part 2: deficiency and its association with autoimmune disease, cancer, infection, asthma, dermopathies, Insulin resistance, and type 2 …
3439. … of α-interferon on Insulin-like growth factor-I, Insulin-like growth factor-II and Insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in …
3440. … oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and Insulin pathway gene expression
3441. … oligonucleotide targeting Insulin-like growth factor-1 receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer …
3442. … on circulating free prostate-specific antigen, Insulin-like growth factor-I, and Insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer
3443. … on PI3K/Akt/mTOR rather than MAPK pathways in upregulation of basal growth following long-term oestrogen deprivation in three human breast cancer cell …
3444. … on the downregulation of MYC, Insulin and IGF-1 receptors: a possible mechanism underlying the anti-growth and anti-migration in chemoresistant colorectal cancer …
3445. … P2-05-05: Canine invasive mammary carcinoma as a spontaneous model for Insulin-like growth factor-1 receptor-overexpressing triple negative breast cancer
3446. … pathway calcium ATPase 1 (SPCA1) is a key regulator of Insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA …
3447. … pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer
3448. … patterns of AKT/protein kinase B, Insulin-like growth factor-1, Insulin-like growth factor-2 and Insulin-like growth factor binding protein-3 in human prostate cancer
3449. … PD01-06: Activation of the Insulin-Like Growth Factor Pathway Distinguishes African American from European American Patients with Triple-Negative Breast cancer …
3450. … phosphorylation correlates with Insulin-like growth factor-1 receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer cells
3451. … plasma levels of Insulin-like growth factor (IGF)-1, IGF-binding protein 3 and vascular endothelial growth factor in patients with advanced non-small cell lung cancer …
3452. … polymorphisms of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3, xenoestrogen, phytoestrogen, and premenopausal breast cancer
3453. … Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor …
3454. … prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human Insulin …
3455. … protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer
3456. … protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer …
3457. … quality and quantity of visceral fat tissue are associated with Insulin resistance and survival outcome after chemotherapy for patients with early-stage breast cancer
3458. … re: Chokkalingam A. et al., Insulin-like Growth Factors and Prostate cancer: A Population-based Case-Control Study in China. cancer Epidemiol. Biomark. Prev., 10 …
3459. … receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric cancer
3460. … receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′, 5′-monophosphate, estradiol, Insulin-like growth factor-I …
3461. … receptor sites for Insulin. Insulin brings glucose into the cells…. and cancer cells feed on the glucose. if the cancer cell is not exposed to glucose or Insulin, it is …
3462. … Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant Insulin signaling in development of cancer
3463. … receptor-A with a dual IGF-1R/IR inhibitor: Overcoming a potential escape mechanism from IGF-1R-specific signaling inhibition in Insulin receptor-A transfected cancer …
3464. … receptor–positive locally advanced/metastatic breast cancer: randomized phase 2 results. Paper presented at: 41th Annual San Antonio Breast cancer …
3465. … receptor, mesenchymal–epithelial transition factor, and Insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer
3466. … regulates Insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3)
3467. … relationship between the Insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer
3468. … RESPONSE AFTER VACCINATION TARGETING Insulin GROWTH FACTOR BINDING PROTEIN 2 IN A SYNGENEIC MOUSE MODEL OF OVARIAN cancer …
3469. … role of Insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer
3470. … roles for the Insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer …
3471. … scrapes levels of Insulin-like growth factor-II and Insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer
3472. … sensitivity and Insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer
3473. … sensory neuropeptides, epidermal growth factor, Insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT …
3474. … signaling cascade in the mononuclear cells of peripheral blood: association with Insulin and Insulin-like growth factor levels in the blood of patients with cancer and …
3475. … significance of combined determination of serum levels of free prostate specific antigen (fPSA) and Insulin-like growth factor-1 (IGF-1) in patients with prostatic cancer
3476. … significance of immunohistochemical expression of Insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer
3477. … significance of Insulin-like growth factor 1 and Insulin like growth factor binding protein 3 in serum and bronchoalveolar lavagae fluids of patients with lung cancer
3478. … significance of pretreatment plasma levels of Insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer
3479. … Stem Cell Plasticity Through Modulation of Epidermal Growth Factor and Insulin‐Like Growth Factor Receptor Signaling in Head and Neck Squamous Cell cancer
3480. … study of the association of circulating levels of serum Insulin-like growth factor I and Insulin-like growth factor binding protein 3 with breast cancer in young women in …
3481. … STUDY ON EXPRESSION OF Insulin-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) IN CHINESE PROSTATE cancer AND BENIGN PROS TATIC …
3482. … subcellular and extracellular localisations of proteins required for Insulin-like growth factor-and extracellular matrix-induced signalling events in breast cancer …
3483. … Suppresses the Insulin-Like Growth Factor 1 Receptor (IGF1R) Ablating Epidermal Growth Factor Receptor Inhibitor Resistance in Adult High Grade Gliomas.”[cancer …
3484. … tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and Insulin-like growth factor …
3485. … target of metformin indirectly is mammalian target of rapamycin, then the Insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical …
3486. … targeting the Insulin-like growth factor receptor (IGF-1R), in combination with cetuximab, can reverse acquired resistance to cetuximab in pancreatic and colon cancer …
3487. … Tensin homologue deleted on chromosome 10 engages ErbB3 and Insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer
3488. … the effects of alcohol, Insulin, glucose analogues, hypoglycaemic agents, 434 MHz and ionizing electromagnetic radiation and other agents upon normal and cancer …
3489. … the Expression Reduction of Insulin-like Growth Factor Binding Protein (IGFBP)-3 and PTEN and the Clinicopathological Parameters in Breast cancer
3490. … the Insulin/Insulin-Like Growth Factor-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Estrogen Receptor-Positive Breast cancer
3491. … the mitogenicity of Insulin analogues relative to human Insulin—response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF‐I …
3492. … the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and Insulin‐like growth factor‐1 in advanced prostate cancer …
3493. … the World cancer Research Fund/American Institute for cancer Research cancer prevention recommendations and biomarkers of inflammation, hormonal, and Insulin …
3494. … to the Editor‐responses to Weisntein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF‐I‐like mitogenic and antiactivity in cultured cancer …
3495. … to the role of fatty acid binding protein-7, Insulin like growth factor binding protein-2 and phosphatase and tensin homolog in triple negative breast cancer, in vitro and …
3496. … transition and γ‐radiation‐resistant subtypes by focal adhesion kinase‐associated Insulin‐like growth factor 1 receptor activation in non‐small‐cell lung cancer cells
3497. … value of Insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer
3498. … variation at the ‐202 locus in IGFBP3: Influence on serum levels of Insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk
3499. … via the PI3-kinase/Akt/mTOR pathway and of the anit-apoptotic translationally controlled tumour protein TCTP in the development of drug resistance in colon cancer …
3500. … with cyclophosphamide, methotrexate and 5‐fluorouracil on plasma Insulin‐like growth factor‐I and chosen hormones in breast cancer pre‐menopausal patients
3501. … with the anti-Insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
3502. * Association of the Insulin-like growth factor 1 microsatellite with predisposition to colorectal cancer
3503. 1323 FOXA1 PROMOTES TUMOR PROGRESSION VIA Insulin-LIKE GROWTH FACTOR BINDING PROTEIN 3 PATHWAY IN PROSTATE cancer
3504. Physical activity and Insulin-like growth factors in breast cancer survivors: A metaanalysis
3505. 15-Lipoxygenase-1 expression upregulates and activates Insulin-like growth factor-1 receptor in prostate cancer cells
3506. 1668: Insulin-Like Growth Factor Binding Protein 2 is an Independant Predictor of Prostate cancer Survival
3507. 17β-estradiol levels during an entire menstrual cycle in response to adult stature and Insulin, of possible importance for breast cancer risk. The EBBA-I study.
3508. 17β-Estradiol up-regulates the Insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells
3509. 184: Targeting the type 1 Insulin-like growth factor receptor (IGF1R) in renal cancer.
3510. 1P280 Possible involvement of glucose metabolism regulation in Insulin-mediated modulation of radiosensitivity in human breast cancer cells.(Radiobiology & Active …
3511. 2-Deoxyglucose Reverses the Promoting Effect of Insulin on Colorectal cancer Cells In Vitro
3512. 2052 Insulin-LIKE GROWTH FACTOR-I (IGF-I) POLYMORPHISMS PREDICT THE SURVIVAL OF PROSTATE cancer PATIENTS WITH BONE METASTASIS AT …
3513. 239: Silencing of the Type 1 Insulin-Like Growth Factor Receptor (IGF1R) Gene Enhances Sensitivity of Prostate cancer to Dna Damaging Agents Through Impaired …
3514. 316 DECREASED MITOCHONDRIAL AND Insulin PATHWAY GENE EXPRESSION SIGNAL IN PROSTATE cancer XENOGRAFT MOUSE MODEL WITH …
3515. 40 YEARS OF IGF1: Anti-Insulin-like growth factor therapy in breast cancer
3516. 409: High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate cancer Risk. A Prospective Study
3517. 412 Insulin resistance in amino acid transport system A in head and neck cancer patients studied by positron emission tomography (PET) and carbon-11-methionine
3518. 461: Insulin Resistance is Inversely Related to Prostate cancer; A Prospective Study in Northern Sweden
3519. 54 Diagnostic accuracy of serum Insulin-like growth factor binding protein 2 for ovarian cancer
3520. 643 Insulin-like growth faCtors (igfs) and igf binding Proteins in Psa-deteCted Prostate cancer: Control study (ProteCt)
3521. 725: Overexpression of Insulin-Like Growth Factor Binding Protein-2 in Human Bladder cancer Cells Enhances their Metastatic Potential
3522. 726 Insulin-LIKE GROWTH FACTOR-2 (IGF2) LOSS OF IMPRINTING MARKS A FIELD DEFECT WITHIN HUMAN PROSTATES CONTAINING cancer
3523. 735 THE IMPACT OF Insulin AND ITS RECEPTORS ON IGF TARGETING THERAPIES IN PROSTATE cancer
3524. 736: The Type-1 Insulin-Like Growth Factor Receptor is Overexpressed in Bladder cancer, and Targeting by RNA Interference Reduces in Vitro Survival
3525. 9 The Insulin-Like Growth Factor A Target for cancer Treatment